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  Abstract	  	  Xenon	  is	  a	  general	  anaesthetic	  gas	  with	  neuroprotective	  properties.	  Inhibition	  of	  the	   N-­‐methyl-­‐D-­‐aspartate	   (NMDA)	   receptor	   glycine	   co-­‐agonist	   site	   has	   been	  shown	  to	  mediate	  xenon	  neuroprotection	  against	  ischemic	  injury	  in	  vitro.	  	  	  Site-­‐directed	   mutagenesis	   was	   used	   to	   produce	   point	   mutations	   in	   the	   GluN1	  subunit	  of	  rat	  NMDA	  receptors.	  These	  were	  then	  expressed	  in	  HEK293	  cells	  and	  the	   responses	   of	   mutant	   GluN1/GluN2A	   receptors	   to	   glycine	   and	   anaesthetics	  assessed	   using	   patch-­‐clamp	   electrophysiology.	   Two	   mutations	   of	   the	  phenylalanine	   758	   site	  were	   found	   to	   eliminate	   xenon	   binding	   to	   the	   receptor	  without	   altering	   glycine	   affinity	   or	   the	   binding	   of	   sevoflurane	   and	   isoflurane.	  These	  selective	  mutations	  will	  allow	   for	  knock-­‐in	  animals	   to	  be	  used	   to	  dissect	  the	  mechanism(s)	  underlying	  xenon	  neuroprotection	  and	  anaesthesia	  in	  vivo.	  	  The	   ability	   of	   the	   other	   noble	   gases	   (helium,	   neon,	   argon,	   and	   krypton)	   to	  influence	   two	  known	  molecular	   targets	  of	  xenon	  –	   the	  NMDA	  receptor	  and	   the	  TREK-­‐1	  channel	  –	  was	  also	  assessed	  using	  patch-­‐clamp	  electrophysiology.	  These	  were	  found	  to	  have	  no	  influence	  on	  either	  NMDA	  receptors	  or	  TREK-­‐1	  channels.	  	  Finally,	  xenon’s	  neuroprotective	  efficacy	  against	  traumatic	  brain	   injury	  (TBI)	   in	  
vivo	  was	  assessed	  using	  the	  rodent	  controlled	  cortical	  impact	  model	  of	  TBI.	  Focal	  contusion	  injury	  was	  administered	  to	  male	  C57	  mice	  and	  animals	  administered	  either	  75%	  xenon	  or	   control	   treatment	   for	   three	  hours.	  Xenon-­‐treated	  animals	  performed	  better	  in	  functional	  tests	  and	  displayed	  favourable	  outcomes	  in	  brain	  histology,	  as	  compared	  to	  control	  animals.	  This	  data	  provides	  the	  first	  evidence	  of	  a	  neuroprotective	  effect	  for	  xenon	  against	  TBI	  in	  vivo.	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1.1	  Nobles	  gases,	  neuroprotection,	  and	  brain	  trauma	  
	  That	   the	   inert	   gas	   xenon	   is	   capable	   of	   eliciting	   both	   profound	   anaesthesia	   and	  analgesia	  when	   inhaled	   has	   been	   known	   for	   several	   decades;	   far	  more	   elusive	  was	  the	  biological	  mechanism	  by	  which	  a	  simple	  monatomic	  element	  renowned	  for	  its	  low	  chemical	  reactivity	  could	  produce	  these	  unexpected	  effects.	   	  The	  use	  of	  xenon	  as	  an	  anaesthetic	  agent	  has	  been	  described	  from	  as	  early	  as	  the	  1950’s,	  and	   yet	   it	  was	   close	   to	   the	   turn	   of	   the	  new	  millennium	  before	   any	   real	   details	  regarding	  an	  anaesthetic	  mechanism	   for	   the	  gas	  was	  uncovered,	  when	  work	   in	  the	   laboratory	   of	  Nicholas	   Franks	   identified	   the	  N-­‐methyl-­‐D-­‐aspartate	   (NMDA)	  receptor	  as	  a	  molecular	  target	  for	  xenon.	  	  Following	   the	   identification	   of	   NMDA	   receptor	   inhibition	   as	   the	   mechanism	  potentially	  underlying	  xenon	  anaesthesia,	  it	  was	  a	  small	  leap	  of	  logic	  that	  led	  to	  the	   idea	   of	   using	   xenon	   as	  a	   treatment	   to	   prevent	  brain	   damage	   in	   conditions	  such	   as	   neonatal	   hypoxia/ischemia	   and	   traumatic	   brain	   injury.	   To	   date	   there	  exists	  no	  clinically	  available	  pharmacological	   treatment	  designed	  specifically	   to	  protect	   the	   brain	   against	   these	   types	   of	   brain	   damage,	   even	   though	   such	   drug	  treatments	  are	  urgently	  required;	  brain	  trauma,	  in	  particular,	  is	  a	  silent	  epidemic	  responsible	  for	  close	  to	  a	  million	  visits	  to	  A&E	  each	  year,	  and	  is	  the	  leading	  cause	  of	  death	  and	  disability	  in	  under	  45’s	  in	  the	  developed	  world.	  	  The	  World	   Health	   Organisation	   predicts	   that	   brain	   trauma	   will	   surpass	   many	  other	   diseases	   as	   the	   major	   cause	   of	   death	   and	   disability	   by	   the	   year	   2020,	  largely	   as	   a	   result	   of	   car	   ownership	   in	   developing	   nations.	   Despite	   this,	   drug	  treatments	   with	   any	   sort	   of	   targeted	   efficacy	   remain	   severely	   lacking.	   The	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serendipitous	   story	   of	   a	   chemical	   element	   defined	   by	   low	   chemical	   reactivity	  potentially	  holding	   the	  answer	   to	   these	  problems	   is	  an	   intriguing	  one,	  and	  one	  that	  is	  continued	  towards	  its	  conclusion	  across	  the	  course	  of	  this	  thesis.	  Through	  a	  deeper	  understanding	  of	   the	  mechanisms	  governing	  xenon’s	  pharmacological	  effects,	  and	  the	  first	  pre-­‐clinical	  study	  proving	  neuroprotective	  efficacy	  for	  xenon	  against	  traumatic	  brain	  injury,	  it	  is	  my	  hope	  that	  a	  small	  but	  significant	  step	  will	  be	  taken	  towards	  providing	  a	  first	  safe	  and	  effective	  treatment	  for	  the	  sufferers	  of	  brain	  trauma.	  	  	  	  
1.2	  Xenon	  
	  Occurring	   naturally	   in	   trace	   amounts	   in	   the	   earth’s	   atmosphere,	   the	   gaseous	  element	  xenon	  is	  a	  member	  of	  the	  zero-­‐valence	  family	  of	  noble	  (or	  inert)	  gases,	  so-­‐called	  for	  their	  low	  chemical	  reactivity.	  While	  xenon’s	  lack	  of	  chemical	  activity	  is	  well	  documented,	  xenon	  is	  also	  known	  to	  possess	  an	  array	  of	  pharmacological	  effects.	  When	  inhaled,	  xenon	  will	  produce	  both	  anaesthesia	  and	  analgesia,	  indeed	  xenon	   has	   found	   use	   as	   an	   inhalational	   anaesthetic	   agent	   from	   as	   early	   as	   the	  1950’s	  [1].	  	  	  Estimates	   of	   xenon’s	   anaesthetic	   potency	   place	   the	   minimum	   alveolar	  concentration	   (MAC;	   the	   concentration	   of	   anaesthetic	   in	   the	   lungs	   required	   to	  prevent	   a	   reflex	   response	   to	   painful	   stimuli	   in	   50%	   of	   patients)	   for	   xenon	   at	  between	  63	  and	  68%	  [2,3].	  Xenon	  anaesthesia	  has	  the	  benefits	  of	  fast	  induction	  and	  emergence,	  good	  cardiovascular	  stability,	  and	  a	  favourable	  metabolic	  profile,	  making	  xenon	  in	  many	  respects	  the	  ideal	  anaesthetic	  agent.	  	  Despite	  this,	  the	  routine	  use	  of	  xenon	  as	  an	  anaesthetic	  has	  been	  limited,	  in	  large	  part	  due	  to	  its	  comparatively	  high	  cost	  versus	  other	  anaesthetic	  agents.	  Xenon	  is	  obtained	   via	   fractional	   distillation	   of	   atmospheric	   air	   -­‐	   an	   expensive	   process	   -­‐	  with	  the	  cost	  of	  one	  litre	  of	  xenon	  currently	  standing	  at	  around	  £12	  to	  16.	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  From	  the	  Greek	  “without	  feeling”,	  anaesthesia	   is	  the	  pharmacologically	   induced	  state	   of	   having	   lost	   sensation,	   the	   effects	   of	   which	   may	   include	   any	   or	   all	   of;	  analgesia,	   amnesia,	   sedation,	   loss	   of	   responsiveness,	   and	   loss	   of	  muscle	   reflex,	  depending	  upon	  the	  particular	  type	  of	  anaesthesia	  involved.	  General	  anaesthesia,	  the	   “deepest”	   type	  of	  anaesthesia,	   is	  a	   state	  of	   controlled	  unconsciousness,	  and	  has	  been	  defined	  as	  “a	  reversible,	  drug-­‐induced	  loss	  of	  consciousness”	  [5].	  	  The	   drug	   agents	   able	   to	   elicit	   general	   anaesthesia	   are,	   in	   chemical	   terms,	  incredibly	   diverse,	   and	   range	   from	   simple	   monatomic	   elements	   (xenon)	   to	  complex	   chemical	   structures	   (barbiturates,	   halogenated	   ethers,	   steroids	   etc.).	  This	  structural	  diversity	  may	  have	  contributed	  to	  the	  early	  confusion	  regarding	  the	   mechanism	   by	   which	   such	   a	   broad	   range	   of	   chemical	   agents	   are	   able	   to	  produce	  the	  same	  pharmacological	  endpoint.	  	  	  For	   many	   years,	   general	   anaesthetics	   were	   thought	   to	   act	   non-­‐specifically,	   by	  dissolving	   in	   the	   lipid	   bilayer	   of	   nerve	   membranes,	   thereby	   disrupting	  membrane	  structure	  and	  dynamics	  [5].	  This	  theory	  stood	  until	  pioneering	  work	  by	  Franks	  and	  Lieb	  [6]	  demonstrated	  for	  the	  first	  time	  the	  ability	  of	  anaesthetic	  agents	   to	   bind	   and	   inhibit	   protein	   targets	   directly.	   In	   these	   experiments,	   a	  correlation	  between	  the	  potency	  of	  anaesthetic	  drugs	  and	  their	  ability	  to	  inhibit	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the	   protein	   luciferase’s	   light-­‐producing	   enzymatic	   reaction	   was	   reported.	  Importantly,	   this	   inhibition	   was	   competitive	   with	   the	   normal	   enzymatic	  substrate	  (luciferin),	  suggesting	  that	  anaesthetic	  agents,	  despite	  their	  structural	  and	   chemical	   diversity,	   might	   act	   by	   competing	   with	   endogenous	   ligands	   for	  specific	  receptor	  sites.	  	  It	  is	  now	  generally	  accepted	  that	  general	  anaesthetics	  act	  by	  binding	  to	  specific	  protein	  targets	  in	  the	  brain.	  	  	  
1.2.1	  Molecular	  targets	  of	  anaesthesia	  The	   idea	   that	   general	   anaesthetics	   act	   by	   binding	   and	   influencing	   neuronal	  receptors	  is	  now	  generally	  accepted,	  with	  general	  anaesthetics	  believed	  to	  act	  at	  only	  a	  small	  number	  of	  molecular	  targets	  at	  critical	  loci	  in	  the	  brain	  [5,7-­‐10].	  The	  search	  for	  protein	  targets	  underlying	  general	  anaesthesia	  has	  focussed	  on	  three	  main	   receptor	   families:	   γ-­‐aminobutyric	   acid	   (GABA)A	   receptors,	   N-­‐methyl-­‐D-­‐aspartate	  (NMDA)	  receptors,	  and	  two	  pore-­‐domain	  potassium	  (K2P)	  channels. 	  Of	   these,	   the	   role	   of	   inhibitory	   GABAA	   receptors	   in	   anaesthesia	   is	   best	  understood.	   The	   majority	   of	   anaesthetic	   drugs	   have	   been	   demonstrated	   to	  potentiate	  inhibitory	  GABAA	  receptor	  currents,	  thereby	  increasing	  the	  degree	  of	  inhibitory	  transmission	  and	  producing	  a	  global	  depression	  of	  the	  central	  nervous	  system.	  The	  importance	  of	  GABAA	  in	  the	  mechanism	  of	  general	  anaesthesia	  has	  been	   further	   demonstrated	   in	   mutational	   studies.	   Point	   mutations	   reducing	  GABAA	  receptor	  sensitivity	  to	  anaesthetics	  in	  vitro	  have	  been	  shown	  to	  result	  in	  reduced	   anaesthetic	   sensitivity	   in	   vivo,	   in	   transgenic	   animals	   expressing	   these	  receptor	  mutants	  [11,12].	  	  Two	  pore	  domain	  potassium	  channels	  are	  a	  family	  of	  K+	  “leak”	  channels,	  unusual	  in	   their	   being	   formed	   of	   two	   subunits	   rather	   than	   the	   typical	   four	   from	  which	  voltage-­‐gated	   potassium	   channels	   are	   formed.	   Each	   subunit	   has	   two	   pore-­‐forming	  domains,	   hence	   the	   “two	  pore	  domain”	   classification.	  K2P	   channels	   are	  responsible	  for	  the	  K+	  leak	  current,	  are	  open	  at	  resting	  membrane	  potentials,	  and	  act	   to	  hyperpolarise	  neurons.	  Their	   activation	   thus	   limits	  neuronal	   excitability,	  causing	   inhibition.	   Several	   members	   of	   the	   K2P	   family,	   TREK-­‐1	   included,	   are	  known	  to	  be	  activated	  by	  volatile	  anaesthetics.	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  While	  most	  anaesthetics	  are	  believed	  to	  act	  via	  potentiation	  of	  inhibitory	  GABAA	  receptors,	  the	  anaesthetic	  gas	  xenon	  has	  been	  found	  to	  exert	  little	  to	  no	  influence	  over	   these	  [13,14],	  with	  xenon	  anaesthesia	  now	  believed	  to	  arise	  via	  actions	  at	  the	   NMDA	   receptor	   [13]	   or	   other	   targets.	   Most	   inhalational	   anaesthetics	   will	  inhibit	  NMDA	  receptors	  to	  some	  extent	  [15],	  however	  most	  exert	  this	   influence	  secondary	   to	   inhibition	  of	  GABAA.	  Nitrous	  oxide	   [16,17]	  and	  cyclopropane	   [18]	  are,	  like	  xenon,	  two	  exceptions	  to	  this	  rule.	  	  It	  is	  unclear	  whether	  agents	  acting	  solely	  at	  the	  NMDA	  receptor	  are	  able	  to	  elicit	  general	  anaesthesia;	  xenon,	  at	  least,	  has	  a	  number	  of	  other	  identified	  molecular	  targets.	   These	   include	   the	   K2P	   channel	   TREK-­‐1	   [19],	   the	   plasmalemmal	   ATP-­‐sensitive	   potassium	   (KATP)	   channel	   [20],	   a	   number	   of	   nicotinic	   acetylcholine	  receptor	  subtypes	  [17,21],	  and	  5-­‐HT3	  receptors	  [22].	  Actions	  at	  any	  and/or	  all	  of	  these	   other	   targets	   (in	   addition	   to	   the	   well-­‐established	   inhibition	   of	   NMDA	  receptors)	   may	   contribute	   to	   xenon’s	   anaesthetic,	   analgesic,	   and	   other	  pharmacological	  effects.	  	  Of	  these,	  activation	  of	  the	  TREK-­‐1	  channel	  in	  particular	  is	  likely	  to	  play	  a	  role.	  	  	  	  
1.4	  The	  N-­‐methyl-­‐D-­‐aspartate	  (NMDA)	  receptor	  
	  The	   NMDA	   receptor	   is	   a	   member	   of	   a	   family	   of	   ionotropic	   glutamatergic	  receptors	   mediating	   the	   major	   portion	   of	   excitatory	   neurotransmission	   in	   the	  brain.	   Three	   main	   classes	   of	   ionotropic	   glutamatergic	   receptors	   exist,	  characterised	   pharmacologically	   based	   upon	   their	   selective	   (exogenous)	  agonists;	   namely	   α-­‐amino-­‐3-­‐hydroxy-­‐5-­‐methyl-­‐4-­‐isoxazolepropionic	   acid	  (AMPA),	   kainate,	   and	   NMDA	   receptors.	   These	   are	   permeable	   to	   positively	  charged	   ions,	   with	   different	   receptor	   types	   (and	   subtypes)	   being	   selectively	  permeable	  to	  particular	  cations	  [23].	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While	  AMPA	  and	  kainate	  receptors	  mediate	  fast	  excitatory	  transmission,	  NMDA	  receptors	   are	   responsible	   for	   the	   characteristic	   late	   portion	   of	   glutamatergic	  transmission.	   Activation	   of	   NMDA	   receptors	   is	   particularly	   unusual	   in	   that	   the	  presence	   of	   two	   agonists	   –	   both	   glutamate	   and	   the	   co-­‐agonist	   glycine	   –	   is	  required	   [24,25].	   Additionally,	   at	   resting	   membrane	   potentials	   the	   NMDA	  receptor	   channel	   is	   blocked	   by	   Mg2+,	   with	   an	   initial	   small	   membrane	  depolarisation	  required	  for	  this	  to	  be	  overcome	  [26,27].	  	  NMDA	   receptors	   are	   predominantly	   located	   postsynaptically	   at	   excitatory	  synapses,	   where	   AMPA	   and	   kainate	   receptors	   provide	   the	   initial	   rapid	  depolarisation	   that	   is	   required	   to	   overcome	   Mg2+	   channel	   blockade.	   Once	  activated,	   NMDA	   receptors	   generate	   a	   slower	   current,	   in	   which	   Ca2+	   ion	   flux	  forms	  a	  major	  component	  [23].	  	  
1.4.1	  NMDA	  receptor	  molecular	  biology	  	  NMDA	  receptors	  are	  tetrameric,	  made	  up	  of	  four	  subunits	  in	  a	  “dimer	  of	  dimers”	  [28].	  Normally	  this	  arrangement	  comprises	  two	  GluN1	  subunits	  and	  two	  GluN2	  subunits,	  with	  GluN2	  subunit	  variability	  conferring	  the	  majority	  of	  differences	  in	  receptor	   functional	   heterogeneity.	   Four	   GluN2	   subunit	   variations	   (A-­‐D),	   each	  coded	  by	  a	  different	  gene,	  have	  been	  described.	  In	  contrast,	  only	  a	  single	  GluN1	  subunit	   exists,	   albeit	   with	   multiple	   splice	   variants	   (GluN1-­‐1a	   –	   GluN1-­‐4a	   and	  GluN1-­‐1b	  –	  GluN1-­‐4b)	  [29].	  	  	  An	   additional	   pair	   of	   NMDA	   receptor	   subunits	   (GluN3A	   and	   GluN3B)	   has	   also	  been	   described;	   proposed	   physiological	   functions	   for	   these	   subunits	   include	  roles	  in	  synaptogenesis	  and	  synaptic	  plasticity	  [30].	  Additionally,	  GluN3	  subunits	  have	   been	   found	   to	   assemble	   with	   GluN1	   subunits	   to	   form	   excitatory	   glycine	  receptors	   [31].	   Despite	   this,	   the	   function	   of	   GluN3	   subunits	   remains	   poorly	  understood.	  	  Like	  most	   other	   ligand-­‐gated	   ion	   channels,	   NMDA	   receptor	   subunits	   comprise	  four	   hydrophobic,	   membrane-­‐spanning	   domains.	   The	   ionotropic	   glutamate	  receptor	   subunits	   are,	   however,	   unusual	   in	   that	   the	   second	   transmembrane	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domain	   forms	   a	   re-­‐entrant	   loop,	   giving	   these	   subunits	   an	   extracellular	   N-­‐terminus	  and	   intracellular	  C-­‐terminus.	  The	  extracellular	   loop	  between	  domains	  three	  and	  four	  is	  long,	  and	  forms	  an	  integral	  part	  of	  the	  ligand	  binding	  domain	  in	  a	  three	  dimensional	  interaction	  with	  the	  N-­‐terminus	  (Figure	  1.1).	  	  NMDA	  receptors	  are	  highly	  permeable	  to	  Ca2+	  ions:	  a	  property	  dependent	  upon	  post-­‐transcriptional	   editing	   of	   an	   amino	   acid	   site	   (the	   Q/R	   site)	   in	   the	   second	  transmembrane	   domain.	   The	   presence	   of	   an	   asparagine	   residue	   at	   this	   site	  allows	  the	  flow	  of	  Na+	  and	  Ca2+	  ions,	  but	  not	  Mg2+.	  A	  string	  of	  negatively	  charged	  residues	   just	  before	   this	   region	  may	  also	  be	   important	   for	  attracting	  Mg2+	   ions	  into	  the	  receptor	  channel	  [32].	  	  Binding	  sites	  for	  both	  of	  the	  endogenous	  agonists	  of	  the	  receptor	  are	  made	  up	  of	  a	   three-­‐dimensional	   structure	   formed	   by	   the	   extracellular	   N-­‐terminus	   and	  extracellular	   loop	   between	   the	   third	   and	   fourth	   transmembrane	   domains.	  Glutamate	   (and	   NMDA)	   binds	   to	   this	   structure	   on	   the	   GluN2	   subunit,	   while	  glycine	  binds	  to	  an	  analogous	  site	  on	  the	  GluN1	  subunit	  [33].	  	  
1.4.2	  NMDA	  receptor	  expression	  	  Consistent	  with	   the	   important	   role	  of	  glutamate	   in	  excitatory	   transmission	  and	  the	   widespread	   distribution	   of	   the	   NMDA	   receptor	   throughout	   the	   CNS,	   the	  GluN1	  subunit	   is	  expressed	  ubiquitously	   from	  embryonic	  development	  through	  to	  adulthood	  [34,35].	  Differences	  in	  GluN1	  isoform	  expression	  exist,	  however	  the	  functional	  significance	  of	  this	  differential	  expression	  remains	  unclear.	  	  The	   four	   GluN2	   subunits	   have	   widely	   differing	   spatiotemporal	   expression	  profiles	   [35,36].	   Developmentally,	   only	   GluN2B	   and	   GluN2D	   subunits	   are	  expressed,	   indicative	   of	   important	   roles	   in	   synaptogenesis	   and	   synaptic	  maturation.	  GluN2A	  expression	  emerges	  shortly	  after	  birth	  and	  rises	  steadily	  to	  become	   the	  most	   abundant	   and	  widely	   expressed	  GluN2	   subunit	   by	   adulthood	  [37].	  GluN2D	  expression	  falls	  in	  parallel	  with	  this	  rise	  in	  GluN2A,	  and	  in	  the	  adult	  is	   restricted	   largely	   to	   low	   levels	   in	   the	  diencephalon	  and	  mesencephalon	   [35],	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Figure	  1.1:	  NMDA	  receptor	  subunit	  topology,	  receptor	  structure,	  and	  subunit	  expression.	  
A.)	  All	  GluN	  subunits	   share	  a	  modular	  architecture	   consisting	  of:	   the	  N-­‐terminal	  domain	  
(NTD);	  four	  membrane	  segments	  (M1-­‐M4);	  an	  intracellular	  C-­‐terminal	  domain	  (CTD);	  and	  
a	   ligand	   binding	   domain	   formed	   by	   the	   N-­‐terminus	   and	   the	   long	   extracellular	   loop	  
between	   membrane	   segments	   3	   and	   4.	   B.)	   Functional	   NMDA	   receptors	   comprise	   four	  
subunits,	  usually	   two	  GluN1	  and	   two	  GluN2.	  The	  channel	  pore	   is	  permeable	   to	  Ca2+,	  Na+,	  
and	  K+,	  but	  is	  blocked	  by	  Mg2+	  ions	  at	  resting	  membrane	  potentials.	  C.)	  Expression	  profile	  
of	   the	  various	  GluN2	  subunits	   in	   the	  adult	  mouse	  brain.	  The	  GluN1	  subunit	   is	  expressed	  
ubiquitously.	  Re-­‐drawn	  from	  Paoletti	  et	  al,	  2013	  [29].	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possibly	   only	   at	   extrasynaptic	   sites	   [38].	   Unlike	   GluN2D,	   GluN2B	   levels	   are	  maintained	  following	  birth.	  GluN2C	  expression	  begins	   late	   in	  development,	  and	  is	  confined	  largely	  to	  the	  cerebellum.	  	  In	   the	   adult	   brain,	   GluN2A	   and	   GluN2B	   are	   the	   predominant	   GluN2	   subunits,	  particularly	   in	   the	   hippocampus	   and	   cortex	   [29].	   Conversely,	   GluN2C	   and	  GluN2D	  dominate	  the	  spinal	  cord	  [39].	  	  
1.4.3	  NMDA	  receptor	  function	  and	  anaesthesia	  NMDA	   receptors	   are	   plausible	   candidate	   targets	   for	   general	   anaesthetics	   given	  their	   ubiquity	   throughout	   the	   CNS	   and	   their	   importance	   in	   normal	   excitatory	  transmission.	   NMDA	   receptors	   mediate	   the	   characteristic	   late	   portion	   of	  glutamatergic	   transmission,	   requiring	   an	   initial	   degree	   of	   membrane	  depolarisation	   provided	   by	   AMPA	   or	   kainite	   receptors	   before	   activation	   can	  occur	   [26,27].	   They	   are	   essential	   mediators	   of	   brain	   plasticity,	   capable	   of	  converting	   specific	   patterns	   of	   neuronal	   activity	   into	   long-­‐term	   changes	   in	  structure	  and	  function,	  which	  are	  believed	  to	  underlie	  higher	  cognitive	  functions	  such	  as	  learning	  and	  memory	  [29].	  	  	  In	   addition	   to	   the	   complex	   spatial	   and	   temporal	   distribution	   patterns	   of	   the	  particular	   receptor	   subunits	   (detailed	   in	   1.3.2	   NMDA	   receptor	   expression,	  above),	  NMDA	  receptor	  subunits	  also	  vary	  according	  to	  subcellular	   localisation.	  In	   the	   adult	   brain,	   synaptic	   NMDA	   receptors	   are	   typically	   GluN1/GluN2A	  containing	  receptors,	  while	  GluN2B	  containing	  receptors	  are	  more	  predominant	  at	   extrasynaptic	   sites	   [40,41]	   although	   in	   practice	   it	   is	   likely	   that	   the	   synaptic	  balance	  of	  GluN2A	  and	  GluN2B	  containing	  receptors	   is	  plastic	   [29].	   It	  has	  been	  suggested	  that	  activation	  of	  GluN2A	  containing	  receptors	  contributes	  more	  to	  the	  process	   of	   long-­‐term	   potentiation,	   while	   activation	   of	   GluN2B	   containing	  receptors	   is	   more	   important	   in	   the	   induction	   of	   long-­‐term	   depression	   [42].	  	  GluN2B	  containing	  receptors	  at	  extrasynaptic	  sites	  have	  also	  been	  implicated	  as	  having	  an	  important	  role	  in	  excitotoxic	  damage,	  by	  acting	  as	  a	  hub	  for	  pathways	  leading	  to	  neuronal	  death	  [40,41].	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Inhibition	  of	  NMDA	  receptors	  has	  been	  demonstrated	   for	   the	  anaesthetic	  gases	  xenon	   and	   nitrous	   oxide	   [13,16,43]	   using	   in	   vitro	   electrophysiology.	  Cyclopropane,	   another	   anaesthetic	   gas,	   has	   also	   been	   shown	   to	   inhibit	   NMDA	  receptors	  while	  having	  little	  influence	  on	  GABAA	  receptors	  [44].	  	  A	  number	  of	  other	  anaesthetic	  agents	  capable	  of	  producing	  general	  anaesthesia	  have	   also	   been	   shown	   to	   inhibit	   NMDA	   receptors	   when	   applied	   at	   clinically	  relevant	   concentrations.	   These	   include	   hexanol,	   octanol,	   isoflurane,	   halothane,	  chloroform,	   and	   benzene	   [44].	  Many	   of	   these	   also	   potentiate	  GABAA	   receptors,	  however,	   with	   NMDA	   receptor	   inhibition	   considered	   to	   be	   of	   secondary	  importance	  in	  their	  anaesthetic	  mechanism.	  	  	  Inhibition	   of	   the	  NMDA	   receptor	   is	   known	   to	   result	   in	   sedation,	   loss	   of	  motor	  coordination,	   analgesia,	   and	   immobility	   [45],	   however	   the	   ability	   of	   NMDA	  receptor	  antagonism	  alone	  to	  induce	  a	  reversible	  loss	  of	  consciousness	  remains	  contentious.	  	  NMDA	  receptor	  blockers	  such	  as	  ketamine	  and	  phencyclidine	  (PCP)	  will,	  at	  high	  enough	   concentrations,	   produce	   sedation	   and	   then	   loss	   of	   consciousness.	  	  However,	   even	   apparently	   selective	   NMDA	   antagonists	   are	   believed	   to	   recruit	  additional	  receptor	  targets	  at	  sufficiently	  elevated	  concentrations	  [46].	  Ketamine	  in	  particular	   is	  known	   to	  affect	  a	  number	  of	   receptor	   targets	   [15].	  Further,	   the	  loss	  of	  consciousness	  produced	  by	  ketamine	  and	  agents	  like	  it	  is	  unlike	  that	  seen	  for	  other	  anaesthetic	  agents,	  more	  akin	  to	  a	  state	  of	  catalepsy	  than	  the	  true	  loss	  of	  consciousness	  observed	  with	  other	  general	  anaesthetics.	  	  	  NMDA	  blockers	   are	   thus	   often	   referred	   to	   as	   dissociative	   anaesthetics,	   as	   they	  produce	  behaviours	  and	  patterns	  of	  brain	  activity	  [15]	  unlike	  those	   induced	  by	  other	  general	  anaesthetics,	  even	  those	  anaesthetics	  acting	  at	   the	  same	  receptor	  (e.g.	   xenon).	   The	   reasons	   for	   the	   differences	   between	   xenon	   and	   ketamine	  anaesthesia	   may	   be	   due	   to	   the	   molecular	   mechanism	   of	   receptor	   inhibition;	  ketamine	   and	   PCP	   inhibit	   the	   NMDA	   receptor	   by	   high	   affinity	   open	   channel	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blockade	   [47],	   while	   xenon	   and	   nitrous	   oxide	   bind	   competitively	   at	   the	   co-­‐agonist	  glycine	  site	  [48].	  	  There	  is	  little	  doubt	  that	  inhibition	  of	  the	  NMDA	  receptor	  plays	  an	  important	  role	  in	   the	   actions	   of	   xenon,	   nitrous	   oxide,	   and	   certain	   other	   volatile	   agents,	  particularly	  in	  regards	  to	  their	  analgesic	  effects	  [15].	  However,	  it	  is	  also	  true	  that	  certain	  NMDA	  receptor	  antagonists	  (e.g.	  gavestinel)	  have	  little	  or	  no	  anaesthetic	  potency.	   The	   role	   of	   NMDA	   receptor	   antagonism	   in	   general	   anaesthesia	   thus	  remains	  interesting	  but	  unproven;	  it	  is	  possible	  that	  actions	  at	  additional	  targets	  may	   account	   for	   the	   ability	   of	   xenon	   and	   other	   agents	   to	   produce	   loss	   of	  consciousness.	  Definitive	  data	  on	  the	  subject	  is	  required.	  	  	  	  
1.5	  TREK-­‐1	  (K2P2.1)	  channels	  	  TREK-­‐1	  channels	  (designated	  K2P2.1	  in	  current	  IUPHAR	  nomenclature)	  are	  a	  part	  of	   the	   15-­‐member	   family	   of	   two	   pore	   domain	   potassium	   (K2P)	   channels,	  responsible	  for	  the	  K+	  “leak”	  or	  “background”	  current	  first	  predicted	  by	  Hodgkin	  and	  Huxley	  in	  1952	  [49].	  They	  are	  open	  at	  resting	  membrane	  potentials	  and	  thus	  act	   to	   hyperpolarise	   neurons	   and	   limit	   neuronal	   excitability.	   K2P	   channels	   are	  unusual	   in	   that	   they	   are	   formed	   from	   dimers	   of	   subunits	   comprising	   four	  transmembrane	  domains,	  each	  with	  two	  pore-­‐forming	  domains	  (Figure	  1.2).	  This	  is	   in	   contrast	   to	   the	   typical	   four	   subunits	   from	  which	   voltage-­‐gated	   potassium	  channels	  are	  formed	  [50].	  	  	  As	  a	  family,	  the	  K2P	  channels	  are	  expressed	  widely	  and	  differentially	  throughout	  the	   body,	   playing	   important	   roles	   in	   immune,	   heart,	   and	   kidney	   function.	   	   K2P	  channels	  are	   insensitive	   to	  conventional	  K+	  channel	  blockers	  (4-­‐aminopyridine,	  tetraethylammonium,	  Cs+,	  and	  Ba2+)	  [51]	  with	  certain	  subfamilies	  (differentially)	  regulated	   by	   G-­‐protein	   coupled	   receptors	   (see	   	   Mathie,	   2007	   [52]	   for	   a	  comprehensive	  review).	  Several	  members	  of	  the	  K2P	  family,	  TREK-­‐1	  included,	  are	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Figure	  1.2:	  TREK-­‐1	  channel	  subunit	  topology,	  dimeric	  channel	  structure,	  and	  expression.	  
A.)	   Channel	   subunits	   consist	   of	   four	   transmembrane	   segments	   (M1-­‐M4),	   and	   two	   pore-­‐
forming	  (P)	  domains,	  arranged	  in	  tandem.	  B.)	  Two	  subunits	  associate	  to	  form	  a	  functional	  
ion	  channel,	  permeable	  to	  K+	  ions.	  The	  channel	  opens	  in	  response	  to	  a	  variety	  of	  stimuli,	  
including	  stretch,	  heat,	   intracellular	  acidosis,	   lipids,	  and	  general	  anaesthetic	  agents.	  The	  
cytosolic	  C-­‐terminal	  domain	  (CTD)	  has	  a	  key	  role	  in	  the	  regulation	  of	  TREK-­‐1	  activity.	  C.)	  
TREK-­‐1	   is	  expressed	   in	  GABA-­‐containing	   interneurons	  of	   the	  caudate	  nucleus,	  as	  well	  as	  
the	   prefrontal	   cortex,	   hippocampus,	   and	   hypothalamus.	   Re-­‐drawn	   in	   part	   from	  Honore,	  
2007	  [41].	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Figure	  1.3:	  Xenon	  is	  an	  NMDA	  receptor	  inhibitor.	  A.)	  80%	  xenon	  inhibits	  NMDA	  activated	  
currents	   in	   neurons	   clamped	   at	   -­‐60mV.	   Maximal	   response	   is	   reduced	   by	   around	   60%,	  
while	   EC50	   and	   Hill	   co-­‐efficient	   values	   are	   not	   significantly	   changed	   –	   i.e.	   receptor	  
inhibition	  by	  xenon	  is	  non-­‐competitive	  with	  NMDA.	  B.)	  Xenon	  selectively	  inhibits	  the	  late,	  
NMDA-­‐mediated	   component	   of	   glutamatergic	   excitatory	   postsynaptic	   currents	   (EPSCs).	  
Reproduced	  from	  Franks	  et	  al,	  1998	  [13].	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This	   insight	  allows	   for	  a	  structured	  series	  of	  mutagenesis	  studies,	   investigating	  which	  of	  these	  amino	  acids	  are	  critical	  for	  the	  binding	  of	  xenon	  at	  the	  GluN1	  co-­‐agonist	   site;	   one	   of	   the	   main	   aims	   of	   the	   present	   study.	   Care	   must	   be	   taken,	  however,	   when	  mutating	   residues	   within	   the	   co-­‐agonist	   site	   as	   any	   change	   in	  glycine	   affinity	   of	   the	   mutant	   receptor	   will	   severely	   impact	   the	   competitive	  interaction	  between	  glycine	  and	  xenon	  at	  the	  binding	  site.	  	  	  For	   example,	   one	   particular	   GluN1	   mutation,	   F639A,	   known	   to	   reduce	   xenon	  sensitivity	  of	  NMDA	  receptors	  has	  previously	  been	  described	  [44].	  Dickinson	  et	  al	   [48]	   have	   shown	   that	   the	   F639A	   mutation	   actually	   produces	   this	   effect	   by	  increasing	   the	   NMDA	   receptor’s	   apparent	   affinity	   for	   glycine.	   It	   is	   therefore	  important	   to	   ensure	   that	   the	   anaesthetic	   inhibition	   of	   any	   mutant	   receptor	   is	  assessed	  at	  the	  same	  relative	  glycine	  concentration	  on	  the	  glycine	  concentration-­‐response	  curve,	   lest	   increases	   in	  glycine	  affinity	  be	  mistaken	   for	  a	   reduction	   in	  anaesthetic	  sensitivity.	  	  	  	  
	  
1.7	  Anaesthesia	  and	  neuroprotection	  
	  The	   term	   “neuroprotection”	   refers	   to	   strategies	   intended	   to	   preserve	   neuronal	  structure	  and/or	  function	  in	  the	  event	  of	  an	  injury	  to	  the	  brain,	  and	  may	  refer	  to	  protection	  against	   either	  acute	   injury	   to	   the	  brain	   (stroke,	   trauma,	   etc.),	   or	   the	  cellular	   events	   associated	   with	   chronic	   neurodegenerative	   disorders	  (Alzheimer’s,	   Parkinson’s,	   etc.).	   Smith	   et	   al	   [67]	   have	   recently	   defined	  neuroprotection	  as	  “any	  strategy,	  or	  combination	  of	  strategies,	  that	  antagonizes,	  interrupts,	  or	  slows	  the	  sequence	  of	  injurious	  biochemical	  and	  molecular	  events	  that,	  if	  left	  unchecked,	  would	  eventuate	  in	  irreversible	  […]	  injury”.	  	  Anaesthetic-­‐related	   neuroprotection	   has	   been	   discussed	   from	   as	   early	   as	   the	  1960’s,	   in	   the	   first	   instance	   regarding	   the	   ability	   of	   barbiturates	   to	   protect	  against	   ischemic	   injury	   by	   reducing	   neuronal	   energy	   consumption.	   This	  proposed	  mechanism	  of	  neuroprotection	  proved	   controversial,	   given	   that	   even	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high-­‐dose	  barbiturates	  were	  not	  believed	  to	  reduce	  brain	  metabolism	  any	  more	  than	   brain	   ischemia	   itself	   [68],	   indeed	   clinical	   trials	   in	   human	   cardiac	   arrest	  found	   no	   protective	   effect	   for	   the	   barbiturate	   thiopental	   [69].	   Confusingly,	  thiopental	   did	   show	   some	   neuroprotective	   efficacy	   against	   focal	   cerebral	  ischemic	  injury	  in	  vivo	  [70].	  	  	  Presently,	   the	   debate	   regarding	   anaesthetic-­‐related	   neuroprotection	   remains	  just	   as	   active,	   with	   some	   studies	   arguing	   for	   a	   neuroprotective	   effect	   for	  anaesthetics	   [71-­‐77],	   and	   others	   arguing	   a	   neurotoxic	   effect	   [78-­‐81].	   Similarly,	  the	   longevity	   of	   any	   neuroprotection	   conferred	   by	   anaesthetics	   remains	  contentious;	   most	   studies	   have	   thus	   far	   failed	   to	   show	   effective	   long-­‐term	  protection,	   even	  when	   significant	   degrees	   of	   short-­‐term	   neuroprotection	  were	  observed.	  	  Nevertheless,	  a	  consensus	  is	  emerging	  that	  certain	  anaesthetic	  agents	  are	  able	  to	  provide	   neuroprotection	   against	   a	   number	   of	   neuronal	   insults.	   Similarly,	   it	   is	  now	  apparent	   that	   anaesthetics	   are	   able	   to	   influence	   the	   injurious	  biochemical	  and	  molecular	  processes	  involved	  in	  neuronal	  injury	  beyond	  a	  simple	  reduction	  in	  neuronal	  energy	  consumption,	  acting	   instead	  at	  specific	  molecular	   targets	   in	  the	  brain.	  	  
1.7.1	  Molecular	  targets	  of	  neuroprotection	  The	   link	   between	   anaesthesia	   and	   neuroprotection	   suggests	   an	   obvious	  involvement	   of	   some	   of	   the	   same	   molecular	   targets	   in	   both	   pharmacological	  phenomena.	   A	   growing	   understanding	   of	   the	   biochemical	   pathways	   and	  processes	   underlying	   the	   different	   forms	   of	   neuronal	   injury	   also	   supports	   this	  theory.	   Proposed	   mechanisms	   of	   neuroprotection	   now	   include	   inhibition	   of	  excitatory	   activity,	   potentiation	   of	   inhibitory	   activity,	   and	   influences	   on	  intracellular	  signalling	  cascades	  resulting	  in	  changes	  in	  gene	  expression.	  	  	  The	   overactivation	   of	   NMDA	   receptors	   is,	   in	   particular,	   believed	   to	   form	   an	  important	   component	  of	   the	  pathology	  of	  degenerative	  processes	  as	  diverse	  as	  stroke,	   traumatic	   brain	   injury,	   and	   certain	   of	   the	   neurodegenerative	   disorders	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[82].	  The	  excessive	  entry	  of	  calcium	  into	  cells	  following	  overactivation	  of	  NMDA	  receptors	   initiates	  numerous	  biological	   cascades	   terminating	   in	   cell	   damage	  or	  death,	  in	  a	  process	  now	  termed	  excitotoxicity.	  Potentiation	  of	  inhibitory	  systems,	  or	   inhibition	   of	   excitatory	   systems	   may	   thus	   act	   to	   limit	   excitotoxic	   damage.	  Given	  its	  pivotal	  role	  and	  relatively	  upstream	  position	  in	  the	  excitotoxic	  cascade,	  the	   NMDA	   receptor	   is	   considered	   to	   be	   an	   important	   molecular	   target	   for	  neuroprotective	  treatments.	  	  The	  potential	  for	  NMDA	  antagonists	  to	  act	  as	  neuroprotective	  interventions	  has,	  in	   fact,	   been	   recognised	   for	   some	   time	   [83].	   However,	   NMDA	   receptor	  antagonists	  have	  thus	  far	  performed	  poorly	  in	  the	  majority	  of	  clinical	  trials,	  due	  either	   to	   disruption	   of	   normal	   glutamatergic	   transmission	   [82],	   undesirable	  cardiovascular	  complications	  [84],	  or	  psychotomimetic	  side	  effects	  [85].	  	  The	   activation	   of	   K2P	   channels	   (or	   other	   inhibitory	   systems)	   will	   result	   in	  neuronal	   hyperpolarisation,	   an	   effect	  which	  may	   act	   to	   limit	   excitoxic	   damage.	  For	   example,	   activation	   of	   the	   K2P	   channel	   TREK-­‐1	   has	   been	   implicated	   in	   the	  neuroprotective	   actions	   of	   the	   fatty	   acid	   linolenate	   [63].	   TREK-­‐1	   activation	   at	  pre-­‐synaptic	  sites	  will	  act	  to	  limit	  glutamate	  release,	  while	  TREK-­‐1	  activation	  at	  postsynaptic	   sites	   will	   limit	   neuronal	   depolarisation	   and	   excitation	   by	  postsynaptic	  glutamatergic	  ion	  channels.	  	  It	   is	   likely	   that	   anaesthetics	   are	   neuroprotective	   by	   one	   of	   the	   mechanisms	  discussed	   above;	   antagonistic	   action	   at	   NMDA	   receptors,	   potentiation	   of	  inhibitory	   transmission	  at	  GABA	  or	  TREK-­‐1,	  or	  other	  actions	   limiting	  excitotxic	  damage	  and	  thus	  immediate	  neuronal	  death.	  Additional	  neuroprotective	  benefit	  may	  come	  from	  limiting	  the	  apoptotic	  cell	  death	  of	  damaged	  neurons,	  or	  at	  other	  downstream	  sites	  following	  glutamate	  excitotoxicity.	  	  
1.7.2	  Neuroprotection	  by	  xenon	  It	   was	   the	   discovery	   that	   xenon	   inhibits	   the	   NMDA	   receptor	   [13]	   that	   first	  prompted	   interest	   in	  whether	  xenon	  might	  hold	  potential	   as	  a	  neuroprotective	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intervention.	  The	  active	  focus	  of	  xenon	  research	  is	   for	   its	  role	   in	  this	  particular	  application.	  	  	  Shortly	   after	   the	   discovery	   that	   xenon	   is	   an	   NMDA	   receptor	   inhibitor,	   it	   was	  shown	   that	   xenon	   provides	   neuronal	   cells	   a	   concentration-­‐dependent	  neuroprotection	   against	   NMDA,	   glutamate,	   and	   oxygen-­‐glucose	   deprivation	  induced	  injury	  when	  co-­‐administered	  with	  the	  injuring	  agent	  both	  in	  vitro	  and	  in	  
vivo	  [86].	  This	  acute	  neuroprotection	  has	  been	  proven	  effective	  against	  insults	  as	  diverse	   as	   ischemia,	   neonatal	   asphyxia,	   and	   neurocognitive	   deficit	   following	  cardiac	  bypass	  surgery	  in	  a	  number	  of	  in	  vitro	  and	  in	  vivo	  models	  [75-­‐77,87-­‐90].	  	  	  Given	  the	  known	  link	  between	  NMDA	  receptor	  antagonism	  and	  neuroprotection,	  inhibition	   of	   NMDA	   receptors	   by	   xenon	   is	   a	   plausible	   mechanism	   for	   xenon’s	  neuroprotective	  action.	  However,	  it	  is	  only	  recently	  that	  any	  direct	  link	  between	  NMDA	   receptor	   inhibition	   and	   xenon	   neuroprotection	   has	   been	   demonstrated.	  Experiments	   by	   Banks	   et	   al	   [91]	   suggest	   that	   xenon	   neuroprotection	   against	  hypoxic/ischemic	   injury	   in	   vitro	   is	   mediated	   via	   xenon’s	   now	  well	   established	  competitive	   antagonism	   at	   the	   NMDA	   receptor	   glycine	   site.	   Raising	   glycine	  concentration	  in	  these	  experiments	  reversed	  xenon	  neuroprotection,	  consistent	  with	  a	  neuroprotective	  action	  mediated	  by	  xenon	  binding	  at	  the	  receptor	  glycine	  site.	  	  Further	   to	   this	   action	   as	   an	   acute	   neuroprotectant,	   xenon	   can	   also	   provide	  neuroprotection	  when	  administered	  in	  pre-­‐conditioning	  paradigms	  where	  xenon	  is	  present	  before,	  but	  not	  during	  or	  after,	  the	  insult	  [92].	  	  At	   present	   there	   exist	   no	   effective	   pharmacological	   intervention	   strategies	  addressing	   neuroprotection	   in	   the	   treatment	   of	   ischemic	   or	   traumatic	   brain	  injuries.	   However,	   rapid	   onset	   of	   action,	   good	   cardiovascular	   stability,	   a	  favourable	  metabolic	  profile,	  and	   lack	  of	   inherent	  neurotoxicity	  make	  xenon	  an	  extremely	   promising	   neuroprotective	   therapy.	   Xenon	   is	   currently	   undergoing	  clinical	   trials	   assessing	  neuroprotective	   efficacy	   against	   ischemic	  brain	   injuries	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1.8	  Traumatic	  brain	  injury	  	  Traumatic	   brain	   injury	   (TBI)	   is	   a	   silent	   epidemic;	   responsible	   for	   close	   to	   a	  million	  visits	  to	  A&E	  in	  the	  UK	  each	  year,	  and	  representing	  the	  leading	  cause	  of	  death	  and	  disability	  in	  under	  45’s	  in	  the	  developed	  world	  [94].	  TBI	  is	  associated	  with	  a	  poor	  prognosis,	  often	  resulting	  in	  permanent	  neurological	  deficits	  in	  both	  motor	   and	   cognitive	   function	   [95],	   thus	   the	   economic	   (and	   social)	   burdens	  associated	  with	  long-­‐term	  healthcare	  following	  TBI	  are	  substantial;	  estimated	  at	  around	  €33	  billion	  annually	  in	  Europe	  alone	  [96].	  	  Blunt	   trauma	   TBI	   is	   a	   form	   of	   acquired	   brain	   injury,	   caused	   by	   an	   external	  trauma	  damaging	   the	  brain.	  Blunt	   trauma	  brain	   injury	   can	  be	   classified	  by	   the	  mechanism	  and	  severity	  of	  injury,	  and	  is	  characterised	  by	  a	  “primary	  injury”	  -­‐	  the	  direct	   outcome	   of	   the	   traumatic	   insult	   –	   followed	   by	   a	   “secondary	   injury”	  beginning	   soon	   after	   the	   initial	   mechanical	   trauma	   and	   spreading	   into	  neighbouring	  brain	  tissue	  in	  the	  hours	  and	  days	  following	  trauma	  [95,97].	  	  	  The	  primary,	  mechanical,	  injury	  is	  usually	  focal	  and	  irreversible,	  while	  secondary	  injury	   is	   often	   the	  more	  damaging	   stage,	   responsible	   for	   the	  majority	  of	   short-­‐	  and	  long-­‐term	  neurological	  and	  cognitive	   impairments	  resulting	  from	  TBI.	  That	  the	   major	   burden	   of	   injury,	   responsible	   for	   the	   majority	   of	   trauma-­‐related	  deaths,	   occurs	   only	  after	   the	  physical	   insult	   is	   reflected	   in	   the	   fact	   that	   a	   large	  percentage	  of	  trauma	  deaths	  occur	  weeks	  after	  the	  event.	  Treatments	  to	  prevent	  or	   limit	   the	   development	   of	   secondary	   injury	   are	   thus	   of	   considerable	   clinical	  importance.	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1.8.1	  Pathophysiology	  of	  secondary	  injury	  The	  cellular	  and	  molecular	  processes	  underlying	  secondary	   injury	  are	  complex,	  and	   involve	   multiple	   signalling	   pathways	   [98].	   Glutamate	   excitotoxicity	   is,	  however,	  considered	  to	  play	  a	  key	  role	   in	   the	  development	  of	  secondary	   injury	  [99-­‐101],	  and	  represents	  a	  relatively	  upstream	  event	   in	   the	  neurotoxic	  cascade	  that	   terminates	   in	   neuronal	   death	   (Figure	   1.4).	   Glutamate	   excitotoxicity	   is	  believed	  to	  be	  a	  common	  mechanism	  in	  many	  different	   types	  of	  TBI,	  as	  well	  as	  other	  pathological	  conditions	  such	  as	  brain	  ischemia	  [82,102].	  	  Trauma-­‐related	  release	  of	  glutamate	  and	  other	  excitatory	  amino	  acids	  will	  result	  in	   the	   over-­‐activation	   of	  NMDA	   and	   other	   glutamatergic	   receptors.	   Reversal	   of	  glutamate	   transporters	   and	   mechanoporation	   of	   cell	   membranes	   will	   further	  contribute	   to	   the	   massive	   spillover	   of	   glutamate	   following	   trauma	   [102-­‐104].	  NMDA	  receptor	  over-­‐activation	  causes	  a	  massive	  influx	  of	  Ca2+	   into	  cells,	  which	  will	  in	  turn	  promote	  additional	  Ca2+	  release	  from	  intracellular	  stores.	  	  Raised	   intracellular	   Ca2+	   initiates	   a	   variety	   of	   intracellular	   processes	   that	   can	  result	  in	  neuronal	  injury	  and	  eventually	  neuronal	  death.	  	  Prime	  among	  these	  are	  activation	   of	   the	   caspase	   and	   calpain	   cysteine	   proteases	   [97,101,105],	   two	  pathways	   resulting	   in	   apoptotic	   and	   necrotic	   cell	   death.	   Other	   factors	   now	  believed	   to	   be	   important	   in	   the	   neurotoxic	   cascade	   include	   mitochondrial	  dysfunction,	  free	  radical	  generation,	  and	  the	  disruption	  of	  lysosomal	  membranes.	  Cell	  survival	  or	  death	  following	  TBI	  is	  likely	  influenced	  by	  the	  ultimate	  balance	  of	  all	  these	  factors	  [98,105,106].	  	  Another	   important	   consideration	   and	   complicating	   factor	   in	   the	   outcome	  following	   TBI	   are	   secondary	   and	   systemic	   complications	   such	   as	   traumatic	  haematoma,	  oedema,	  elevated	  intracranial	  pressure	  (ICP),	  and	  hypoxic-­‐ischemic	  injury.	   TBI	   most	   often	   occurs	   in	   the	   context	   of	   polytrauma,	   alongside	   other	  injuries	   such	   as	   blood	   loss,	   hypoxia,	   infection,	   and	   other	   related	   problems.	   All	  these	   factors	   will	   complicate	   treatment	   of	   TBI	   and	   potentially	   increase	   post-­‐traumatic	  mortality	  and	  morbidity	  [97].	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Figure	  1.4:	  A	  simplified	  summary	  of	  the	  cellular	  injury	  cascades	  associated	  with	  traumatic	  
brain	   injury.	   An	   initial,	   primary,	   impact	   triggers	   a	   number	   of	   deleterious	   intracellular	  
processes	  that	  play	  out	  over	  the	  hours	  to	  weeks	  following	  injury.	  Often	  it	  is	  this	  secondary,	  
expanding	   injury	   that	   is	   responsible	   for	   the	   majority	   of	   damage	   associated	   with	   a	  
traumatic	  injury.	  Re-­‐drawn	  from	  McAllister,	  2011	  [97].	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1.9	   Xenon’s	   clinical	   profile	   and	   suitability	   as	   a	  
neuroprotective	  intervention	  in	  traumatic	  brain	  injury	  	  In	   regards	   to	   anaesthetic	   properties	   and	   suitability	   for	   use	   in	   general	  anaesthesia,	  xenon	  has	  been	  described	  as	  the	  “ideal”	  anaesthetic.	  This	  is	  thanks	  to	  its	  favourable	  properties	  of	  fast	  induction	  and	  emergence,	  good	  cardiovascular	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stability,	  and	  a	   favourable	  metabolic	  profile	   that	   leaves	  xenon	   largely	  devoid	  of	  toxic	  side-­‐effects.	  	  Xenon’s	   favourable	  properties	  of	   rapid	   induction	  and	  emergence	  arise	   from	   its	  low	   solubility	   in	   both	   lipids	   and	   blood.	   At	   0.115	   and	   1.9	   respectively,	   xenon’s	  blood-­‐gas	   and	  oil-­‐gas	  partition	   coefficients	   are	   considerably	   lower	   than	   that	   of	  other	   inhalational	   anaesthetics	   [93].	   In	   real	   terms,	   this	   low	   blood	   solubility	  translates	   to	  a	   rapid	  equilibration	  of	  xenon	  between	   inhaled	  air	  and	   the	  blood,	  with	  the	  concentration	  of	  anaesthetic	  in	  the	  brain	  closely	  tracking	  that	  in	  arterial	  blood.	  Similarly,	  low	  lipid	  solubility	  prevents	  xenon	  entering	  body	  fat;	  a	  process	  responsible	   for	   a	   slow	   phase	   of	   anaesthetic	   equilibration	   and	   thus	   prolonged	  induction	  period.	  The	  same	  processes	  in	  reverse	  result	  in	  rapid	  elimination	  from	  the	  body	  and	  account	  for	  rapid	  emergence	  from	  xenon	  anaesthesia,	  regardless	  of	  the	  anaesthetic	  duration	  [112].	  	  	  Being	  a	  simple	  monatomic	  element	  renowned	  for	  low	  chemical	  reactivity,	  xenon	  does	   not	   undergo	   any	   form	  of	  metabolism	   in	   either	   the	   kidney	   or	   liver,	   and	   is	  instead	  excreted	  unchanged	  from	  the	  lungs.	  The	  functional	  consequence	  of	  this	  is	  a	  favourable	  safety	  profile,	  and	  indeed	  xenon	  has	  thus	  far	  been	  found	  devoid	  of	  allergic,	   mutagenic,	   carcinogenic,	   and	   foetotoxic	   effects	   [113,114].	   Further,	  unlike	  other	  inhaled	  anaesthetic	  agents,	  xenon	  does	  not	  appear	  to	  interact	  with	  or	   alter	   the	   pharmacodynamic	   profile	   of	   anaesthetic	   pre-­‐medication	  neuromuscular	  blockers	  [115,116].	  	  When	   compared	   against	   other	   anaesthetic	   agents,	   xenon	   anaesthesia	   exhibits	  excellent	   haemodynamic	   stability	   [117,118],	   with	   mean	   arterial	   pressure	  remaining	   higher,	   and	   heart	   rate	   lower,	   than	   for	   certain	   other	   anaesthetic	  protocols	   [119].	   Evidence	   also	   indicates	   that	   xenon	  has	  no	   effect	   on	   either	   left	  ventricular	   function	   or	   myocardial	   contractility	   [120,121].	   Studies	   in	   both	  cardiac	   and	   non-­‐cardiac	   patients	   confirm	   this	   lack	   of	   detrimental	   effect	   upon	  cardiovascular	  function	  [122-­‐124],	  indeed	  there	  is	  some	  indication	  that	  xenon	  is	  cardioprotective	  after	  coronary	  artery	  occlusion,	  and	  may	  even	  precondition	  the	  heart	  against	  the	  same	  [125,126].	  	  
41	  





1.10	  Pharmacology	  of	  the	  other	  noble	  gases	  	  That	  xenon	  is	  both	  anaesthetic	  and	  neuroprotective	  suggests	  that	  other	  members	  of	   the	   family	  of	   inert	  gases	  might	  also	  possess	  similar	  pharmacological	  activity.	  The	   early	   promise	   shown	   by	   xenon	   in	   studies	   of	   neuroprotection	   has	   led	   to	  growing	   interest	   in	   the	   neuroprotective	   potential	   of	   the	   gases	   helium,	   neon,	  argon,	   and	   krypton,	   in	   part	   prompted	   by	   their	   relative	   abundance,	   and	   thus	  reduced	  cost,	  as	  compared	  with	  xenon.	  	  Historically,	   these	   have	   received	   little	   attention	   from	   the	   research	   community,	  although	   the	   lighter	  members	   of	   the	   group	   –	   namely	   neon	   and	   helium	   -­‐	   have	  been	   proven	   devoid	   of	   anaesthetic	   potency	   [93],	   and	   the	   sparse	   (and	   divisive)	  accounts	   of	   helium	   neuroprotection	   are	   believed	   to	   arise	   through	   a	   physical	  rather	   than	   pharmacological	   mechanism	   [133],	   whereby	   breathing	   helium	  causes	   hypothermia.	   The	   neuroprotective	   effects	   of	   hypothermia	   are	   well	  established,	  indeed	  hypothermia	  is	  even	  used	  clinically	  in	  this	  application	  [108].	  	  	  Conversely,	   the	   heavier	  members	   of	   the	   group	   -­‐	   argon	   and	   krypton	   -­‐	   are	   both	  anaesthetic	  at	  elevated	  pressures:	  15atm	  and	  4.5atm	  respectively	  [93].	  Further,	  argon	  at	  normobaric	  pressures	  (74-­‐95%)	  has	  displayed	  neuroprotective	  efficacy	  in	   a	   number	   of	   in	   vitro	   studies	   against	   various	   insults	   [134-­‐136].	   This	  neuroprotective	   effect	   for	   argon	   has	   also	   been	   observed	   in	   vivo	   against	  hypoxic/ischemic	  injury	  [137,138].	  The	  single	  literature	  study	  assessing	  in	  vitro	  neuroprotection	   afforded	   by	   krypton	   found	   no	   evidence	   for	   a	   neuroprotective	  effect	  [134].	  However,	   it	  remains	  unclear	  why	  this	  might	  be,	  or	  indeed	  whether	  lack	  of	  efficacy	  is	  limited	  only	  to	  this	  model	  of	  hypoxic/ischemic	  injury.	  	  Regardless	   of	   this	   divisive	   literature,	   evidence	   that	   xenon	   activates	   TREK-­‐1	  channels	   [19]	   and	   inhibits	  NMDA	   receptors	   [13]	   in	   a	   concentration-­‐dependent	  manner	  suggests	  that	  the	  other	  noble	  gases	  may	  exert	  a	  similar	  effect	  at	  the	  same	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1.11	  Aims	  and	  hypotheses	  	  This	   study	   was	   designed	   broadly	   as	   an	   investigation	   of	   the	   molecular	   targets	  underlying	   neuroprotection,	   and	   as	   an	   assessment	   of	   the	   neuroprotective	  potential	  of	  the	  entire	  series	  of	  inert	  gases.	  	  	  The	  anaesthetic	  gas	  xenon	  thus	  far	  appears	  to	  confer	  neuroprotection	  against	  a	  number	   of	   injury	   types,	   without	   the	   adverse	   side	   effects	   that	   have	   hampered	  many	  other	  putative	  neuroprotective	  interventions.	  Competitive	  inhibition	  at	  the	  NMDA	  receptor	  glycine	  site	  is	  a	  plausible	  mechanism	  for	  xenon	  neuroprotection;	  indeed	   xenon’s	   actions	   at	   this	   site	   have	   been	   shown	   to	   underlie	   its	  neuroprotective	  effect	  against	  hypoxic/ischemic	  brain	  injury	  in	  vitro.	  	  Chapter	   3	   describes	   a	   series	   of	   experiments	   designed	   to	   further	   dissect	   the	  molecular	   interaction	  between	  xenon	  and	   the	  NMDA	  receptor	  at	   the	  GluN1	  co-­‐agonist	  glycine	  site.	  The	  aim	  of	  this	  chapter	  was	  to	  identify	  point	  mutations	  in	  the	  NMDA	   receptor	   that	   prevent	   xenon	   binding	   at	   the	   co-­‐agonist	   glycine	   site	   but	  which	   leave	   normal	   receptor	   function	   otherwise	   intact.	   Previous	   modelling	  simulations	  have	  identified	  a	  small	  number	  of	  amino	  acids	  of	  high	  importance	  in	  xenon	  binding;	  determining	  which	  of	  these	  are	  critical	   for	  the	  binding	  of	  xenon	  was	  the	  focus	  of	  this	  investigation.	   	  Further,	  the	  hypothesis	  that	  the	  anaesthetic	  agents	   sevoflurane,	   nitrous	   oxide,	   and	   cyclopropane	   also	   act	   at	   the	   GluN1	   co-­‐agonist	  glycine	  site	  was	  also	  tested.	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Set	   out	   in	   chapter	   4	   are	   the	   results	   of	   a	   series	   of	   experiments	   designed	   to	  investigate	  the	  effects	  of	  the	  other	  noble	  gases	  on	  two	  known	  molecular	  targets	  of	   xenon:	   the	   NMDA	   receptor	   and	   the	   K2P	   TREK-­‐1	   channel.	   Data	   from	   a	  companion	  study	  (Katie	  Harris)	  has	  determined	  that	  xenon	  and	  argon	  are	  both	  neuroprotective	   against	   traumatic	   injury	   in	   vitro,	   while	   helium,	   neon,	   and	  krypton	  are	  not.	  The	  aim	  of	   this	   chapter	  was	   to	   test	   the	  hypothesis	   that	  xenon	  and	  argon	  share	  a	  common	  mechanism	  for	  their	  neuroprotective	  effects,	  and	  to	  determine	   definitively	   whether	   the	   other	   noble	   gases	   have	   effects	   at	   NMDA	  receptors	  or	  TREK-­‐1	  channels.	  	  Finally,	   Chapter	   5	   describes	   an	   animal	   study	   assessing	   the	   neuroprotective	  efficacy	   of	   xenon	   against	   traumatic	   brain	   injury	   in	   vivo,	   using	   the	   rodent	  controlled	   cortical	   impact	   model.	   The	   aim	   of	   this	   chapter	   was	   to	   test	   the	  hypothesis	  that	  xenon	  can	  protect	  against	  the	  development	  of	  secondary	   injury	  and	   improve	   neurological	   outcome	   after	   traumatic	   brain	   injury	   in	   vivo.	   Xenon	  treatment	  was	  applied	  at	  a	  number	  of	  timepoints	  post-­‐TBI,	  in	  order	  to	  determine	  the	  therapeutic	  time	  window	  in	  which	  treatment	  can	  be	  applied	  and	  still	  remain	  beneficial.	  	  
1.11.1	  Hypotheses	  In	  light	  of	  the	  above,	  the	  hypotheses	  for	  this	  thesis	  are	  as	  follows:	  	  1. Aromatic	   amino	   acid	   residues	   are	   essential	   for	   the	   binding	   of	   xenon	   at	   the	  NMDA	  receptor	  GluN1	  glycine	  site.	  2. Glycine	   and	   xenon	   bind	   to	   distinct	   but	   overlapping	   sites	   on	   the	   NMDA	  receptor	  GluN1	  subunit,	  and	  it	  is	  thus	  possible	  to	  disrupt	  the	  binding	  of	  one	  of	  these	  without	  affecting	  the	  other.	  3. The	  anaesthetic	  agents	  sevoflurane,	  nitrous	  oxide,	  and	  cyclopropane	  are	  also	  able	  to	  inhibit	  NMDA	  receptors,	  by	  acting	  at	  the	  GluN1	  glycine	  site.	  	  4. Xenon	  and	  argon	  share	  a	  common	  mechanism	  of	  neuroprotection.	  5. The	  other	  noble	  gases	  are	  able	  to	  influence	  the	  NMDA	  receptor	  and	  TREK-­‐1	  channels	  in	  the	  same	  way	  as	  xenon.	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  6. Xenon	  can	  protect	  against	  the	  development	  of	  secondary	  injury	  in	  an	  in	  vivo	  model	  of	  traumatic	  brain	  injury.	  7. Xenon	   treatment	   can	   improve	   neurological	   function	   after	   traumatic	   brain	  injury.	  8. Xenon	   treatment	   can	   be	   delayed	   by	   clinically	   relevant	   periods	   and	   still	  remain	  neuroprotective.	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  2.0	  Materials	  &	  Methods	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  All	   experiments	   were	   carried	   out	   in	   accordance	   with	   the	   appropriate	   risk	  assessments	  and	  in	  line	  with	  college	  safety	  and	  best	  practice	  policies.	  	  
	  
2.1	  Cell	  Culture	  &	  Transfection	  
	  
2.1.1	  Routine	  cell	  passage	  A	  single	  mammalian	  cell	  line	  was	  used	  for	  all	  electrophysiological	  experiments:	  a	  human	   embryonic	   kidney	   cell	   (HEK-­‐293)	   subclone	   stably	   transfected	  with	   the	  SV40	  virus	  large	  T-­‐antigen,	  known	  as	  tsA201.	  Cells	  were	  grown	  in	  T(225)	  culture	  flasks	   in	  a	  routine	  cell	  passage	  medium	  (minimum	  essential	  media	  with	  Earle’s	  salts,	   L-­‐glutamine,	   and	   sodium	   bicarbonate	   (Sigma-­‐Aldrich,	   M4655)	  supplemented	  with	   1%	   non-­‐essential	   amino	   acids,	   1%	   penicillin/streptomycin	  (10,000U/ml	  penicillin,	  10mg/ml	  streptomycin)	  and	  10%	  heat-­‐inactivated	  foetal	  bovine	   serum)	   at	   37°C/5%	   CO2.	   When	   70-­‐80%	   confluent	   (estimated	   by	   light	  microscopy),	   the	   growth	   media	   was	   drained	   and	   3ml	   of	   non-­‐enzymatic	   cell	  dissociation	  solution	  added	  (Sigma-­‐Aldrich,	  C5789).	  	  	  Flasks	  were	  incubated	  at	  37°C/5%	  CO2	  for	  three	  minutes	  to	  allow	  cells	  to	  detach	  from	  the	  flask	  surface	  before	  addition	  of	  3ml	  growth	  medium	  and	  transfer	  of	  the	  entire	  flask	  contents	  to	  a	  15ml	  falcon	  tube.	  Cells	  were	  spun	  down	  at	  800rpm	  for	  three	   minutes,	   after	   which	   the	   supernatant	   was	   drained	   and	   the	   cell	   pellet	  resuspended	  in	  5ml	  of	  growth	  medium	  by	  gentle	  pipetting.	  This	  cell	  suspension	  was	   used	   to	   seed	   fresh	   culture	   flasks,	   as	   well	   as	   to	   plate	   cells	   for	  electrophysiology	  (see	  2.1.2	  Cell	  plating	  for	  electrophysiology).	  	  	  Fresh	   culture	   flasks	  were	   seeded	  with	   0.5-­‐1.5ml	   of	   cell	   suspension	   into	   a	   final	  volume	   of	   5ml	   of	   growth	   medium,	   and	   cultured	   at	   37°C/5%	   CO2.	   Cells	   with	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passage	   number	   in	   the	   thirties	   often	   proved	   unsuitable	   for	   electrophysiology,	  and	  fresh	  cells	  were	  resurrected	  from	  frozen	  stocks	  as	  required.	  	  
2.1.2	  Cell	  plating	  for	  electrophysiology	  For	   electrophysiological	   experiments,	   tsA201	   cells	   were	   plated	   onto	   glass	  coverslips	   treated	   with	   poly-­‐D-­‐lysine	   (1mg/ml),	   in	   four-­‐well	   culture	   plates.	  Coverslip	  dimensions	  varied,	   determined	  by	   the	   size	  of	   the	   recording	   chamber	  on	  the	  electrophysiology	  rig	  (see	  2.2.2	  Recording	  chamber):	  for	  NMDA	  receptor	  experiments,	   in	   which	   a	   wide	   and	   shallow	   recording	   chamber	   was	   used,	  coverslips	   measured	   approximately	   6mm	   x	   10mm;	   for	   TREK-­‐1	   channel	  experiments,	   coverslips	   measured	   approximately	   2.5mm	   x	   10	  mm.	   Cells	   were	  plated	  using	  1ml	  of	  the	  cell	  resuspension	  described	  in	  routine	  cell	  passage	  in	  9ml	  of	   growth	   medium,	   0.5ml	   of	   which	   was	   added	   to	   each	   well	   of	   two	   four-­‐well	  plates.	   Plates	   were	   incubated	   at	   37°C/5%	   CO2	   until	   ready	   for	   transfection	  (normally	  between	  five	  and	  seven	  hours).	  When	  cells	  were	  to	  be	  transfected	  with	  NMDA	   receptor	   DNA,	   the	   cell	   plating	   media	   contained	   the	   NMDA	   receptor	  blocker	  DL-­‐APV	   (450µM)	   and	  MgCl2	   (1mM),	   in	   anticipation	   of	   NMDA	   receptor	  expression	  at	  a	  later	  stage.	  	  
2.1.3	  DNA	  transfection	  Cells	  plated	  onto	  glass	  coverslips	  were	  transfected	  with	  complementary	  DNA	  for	  rat	  NMDA	  receptor	  GluN1/GluN2A	  subunits,	  or	  human	  TREK-­‐1	  channels,	  using	  a	  modified	   calcium	   phosphate-­‐mediated	   transfection	   protocol.	   Green	   fluorescent	  protein	  was	  co-­‐transfected	  with	  both	  NMDA	  and	  TREK-­‐1	  DNA	  for	  identification.	  	  	  Briefly,	  200µl	  HEPES-­‐buffered	  saline	   (HBS)	  was	  mixed	  with	  a	   solution	  of	  CaCl2	  (25µl),	   DNA	   (volume	   determined	   by	   DNA	   concentration,	   see	   below),	   and	   de-­‐ionised	  water	  (balance,	  to	  a	  final	  volume	  of	  200µl)	  to	  form	  a	  calcium	  phosphate-­‐DNA	   precipitate.	   For	   NMDA	   receptor	   experiments,	   1.5µg	   GluN1	   subunit	   DNA,	  3.0µg	   GluN2A	   subunit	   DNA,	   and	   0.75µg	   GFP	   DNA	   was	   added.	   For	   TREK-­‐1	  channel	   experiments,	   1.0µg	   TREK-­‐1	   DNA,	   and	   0.75µg	   GFP	   DNA	   was	   added.	  Reagents	  were	  pre-­‐thawed	  to	  room	  temperature	  and	  added	  together	  drop-­‐wise	  with	   gentle	   vortexing,	   before	   being	   incubated	   at	   room	   temperature	   for	   fifteen	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minutes	  to	  aid	  in	  precipitate	  formation.	  The	  freshly-­‐formed	  calcium	  phosphate-­‐DNA	   precipitate	   was	   added	   immediately	   into	   the	   media	   above	   plated	   cell	  coverslips,	  and	  cells	   incubated	  at	  37°C/3%	  CO2	   for	   fifteen	   to	  eighteen	  hours	   to	  allow	  DNA	  transfection.	  	  	  Following	  this	  incubation	  period,	  cells	  had	  their	  growth	  media	  drained	  and	  were	  washed	   twice	   with	   phosphate	   buffered	   saline	   (PBS)	   to	   remove	   the	   calcium	  phosphate	   precipitate.	   Fresh	   growth	   medium	   was	   added	   and	   cells	   allowed	   to	  recover	   for	   at	   least	   twenty-­‐four	   hours	   at	   37°C/5%	   CO2	   before	   being	   used	   for	  electrophysiology.	  	  
	  
	  
2.2	  Electrophysiology	  	  Investigation	   of	   NMDA	   receptor	   and	   TREK-­‐1	   channel	   currents	   was	   performed	  using	   standard	   patch	   clamp	   electrophysiology	   techniques,	   with	  receptors/channels	   expressed	   transiently	   in	   a	   tsA201	  mammalian	   cell	   line	   and	  clamped	  in	  the	  whole-­‐cell	  voltage	  clamp	  configuration.	  	  	  
2.2.1	  Experimental	  equipment	  	  &	  setup	  Glass	   recording	   pipettes	  were	   pulled	   from	   thin-­‐walled,	   filamented	   borosilicate	  glass	  capillaries	  (GC150TF-­‐7.5;	  Harvard	  Apparatus,	  Holliston,	  MA,	  USA)	  using	  a	  two-­‐stage	   vertical	   puller	   (PP-­‐830;	   Narishige,	   Tokyo,	   Japan)	   and	   fire-­‐polished	  briefly	   using	   a	   custom	   microforge.	   Fabricated	   pipettes	   were	   used	   within	   24	  hours	  of	  pulling,	  and	  were	  stored	  in	  a	  covered	  glass	  dish	  at	  all	  times	  to	  prevent	  dust	  accumulation	  at	   the	   tip.	   Immediately	  before	  use,	  pipettes	  were	  back-­‐filled	  with	   chilled	   and	   filtered	   intracellular	   solution	   using	   a	   glass	   electrode	   filler	  (Microfil	   MF28G-­‐5;	   World	   Precision	   Instruments,	   Sarasota,	   FL,	   USA).	   Pipettes	  prepared	   in	   this	   manner	   typically	   had	   resistance	   between	   4-­‐9MΩ;	   those	   with	  resistance	  deviating	  from	  this	  range	  were	  discarded.	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Electrophysiological	   recordings	  were	  performed	  using	  a	  patch-­‐clamp	  recording	  rig	  under	  both	  electrical	  and	  mechanical	  isolation.	  A	  custom	  recording	  chamber	  and	   perfusion	   system	   (see	   2.2.2	   Recording	   chamber)	  were	  mounted	   above	   an	  inverted	   microscope	   (Nikon	   Eclipse	   TE200;	   Nikon,	   Amstelveen,	   Netherlands)	  fitted	  with	   an	   epifluorescence	   system	   for	   the	   assessment	   and	   selection	  of	   cells	  appropriate	   for	  electrophysiological	  recording.	  Micropipettes	  were	   fitted	   firmly	  into	   a	  pipette	  holder,	  which	  was	   in	   turn	   attached	   to	   a	  headstage	   amplifier	   (CV	  203BU;	   Axon	   Instruments,	   Sunnyvale,	   CA,	   USA).	   Electrical	   connection	  with	   the	  intracellular	  solution	  came	  via	  a	  silver	  chloride-­‐coated	  silver	  wire.	  A	  side	  port	  in	  the	  pipette	  holder	  provided	  a	  means	  to	  apply	  positive	  or	  negative	  pressure	  to	  the	  pipette	  interior,	  while	  manipulation	  of	  pipettes	  into	  position	  was	  performed	  via	  a	   piezoelectric	   micromanipulator	   (Intracel	   MP-­‐225;	   Shutter	   Instrument	  Company,	  Novato,	  CA,	  USA)	  on	  which	  the	  headstage	  amplifier	  was	  mounted.	  	  Following	   the	   establishment	   of	   a	  whole-­‐cell	   patch,	   electrical	   currents	   from	   the	  headstage	   amplifier	   were	   transmitted	   to	   an	   Axopatch	   200B	   amplifier	   (Axon	  Instruments).	  Outputs	  from	  the	  amplifier	  were	  filtered	  with	  an	  eight-­‐pole	  Bessel	  filter	   (model	   900;	   Frequency	  Devices	   Inc.,	   Ottawa,	   IL,	   USA),	   digitised	   (Digidata	  1332A;	  Axon	   Instruments),	   and	   recorded	  on	  a	   computer.	   Series	   resistance	  was	  compensated	   between	   75-­‐90%	   using	   controls	   on	   the	   Axopatch	   amplifier,	   with	  both	   data	   acquisition	   and	   analysis	   performed	   using	   pClamp8	   software	   (Axon	  Instruments).	  	  Mechanical	   isolation	   of	   the	   recording	   rig	   was	   achieved	   by	   mounting	   all	  equipment	   pertinent	   to	   the	   recording	   process	   –	   microscope	   and	  micromanipulators	  included	  –	  upon	  an	  air	  table	  (Newport	  VW-­‐3046-­‐OPT;	  Irvine,	  CA,	   USA)	   regulated	   at	   100psi.	   The	   entire	   recording	   rig	   was	  mounted	  within	   a	  Faraday	   cage	   to	   provide	   electrical	   isolation,	   with	   both	   the	   cage	   and	   any	  conducting	  components	  within	  earthed	  and	  connected	  to	   the	  amplifier	  earth	   in	  order	  to	  eliminate	  any	  ground-­‐loop	  electrical	  noise.	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2.2.2	  Recording	  chamber	  &	  perfusion	  system	  Cell	   coverslips	   were	   mounted	   in	   a	   Perspex	   recording	   chamber	   (designed	   in-­‐house),	   with	   different	   chambers	   employed	   for	   NMDA	   receptor	   and	   TREK-­‐1	  channel	   experiments.	   For	   NMDA	   receptor	   experiments,	   a	   wider,	   shallow	  chamber	   	   (Figure	  2.1)	  was	  used,	   in	  order	   to	  accommodate	   the	  use	  of	  a	  double-­‐barrelled	   perfusion	   arm	   to	   apply	   solutions	  more	   directly	   to	   cells.	   For	   TREK-­‐1	  experiments	   a	   longer,	   narrower	   chamber	   (Figure	   2.2),	   with	   a	   simple	   bath	  perfusion	  method	  was	  employed.	  	  In	   both	   cases,	   the	   recording	   chamber	   was	   perfused	   continuously	   with	  extracellular	  solution	  under	  gravity,	  with	  solution	  entering	   the	  chamber	   to	  one	  side	  of	  cell	  coverslips	  and	  draining	  through	  a	  narrow	  outlet	  at	  the	  opposite	  side	  into	  a	  waste	  reservoir	  emptied	  under	  suction.	  Solution	  in	  the	  recording	  chamber	  was	  earthed	  to	  a	  separate	  reference	  well	  by	  means	  of	  an	  agar	  salt	  bridge;	  a	  short	  length	  of	  glass	  capillary	  filled	  with	  1%	  agar	  gel.	  This	  reference	  well	  contained	  a	  silver	  chloride	  pellet	   connected	   to	   the	  headstage	  amplifier	  earth	  and	  was	   filled	  with	  the	  same	  extracellular	  stock	  as	  the	  bath	  perfusate.	  	  	  For	  TREK-­‐1	  experiments,	  a	  simple	  bath	  perfusion	  system	  in	  which	  application	  of	  test	   solutions	  was	   to	   the	   entire	   recording	   chamber	  was	   employed.	   For	   NMDA	  receptor	   experiments,	   application	   of	   test	   solutions	   to	   cells	   was	   via	   a	   custom	  perfusion	  system	  allowing	  rapid	  solution	  exchanges	  considerably	  quicker	  than	  a	  traditional	  bath	  perfusion	  (Figure	  2.1).	  	  	  A	  perfusion	  arm	  formed	  from	  double	  barrelled	  glass	  capillary	  tubing	  (2GC150F-­‐10,	  Harvard	  Instruments)	  and	  bent	  into	  a	  swan-­‐neck	  configuration	  was	  attached	  by	   lengths	   of	   polytetrafluoroethylene	   (PTFE)	   tubing	   to	   two	   banks	   of	   solution	  reservoirs,	  one	  for	  each	  barrel	  of	  the	  arm.	  When	  both	  arms	  were	  submerged	  into	  the	  recording	  chamber	  bath	  and	   flowing	  with	  solution,	  a	  well-­‐defined	   interface	  was	  observed	  between	  the	  two	  flows	  from	  each	  barrel.	  One	  barrel	  was	  then	  used	  to	  apply	  pre-­‐exposure	  solution	   to	   the	  cell,	   and	   the	  other	   to	  apply	  experimental	  test	   solution.	   The	   entire	   perfusion	   arm	   was	   mounted	   on	   a	   mechanical	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Figure	  2.1:	  Electrophysiological	  recording	  chamber	  for	  NMDA	  receptor	  experiments.	  Cell	  
coverslips	   were	   mounted	   in	   a	   wide,	   shallow	   chamber,	   perfused	   continuously	   under	  
gravity.	  Extracellular	  solution	  entered	  from	  the	  left	  and	  drained	  to	  the	  right,	  into	  a	  waste	  
reservoir	   emptied	   under	   suction.	   Test	   solutions	   were	   applied	   to	   cells	   via	   a	   double-­‐
barrelled	  perfusion	  arm	  lowered	  into	  the	  chamber	  adjacent	  to	  cells	  selected	  for	  recording.	  	  
Lateral	  movement	  of	  the	  arm	  by	  a	  hydraulic	  manipulator	  allowed	  switches	  between	  pre-­‐
exposure	  and	  test	  solutions	  flowing	  from	  the	  different	  barrels.	  	  	  
	  
Figure	  2.2:	  Electrophysiological	  recording	  chamber	  for	  TREK-­‐1	  channel	  experiments.	  Cell	  
coverslips	  were	  mounted	   in	   a	   narrow	   recording	   chamber,	   perfused	   continuously	   under	  
gravity.	  Extracellular	  solution	  entered	  from	  the	  left	  and	  drained	  to	  the	  right,	  into	  a	  waste	  
reservoir	  emptied	  under	  suction.	  Test	  solutions	  were	  applied	  to	  the	  bath	  as	  a	  whole.	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manipulator,	   used	   to	   position	   the	   arm	  adjacent	   to	   cells	   from	  which	   recordings	  were	   to	  be	  made.	  A	  hydraulic	  manipulator	  was	  used	   to	   introduce	   small	   lateral	  movements	  of	  the	  arm,	  thereby	  performing	  rapid	  switches	  between	  the	  flows	  of	  solution	  to	  which	  a	  cell	  was	  exposed.	  All	  solutions,	  including	  the	  bath	  perfusion,	  flowed	  toward	  the	  waste	  reservoir	  at	  all	  times.	  	  Experimental	   solutions	  were	  housed	   in	   two	  banks	  of	   glass	   syringes	   suspended	  above	  the	  level	  of	  the	  recording	  chamber,	  with	  perfusion	  of	  the	  system	  driven	  by	  gravity.	  A	  system	  of	  two-­‐	  and	  four-­‐way	  changeover	  valves	  allowed	  multiple	  pre-­‐exposure	   and	   test	   solutions	   to	   be	   applied	   in	   a	   single	   experiment.	   Custom	  drippers	  made	  from	  glass	  Pasteur	  pipettes	  and	  syringe	  needles	  were	  attached	  to	  each	  solution	  reservoir,	  allowing	  the	   flow	  rate	   from	  each	  to	  be	  checked	  by	  eye.	  Connection	   of	   reservoirs	   and	   the	   perfusion	   arm	   was	   via	   lengths	   of	   inert	  polytetrafluoroethylene	  (PTFE)	  tubing,	  minimising	  the	  loss	  of	  test	  substrates	  to	  adsorption.	  	  
2.2.3	  Experimental	  solutions	  For	  NMDA	  receptor	  experiments,	   intracellular	  solution	  contained	  (in	  mM):	  110	  K-­‐gluconate,	   2.5	  NaCl,	   10	  HEPES,	   10	   1,2-­‐Bis(2-­‐aminophenoxy)ethane-­‐N,N,N’,N’-­‐tetraacetic	  acid	  (BAPTA),	  titrated	  to	  pH	  7.3	  using	  KOH.	  The	  extracellular	  solution	  contained	   (in	   mM):	   150	   NaCl,	   2.5	   KCl,	   2	   CaCl2,	   10	   HEPES,	   titrated	   to	   pH	   7.35	  using	  NaOH,	  as	  described	  previously	  [48].	  	  	  For	   TREK-­‐1	   experiments	   the	   intracellular	   solution	   contained	   (in	   mM)	   120	  KCH3SO4,	  4	  NaCl,	  1	  MgCl2,	  1	  CaCl2,	  10	  EGTA,	  10	  HEPES,	  3	  MgATP	  and	  0.3	  NaGTP,	  titrated	   to	  pH	  7.3	  with	  KOH.	  The	  extracellular	   solution	   contained	   (in	  mM)	  145	  NaCl,	  2.5	  KCl,	  1	  CaCl2,	  2	  MgCl2,	  10	  HEPES,	  10	  D-­‐Glucose,	   titrated	   to	  pH7.4	  with	  NaOH,	  as	  described	  previously	  [19].	  	  Anaesthetic	   test	   compounds	  were	   applied	   to	   cells	   in	   extracellular	   solution	   and	  were	  prepared	  fresh	  each	  day	  in	  sealed	  volumetric	  flasks.	  These	  solutions	  were	  transferred	  as	  quickly	  as	  possible	  to	  the	  glass	  reservoir	  syringes	  housed	  on	  the	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electrophysiology	  rig;	  these	  contained	  polypropylene	  floats	  shown	  to	  reduce	  the	  evaporation	  of	  anaesthetic	  from	  solution	  to	  negligible	  levels	  [19].	  	  Volatile	   anaesthetics	   halothane,	   isoflurane,	   and	   sevoflurane	   were	   prepared	   as	  volume	   fractions	   of	   a	   saturated	   solution	   –	   the	   concentrations	   of	   which	   were	  taken	   to	   be	   17.5,	   15.3,	   and	   11.8mM	   respectively.	   Saturated	   solutions	   were	  prepared	   by	   adding	   100µl	   of	   anaesthetic	   to	   20ml	   of	   extracellular	   solution	   in	   a	  25ml	  glass	  scintillation	  vial.	  This	  was	  vortexed	  vigorously	  for	  5mins	  and	  allowed	  to	  stand	  for	  approximately	  one	  hour.	  Following	  a	  further	  3mins	  of	  vortexing,	  the	  solution	   was	   spun	   down	   at	   4000rpm	   for	   5mins.	   A	   small	   pellet	   of	   anaesthetic	  visible	   in	   the	   bottom	   of	   the	   vial	   confirmed	   saturation	   of	   the	   solution.	  Experimental	  solutions	  were	  then	  prepared	  as	  volume	  fractions	  by	  diluting	  the	  appropriate	  volume	  of	  saturated	  solution	  into	  extracellular	  solution.	  	  Gaseous	   anaesthetic	   solutions	  were	   prepared	   by	   bubbling	   pure	   gases	   (oxygen,	  nitrogen,	   nitrous	   oxide,	   helium,	   neon,	   argon,	   krypton,	   xenon)	   through	  extracellular	  solution	  for	  45mins	  to	  achieve	  a	  saturated	  solution.	  Bubbling	  was	  in	  250	   or	   500ml	   glass	   Dreschel	   bottles,	   clamped	   into	   position	   2cm	   above	   a	  magnetic	  stirring	  plate	  to	  avoid	  the	  warming	  of	  solutions	  during	  bubbling.	  Glass	  bubblers	   and	   magnetic	   stirrers	   were	   used	   to	   disperse	   gases	   throughout	   the	  solutions.	  Gases	  were	  from	  regulated	  cylinders,	  with	  outflow	  of	  the	  gas	  from	  the	  Dreschel	   bottles	   through	   calibrated	   flow	   meters	   allowing	   feedback	   for	  adjustment	   of	   the	   gas	   flow.	   Experimental	   solutions	   were	   prepared	   as	   80%	   of	  saturated	   anaesthetic	   solution,	   20%	   oxygen,	   with	   nitrogen	   used	   in	   place	   of	  anaesthetic	  for	  control	  solutions.	  	  
2.2.4	  NMDA	  receptor	  experimental	  protocol	  A	  single	  cell	  coverslip	  was	  mounted	  in	  the	  recording	  chamber	  using	  forceps	  and	  cells	   selected	   for	   electrophysiological	   recording	   on	   the	   basis	   of	   fluorescence,	  grouping,	   and	   perceived	   health.	   Fluorescing	   cells	   (i.e.	   those	   successfully	  transfected	   with	   GFP)	   were	   assumed	   to	   also	   be	   expressing	   functional	   NMDA	  receptors;	   this	   assumption	   has	   previously	   been	   corroborated,	   by	   a	   close	  correlation	  between	  cell	  fluorescence	  and	  response	  to	  NMDA	  receptor	  agonists.	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Cells	  with	  no	  GFP	  fluorescence	  were	  thus	  ignored.	  Similarly,	  particularly	  intense	  fluorescence	  was	  found	  to	  be	  indicative	  of	  toxicity,	  and	  poor	  quality	  recordings.,	  thus	  these	  cells	  were	  not	  selected	  for	  recording	  either.	  	  	  Following	   cell	   selection,	   the	   perfusion	   arm	   was	   located	   close	   to	   the	   cell	   and	  lateral	  movement	  of	  the	  arm	  by	  hydraulic	  manipulation	  confirmed	  to	  not	  cause	  disturbance	  of	  the	  coverslip.	  The	  pre-­‐exposure	  barrel	  of	  the	  arm	  was	  positioned	  over	  the	  cell	  first,	  and	  an	  equal	  flow	  rate	  in	  both	  barrels	  confirmed	  by	  eye,	  using	  the	  custom	  drippers	  attached	  to	  the	  solution	  reservoirs.	  	  A	   glass	  micropipette	  was	   attached	   to	   the	   pipette	   holder	   and	   positive	   pressure	  applied	   by	   mouth	   through	   the	   side	   port.	   This	   pressure	   was	   locked	   and	  maintained	   using	   an	   on-­‐off	   valve.	   The	   micropipette	   was	   lowered	   into	   the	  perfusion	  bath	  and	  offset	   corrected	  using	  amplifier	   controls	   so	   that	  no	   current	  flowed	   through	   the	   pipette.	   The	   “seal	   test”	   function	   within	   pClamp8	   software	  was	   then	  used	   to	   apply	   a	  5mV	   square	  wave	   to	   the	   system	  and	   to	   confirm	   that	  electrode	  resistance	  was	  within	  the	  accepted	  range	  (4-­‐9MΩ).	  Micropipettes	  were	  manoeuvred	   into	   position	   close	   to	   the	   cell	   surface	   using	   fine	   controls	   on	   the	  micromanipulator,	  and	  the	  pipette	  tip	  brought	  into	  contact	  with	  a	  central	  part	  of	  the	  cell	  membrane.	  	  	  Upon	   contact,	   a	   slight	   spreading	   of	   the	   cell	   was	   observed,	   with	   marginal	  increases	   in	   the	   pipette	   resistance	   recorded	   by	   pClamp8	   confirming	   interface	  between	  cell	  and	  pipette.	  Positive	  pressure	  to	  the	  pipette	  was	  removed,	  resulting	  in	   increases	   in	   pipette	   resistance.	   When	   necessary,	   negative	   pressure	   was	  applied	  by	  mouth	  in	  order	  for	  resistance	  to	  exceed	  1GΩ	  -­‐	  a	  “gigaseal”	  -­‐	  indicating	  formation	  of	  a	  tight	  seal	  between	  the	  cell	  and	  pipette	  tip.	  A	  holding	  potential	  of	  -­‐60mV	   was	   applied	   through	   pClamp8	   and	   pipette	   transients	   cancelled	   using	  amplifier	   controls.	   Sharp	   bursts	   of	   negative	   pressure	  were	   applied	   in	   order	   to	  rupture	  the	  patch	  of	  membrane	  immediately	  under	  the	  pipette	  tip	  and	  bring	  the	  cell	   into	   the	   whole-­‐cell	   clamp	   configuration;	   this	   is	   observed	   as	   the	   sudden	  appearance	  of	  new	  capacitance	  transients	  in	  response	  to	  capacitance	  of	  the	  cell	  membrane.	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  These	   whole	   cell	   capacitance	   transients	   were	   cancelled	   and	   series	   resistance	  compensation	   applied	   using	   amplifier	   controls.	   Series	   resistance	  was	   normally	  compensated	  to	  at	  least	  70%.	  The	  pClamp8	  “seal	  test”	  wave	  was	  switched	  off	  and	  a	  test	  application	  of	  agonist	  performed	  to	  confirm	  receptor	  DNA	  expression.	  Cell	  currents	   were	   filtered	   at	   100Hz	   (-­‐3dB),	   digitised	   at	   20kHz,	   and	   saved	   to	  computer.	  Solution	  applications	  were	  performed	  by	  “switching”	  between	  barrels	  of	  the	  perfusion	  arm,	  with	  changeover	  valves	  allowing	  application	  of	  up	  to	  eight	  different	  solutions	  from	  each	  barrel.	  	  
2.2.4.1	  Glycine	  concentration-­‐response	  experiments	  For	   glycine	   concentration-­‐response	   experiments,	   cells	  were	   exposed	   to	   100µM	  NMDA	  in	  the	  presence	  of	  a	  range	  of	  glycine	  concentrations.	  Both	  bath	  and	  pre-­‐exposure	   solutions	   were	   glycine-­‐free	   extracellular	   solution.	   Cells	   held	   in	   the	  whole-­‐cell	   configuration	   at	   -­‐60mV	   were	   exposed	   to	   NMDA-­‐	   and	   glycine-­‐containing	  solutions	  by	  switching	  from	  the	  pre-­‐exposure	  barrel	  of	  the	  perfusion	  arm	  to	   the	  test	  arm.	  Cells	  were	  exposed	  to	   test	  solution	   for	  approximately	  10s,	  during	  which	  time	  an	  inward	  current	  through	  NMDA	  receptors	  was	  observed.	  A	  period	   of	   90-­‐180s	   was	   allowed	   between	   such	   test	   exposures	   to	   allow	   for	  recovery	   of	   receptors	   from	   a	   desensitised	   state.	   Where	   possible,	   a	   full	  concentration-­‐response	  range	  was	  tested	  on	  each	  cell.	  	  
2.2.4.2	  Anaesthetic	  inhibition	  experiments	  For	  anaesthetic	  inhibition	  experiments	  all	  bath,	  pre-­‐exposure,	  and	  test	  solutions	  contained	  an	  equal	  concentration	  of	  glycine.	  A	  single	  batch	  of	  glycine-­‐containing	  extracellular	  solution	  was	  prepared	  by	  adding	  glycine	  to	  extracellular	  solution	  at	  the	   appropriate	   dilution	   for	   the	   experiment	   (normally	   1	   or	   100µM).	   All	  subsequent	   solutions,	   including	   anaesthetic-­‐containing	   solutions,	   were	   then	  prepared	   from	   this	   glycine-­‐containing	   master	   solution.	   Control	   (agonist	   only)	  and	   test	   (agonist	   &	   anaesthetic)	   exposures	   were	   performed	   in	   pairs	   –	   10s	  exposures	  with	  90s	  between	  each	  exposure	  as	  in	  glycine	  concentration-­‐response	  experiments.	   Both	   pre-­‐exposure	   and	   test	   barrels	  were	   switched	   to	   anaesthetic	  containing	  solutions	  immediately	  following	  the	  second	  control	  exposure,	  so	  that	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cells	  were	  pre-­‐exposed	  to	  anaesthetic	   for	  90s	  before	  exposure	  to	  agonist	   in	  the	  presence	   of	   anaesthetic.	   Similarly,	   following	   the	   second	   test	   exposure,	   both	  barrels	   were	   returned	   to	   control	   (anaesthetic-­‐free)	   solutions,	   to	   allow	  anaesthetic	   to	  wash-­‐off	   for	   90s	   before	   another	   pair	   of	   control	   exposures	  were	  performed.	   This	   alternation	   between	   pairs	   of	   control	   and	   test	   exposures	   was	  repeated	  for	  all	  concentrations	  of	  anaesthetic,	  when	  possible.	  	  	  
2.2.5	  TREK-­‐1	  channel	  experimental	  protocol	  A	  single	  cell	  coverslip	  was	  mounted	  in	  the	  recording	  chamber	  using	  forceps	  and	  cells	   selected	   for	   electrophysiological	   recording	   on	   the	   basis	   of	   fluorescence,	  grouping,	   and	   perceived	   health.	   Fluorescing	   cells	   (i.e.	   those	   successfully	  transfected	   with	   GFP)	   were	   assumed	   to	   also	   be	   expressing	   functional	   TREK-­‐1	  channels.	  	  	  Following	  cell	  selection	  a	  glass	  micropipette	  was	  attached	  to	  the	  pipette	  holder	  and	  positive	  pressure	  applied	  by	  mouth	  through	  the	  side	  port.	  This	  pressure	  was	  locked	  and	  maintained	  using	  an	  on-­‐off	  valve.	  The	  micropipette	  was	  lowered	  into	  the	   perfusion	   bath	   and	   offset	   corrected	   using	   amplifier	   controls	   so	   that	   no	  current	   flowed	   through	   the	   pipette.	   The	   “seal	   test”	   function	   within	   pClamp8	  software	   was	   then	   used	   to	   apply	   a	   5mV	   square	   wave	   to	   the	   system	   and	   to	  confirm	   that	   electrode	   resistance	   was	   within	   the	   accepted	   range	   (4-­‐9MΩ).	  Micropipettes	  were	  manoeuvred	  into	  position	  close	  to	  the	  cell	  surface	  using	  fine	  controls	  on	  the	  micromanipulator,	  and	  the	  pipette	  tip	  brought	  into	  contact	  with	  a	  central	  part	  of	  the	  cell	  membrane.	  	  	  Upon	   contact,	   a	   slight	   spreading	   of	   the	   cell	   was	   observed,	   with	   marginal	  increases	   in	   the	   pipette	   resistance	   recorded	   by	   pClamp8	   confirming	   interface	  between	  cell	  and	  pipette.	  Positive	  pressure	  to	  the	  pipette	  was	  removed,	  resulting	  in	   increases	   in	   pipette	   resistance.	   When	   necessary,	   negative	   pressure	   was	  applied	  by	  mouth	  in	  order	  for	  resistance	  to	  exceed	  1GΩ	  -­‐	  a	  “gigaseal”	  –	  indicating	  formation	  of	  a	  tight	  seal	  between	  the	  cell	  and	  pipette	  tip.	  A	  holding	  potential	  of	  -­‐80mV	   was	   applied	   through	   pClamp8	   and	   pipette	   transients	   cancelled	   using	  amplifier	   controls.	   Sharp	   bursts	   of	   negative	   pressure	  were	   applied	   in	   order	   to	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rupture	  the	  patch	  of	  membrane	  immediately	  under	  the	  pipette	  tip	  and	  bring	  the	  cell	   into	   the	   whole-­‐cell	   clamp	   configuration;	   this	   is	   observed	   as	   the	   sudden	  appearance	  of	  new	  capacitance	  transients	  in	  response	  to	  capacitance	  of	  the	  cell	  membrane.	  	  These	   whole	   cell	   capacitance	   transients	   were	   cancelled	   and	   series	   resistance	  compensation	   applied	   using	   amplifier	   controls.	   Series	   resistance	  was	   normally	  compensated	  to	  at	  least	  70%.	  The	  pClamp8	  “seal	  test”	  wave	  was	  switched	  off	  and	  a	   voltage	   ramp	   from	   -­‐120mV	   to	   0mV	   performed	   to	   confirm	   TREK-­‐1	   channel	  expression.	  Cell	  currents	  were	  filtered	  at	  100Hz	  (-­‐3dB),	  digitised	  at	  20kHz,	  and	  saved	   to	   computer.	  A	   series	  of	   ten	  250ms	  voltage	   ramps	   from	   -­‐120mV	   to	  0mV	  were	  recorded	  in	  a	  single	  file.	  	  	  Control	   voltage	   ramps	   were	   performed	   in	   the	   absence	   of	   anaesthetic	   (i.e.	  extracellular	  solution	  only)	  both	  before	  and	  after	  voltage	  ramps	  in	  the	  presence	  of	   anaesthetic	   containing	   solutions.	   Solutions	   were	   applied	   to	   the	   bath	   as	   a	  whole,	  via	  a	  four-­‐way	  changeover	  valve	  at	  the	  inlet	  to	  the	  bath.	  In	  the	  majority	  of	  cases,	   a	   positive	   control	   halothane	   (0.82mM)	   application	   (known	   to	   potentiate	  TREK-­‐1	  currents)	  was	  included	  as	  part	  of	  the	  experimental	  protocol.	  	  
2.2.6	  Data	  analysis	  Analysis	   of	   recorded	   currents	   was	   performed	   using	   Clampfit	   8.2	   (Axon	  Instruments),	  and	  data	  plotted	  using	  the	  SigmaPlot	  software	  package	  (Systat	  Inc.,	  Point	  Richmond,	  CA,	  USA).	  	  	  For	   NMDA	   receptor	   glycine	   concentration-­‐response	   experiments,	   responses	  were	   normalised	   to	   the	   amplitude	   of	   the	   maximal	   response,	   Imax.	   Data	   from	  multiple	  cells	  was	  pooled	  and	  fit	  to	  the	  equation:	  	  
	  I	  	  =	  	  	  	  	  	  	  	  	  	  Imax[agonist]nH	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  [agonist]	  nH	  	  +	  [EC50]	  nH	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where	  I	  is	  the	  fitted	  current,	  Imax	  the	  maximum	  value	  of	  the	  curve,	  and	  nH	  the	  Hill	  co-­‐efficient.	   Errors	   quoted	   for	   these	   values	   are	   standard	   errors	   of	   the	   mean	  (SEM)	  calculated	  by	  SigmaPlot.	  	  For	  NMDA	  receptor	  anaesthetic	  inhibition	  experiments,	  control	  and	  anaesthetic	  exposures	  were	  paired	  for	  consistency,	  with	  anaesthetic	  exposures	  preceded	  and	  followed	  by	  control	   responses.	  Anaesthetic	   inhibition	  ratios	  were	  calculated	  by	  dividing	   mean	   anaesthetic	   currents	   by	   the	   mean	   of	   the	   controls	   that	   flanked	  them.	   Data	   are	   presented	   as	   mean±SEM.	   Anaesthetic	   inhibition	   at	   different	  glycine	  concentrations	  were	  compared	  using	  ANOVA	  with	  Tukey	  post	  hoc	  test.	  A	  p	  value	  of	   less	   than	  0.05	  was	  taken	  to	   indicate	  a	  significant	  difference	  between	  groups	  	  For	  TREK-­‐1	  channel	  experiments,	  electrophysiological	  data	   traces	  each	  contain	  3000	  data	  points	   (equally	   spaced,	   sampled	  at	  20	  kHz).	  These	   individual	  points	  were	  plotted	  using	  SigmaPlot.	  Potentiation	  of	  TREK-­‐1	   currents	  by	  anaesthetics	  was	   calculated	   as	   a	  %	   potentiation	   of	   the	   control	   current	   at	   -­‐50mV.	   Data	   are	  presented	  as	  mean±SEM.	  	  	  	  
2.3	  In	  vivo	  traumatic	  brain	  injury	  	  A	   total	   of	   98	   male,	   young	   adult	   C57Bl6N	   mice	   (Charles	   River	   Laboratory,	  Sulzfeld,	   Germany),	   mean	   weight	   24±3g	   (SEM),	   aged	   2.5	   months,	   were	  investigated.	   Animals	   were	   kept	   under	   controlled	   light	   and	   environmental	  conditions	  (12h	  dark/light	  cycle,	  23±1°C,	  55±5%	  relative	  humidity),	  with	  access	  to	   food	   and	   water	   in	   their	   home	   cages	   ad	   libitum	   at	   all	   times	   prior	   to	   and	  following	  the	  experiments.	  Animal	  care	  was	  in	  compliance	  with	  the	  institutional	  guidelines	   of	   the	   Johanes	   Gutenberg	   University,	   Mainz.	   All	   experiments	   were	  approved	   by	   the	   Animal	   Ethics	   Committee	   of	   the	   Landestuntersuchungsamt	  Rheinland-­‐Pfalz	  (protocol	  number:	  G12-­‐1-­‐010).	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2.3.1	  Traumatic	  Brain	  Injury	  Animals	  were	  anaesthetised	  with	  2%	  sevoflurane	  in	  an	  air/oxygen	  mixture	  (40%	  O2	  and	  60%	  N2)	  supplied	  via	  facemask	  in	  spontaneously	  breathing	  animals.	  Core	  temperature	   was	   monitored	   and	   maintained	   at	   37°C	   for	   the	   duration	   of	   the	  experiment	   by	   means	   of	   a	   rectal	   probe	   and	   feedback	   controlled	   heating	   pad	  (Hugo	  Sachs,	  March-­‐Hugstetten,	  Germany).	  	  	  Traumatic	  brain	   injury	  was	  performed	  using	  the	  controlled	  cortical	   imact	  (CCI)	  model,	  as	  described	  previously	  [40].	  Animals	  were	  fixed	  in	  a	  stereotactic	   frame	  (Kopf	   Instruments,	   Tujunga,	   USA)	   and	   a	   4x4mm	   craniotomy	   window	   drilled	  using	   a	   saline-­‐cooled	   high-­‐speed	   drill,	   exposing	   an	   area	   of	   the	   dura	   above	   the	  right	  parietal	  cortex	  and	  between	  the	  sagittal,	  lambdoid,	  and	  coronal	  sutures.	  	  	  Focal	   contusion	   injury	   was	   induced	   by	   positioning	   a	   custom	   built	   controlled	  cortical	   impact	   device	   (L.	   Kopacz,	   Mainz,	   Germany)	   directly	   onto	   the	   exposed	  dura,	  perpendicular	  to	  the	  brain	  surface.	  For	  all	  animals	  an	  impactor	  tip	  of	  3mm	  diameter,	   impact	  velocity	  of	  8m/s,	   and	   impact	  duration	  of	  150ms	  was	  used.	   In	  the	   xenon	  pre-­‐exposure	   experiments,	   a	   brain	  penetration	  depth	  of	   1.5mm	  was	  used.	  In	  all	  other	  experiments,	  a	  penetration	  depth	  of	  1mm	  was	  used.	  	  Following	  CCI	   injury,	   the	   craniotomy	  window	  was	   closed	  and	   fixed	  with	   tissue	  glue	   (Histoacryl,	  Braun-­‐Melsungen,	  Melsungen,	  Germany),	  and	  animals	  wounds	  closed	  with	   filament	   sutures.	   Animals	  were	   returned	   to	   their	   home	   cages	   in	   a	  heated	  incubator	  (33C,	  35%	  humidity;	  IC8000,	  Draeger,	  Luebeck,	  Germany)	  and	  allowed	   to	   recover	   for	   15	   minutes	   before	   being	   assigned	   to	   an	   experimental	  control	  or	  treatment	  group.	  	  	  This	   rodent	   CCI	  model	   is	   recognised	   as	   a	   highly	   reproducible	   in	  vivo	  model	   of	  traumatic	   brain	   injury,	   reproducing	   many	   of	   the	   elements	   representative	   of	   a	  clinical	   traumatic	   brain	   injury.	   	   One	   source	   of	   variability	   in	   the	   surgical	  procedure	  is	  the	  skill	  and	  experience	  of	  the	  surgical	  operator.	  For	  this	  reason,	  as	  well	   as	   the	   surgical	   learning	   curve	   and	   time	   constraints	   associated	   with	   the	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project,	  CCI	  surgeries	  in	  the	  present	  study	  were	  not	  performed	  by	  the	  author,	  but	  instead	   by	  Anne	   Sebastiani,	   an	   experienced	  member	   of	   the	   Johanes	   Gutenberg	  University	  Department	  of	  Anaesthesiology.	  	  
2.3.2	  Experimental	  groups	  Animals	   were	   allowed	   to	   survive	   24	   hours	   or	   5	   days	   after	   CCI	   injury.	   An	  additional	   cohort	   of	   animals	   in	   a	   “primary	   injury”	   group	   was	   sacrificed	   15	  minutes	   after	   CCI	   injury,	   with	   no	   drug	   treatment	   administered.	   Animals	   in	   a	  “naïve”	  group	  underwent	  a	  sham	  surgery	  identical	  to	  the	  other	  groups	  but	  with	  no	  CCI	   injury	  or	  gas	   treatment	  administered.	  Naïve	  animals	  were	   sacrificed	  15	  minutes	   after	   sham	   surgery.	   	   In	   all	   instances,	   the	   operator	   performing	   the	   CCI	  surgery	  was	  blinded	  to	  the	  experimental	  group.	  	  Animals	  not	  in	  the	  naïve	  or	  primary	  injury	  cohorts	  were	  all	  randomly	  assigned	  to	  receive	  either	  75%	  xenon/25%	  oxygen	  or	  a	  control	  75%	  nitrogen/25%	  oxygen	  gas	  mixture.	  Gas	   treatments	  were	  delivered	  15	  minutes,	   1	   hour,	   3	   hour,	   and	  6	  hours	  after	  CCI	  injury.	  	  	  
2.3.3	  Xenon	  or	  control	  gas	  administration	  Gas	   treatments	   (75%	  xenon/25%	  oxygen	  or	  75%	  nitrogen/25%	  oxygen)	  were	  administered	  to	  spontaneously	  breathing	  animals	  for	  a	  duration	  of	  three	  hours,	  in	   a	   series	   of	   custom	   fabricated	   xenon	   exposure	   chambers	   linked	   in	   a	   closed	  circuit	  (Figure	  2.3).	  Both	  chambers	  and	  circuit	  were	  designed	  to	  allow	  individual	  chambers	  to	  be	  added	  or	  removed	  without	  disruption	  of	  the	  gas	  balance	  within	  the	   closed	   circuit.	   Gases	   were	   circulated	   continuously	   around	   the	   circuit	   at	  700ml/min	   by	   a	   small	   animal	   ventilator	   (Inspira	   ASV,	   Harvard	   Apparatus,	  Holliston,	  MA,	  USA).	  	  	  Both	  xenon	  and	  oxygen	  concentrations	   inside	   the	  circuit	  were	  monitored	  at	  all	  times,	   via	   a	   xenon	  meter	   (model	   439	   EX,	   Nyquist	   Ltd,	   UK)	   and	   oxygen	  meter	  (Oxydig,	  Draeger,	  Luebeck,	  Germany)	   included	  as	  part	  of	   the	  circuit.	  Additional	  volumes	   of	   gases	   were	   added	   into	   the	   system	   as	   necessary,	   to	   maintain	   their	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Figure	  2.3:	  A	  closed	  circuit	  system	  of	  xenon	  administration	  chambers.	  The	  chambers	  and	  
circuit	   were	   designed	   to	   allow	   individual	   chambers	   to	   be	   added	   and	   removed	   without	  
disruption	   of	   the	   gas	   balance	   within	   the	   closed	   system.	   Chambers	   could	   be	   sealed	  
individually	   by	   clamps	   at	   their	   inlet	   and	   outlets	   in	   order	   to	   allow	   chambers	   to	   be	  
added/removed	  as	  individual	  units.	  Gas	  concentrations	  in	  the	  system	  were	  monitored	  at	  
all	  times	  by	  xenon	  and	  oxygen	  meters	  included	  as	  part	  of	  the	  circuit.	  Additional	  volumes	  of	  
gases	   were	   added	   as	   necessary,	   to	   maintain	   their	   respective	   concentrations.	   Carbon	  
dioxide	  was	  removed	  by	  soda	  lime	  pellets	  in	  the	  bottom	  of	  each	  chamber.	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respective	   concentrations.	   Carbon	   dioxide	  was	   removed	   from	   the	   system	   by	   a	  small	  volume	  of	  soda	  lime	  pellets	  present	  in	  the	  bottom	  of	  each	  xenon	  chamber.	  	  Animals	  in	  the	  gas	  treatment	  groups	  were	  allowed	  to	  recover	  in	  their	  home	  cages	  following	  CCI	  injury,	  with	  xenon	  or	  control	  treatments	  administered	  15	  minutes,	  1	  hour,	  3	  hours,	  or	  6	  hours	  after	  surgery.	  Surgeries	  were	  performed	  sequentially	  by	   the	   same	   operator,	   thus	   the	   requirement	   for	   a	   circuit	   in	   which	   individual	  xenon	   chambers	   could	   be	   added	   or	   removed.	   In	   any	   run	   of	   surgeries,	   the	   first	  animal	   was	   placed	   into	   a	   xenon	   chamber,	   and	   the	   chamber	   flushed	   with	   gas	  mixture	  as	  part	  of	  the	  entire	  circuit.	  A	  flow	  rate	  of	  1l/min	  for	  2.5	  min	  was	  used,	  with	   the	   desired	   gas	   concentrations	   confirmed	   by	   xenon	   and	   oxygen	   meters	  included	  as	  part	  of	  the	  circuit.	  	  	  Subsequent	  chambers	  were	  added	  into	  the	  circuit	  by	  flushing	  with	  gas	  mixture,	  and	   locking	   the	   chamber	   shut.	   The	   circuit	   ventilator	   was	   paused,	   the	   circuit	  locked	  closed,	  and	  the	  new	  chamber	  added	  into	  the	  circuit.	  Gas	  circulation	  by	  the	  ventilator	  was	  then	  resumed.	  The	  same	  process	  in	  reverse	  was	  used	  to	  remove	  individual	  chambers	  from	  the	  circuit	  after	  a	  period	  of	  three	  hours	  gas	  exposure.	  Once	  removed	  from	  the	  circuit,	  animals	  were	  returned	  to	  their	  home	  cages.	  	  
2.3.4	  Quantification	  of	  functional	  outcome	  Functional	   outcome	  before	   and	   after	   CCI	   injury	  was	   assessed	   using	   a	   15-­‐point	  neurological	   severity	   score	   (NSS).	   The	   neuroscore	   consists	   of	   tasks	   evaluating	  sensorimotor	  function,	  locomotor	  ability,	  balance,	  and	  general	  behaviour	  (Table	  2.1).	  Tasks	  include	  the	  ability	  to	  traverse	  beams	  of	  varying	  width,	  the	  ability	  to	  balance	  on	  a	  beam,	  and	  measures	   	  such	  as	  seeking	  behaviour	  and	  the	  ability	  to	  walk	  in	  a	  straight	  line,	  among	  others.	  	  	  Failure	   to	   successfully	   perform	   a	   task	   results	   in	   the	   animal	   being	   awarded	   1	  point,	   with	   animals	   receiving	   up	   to	   15	   points	   depending	   on	   the	   severity	   of	  functional	  deficits.	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Table	  2.1:	  Criteria	  for	  the	  neurological	  severity	  score.	  Points	  are	  scored	  for	  the	  failure	  to	  
successfully	  perform	  a	  task,	  up	  to	  a	  maximum	  of	  15	  points	  for	  severe	  impairment.	  Healthy	  
animals	  scored	  0	  points.	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Beam	  walking	  tests	  counted	  the	  number	  of	  missteps	  made	  when	  crossing	  a	  one	  metre	  length	  beam	  of	  1,	  2,	  or	  3	  cm	  width.	  One	  point	  was	  scored	  when	  the	  animal	  made	  more	  than	  3	  missteps,	  with	  two	  points	  scored	  when	  the	  animal	  was	  unable	  to	   successfully	   cross	   the	   beam.	   Beam	   balance	   tests	   measured	   the	   ability	   of	  animals	  to	  balance	  on	  a	  0.5cm	  diameter	  stick	  and	  a	  0.5cm	  wide	  square	  stick.	  One	  point	  was	   scored	  when	  animals	  were	  unable	   to	   either	  balance	  upright	  or	   cling	  upside	  down	  to	  the	  stick	  with	  all	  four	  paws,	  for	  longer	  than	  10	  seconds.	  	  Placed	   in	   an	   open-­‐field	   environment,	   1,	   2,	   or	   3	   points	  were	   scored	   by	   animals	  which	   failed	   to	   exit	   a	   25cm	   diameter	   circle	   in	   30,	   60,	   and	   120	   seconds	  respectively.	  The	  presence	  of	  hemiparesis,	  inability	  to	  walk	  in	  a	  straight	  line,	  and	  the	   loss	   of	   seeking	   behaviour	  were	   determined	   by	   eye,	   with	   each	   scoring	   one	  point.	  Loss	  of	  the	  startle	  reflex	  was	  assessed	  by	  clapping	  of	  the	  hands	  above	  the	  animal,	  again	  scoring	  one	  point.	  	  	  The	   neuroscore	   was	   performed	   prior	   to	   CCI	   surgery,	   with	   healthy	   mice	  successful	  in	  all	  tasks	  and,	  in	  general,	  scoring	  0	  points.	  On	  rare	  occasions,	  certain	  healthy	   animals	   were	   found	   to	   score	   points	   on	   the	   beam	   walking	   tests,	  misplacing	   steps	   when	   crossing	   the	   beams	   too	   quickly.	   The	   neuroscore	   was	  repeated	   at	   24	   hour	   intervals	   after	   CCI	   injury,	   with	   the	   final	   test	   applied	  immediately	  before	  animals	  were	  sacrificed.	  	  	  
2.3.5	  Histological	  evaluation	  At	  the	  end	  of	  the	  observation	  period	  (24	  hours	  or	  5	  days),	  and	  following	  the	  final	  neuroscore,	   animals	   were	   anaesthetised	   with	   sevoflurane	   and	   sacrificed	   by	  cervical	  dislocation.	  The	  brain	  was	  carefully	   removed,	   frozen	  on	  powdered	  dry	  ice,	  and	  stored	  at	  -­‐20°C.	  	  	  At	  a	  later	  date,	  frozen	  brains	  were	  embedded	  in	  OCT	  mounting	  media	  (Cell	  Path	  Ltd,	  Newton,	  Powys,	  UK)	  and	  cut	  in	  the	  coronal	  plane	  with	  a	  cryostat	  tissue	  slicer	  (Leica	  CM1950;	  Leica	  Microsystems,	  Milton	  Keynes,	  UK).	  For	  each	  brain,	  16-­‐18	  sections	  (10	  µm	  thickness)	  were	  collected	  on	  Superfrost	  Plus	  microscope	  slides	  (Thermo	  Fisher	  Scientific,	  Loughborough,	  UK)	  every	  500µm	  across	   the	  entirety	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of	   the	   contusion.	   A	   total	   of	   10	   slices	   were	   collected	   at	   each	   brain	   interval,	   to	  allow	   plenty	   of	   material	   for	   histological	   analysis.	   Slide-­‐mounted	   slices	   were	  stored	  at	  -­‐20°C	  until	  ready	  for	  use.	  	  For	   the	   quantification	   of	   brain	   contusion	   volume,	   slide-­‐mounted	   brain	   slices	  were	   stained	   with	   cresyl-­‐violet.	   Briefly,	   slides	   were	   stained	   by	   sequential	  submersion	   in	  70%	  ethanol	   (2mins),	   cresyl-­‐violet	   0.6%	   (15mins),	   dH2O	   (rinse,	  twice),	   70%	   ethanol	   (rinse,	   twice),	   90%	   ethanol	   (rinse,	   twice)	   Roti-­‐Histol	  clearing	  agent	  (5mins),	  Roti-­‐Histol	  clearing	  agent	  (2mins).	  Slides	  were	  air-­‐dried	  for	   5	  minutes	   before	   being	  mounted	  with	   Roti-­‐Histokitt	   (Carl-­‐Roth,	   Karlsruhe,	  Germany)	  mounting	  media	  and	  a	  glass	  coverslip.	  	  Cresyl-­‐violet	  stained	  slices	  were	  imaged	  with	  a	  digital	  imaging	  system	  (Scopetek	  DCM510;	   Scopetek	   Opto-­‐Electric	   Co.,	   Hangzhou,	   China)	   attached	   to	   a	  stereomicroscope	   (Wild	   model	   M8;	   Heerbrugg,	   Switzerland),	   and	   the	   area	   of	  both	  hemispheres	  and	  contused	  brain	  tissue	  measured	  with	  computer	  software	  (Scopephoto	   3.1;	   Scopetek	   Opto-­‐Electric	   Co.,	   Hangzhou,	   China),	   by	   an	  investigator	   blinded	   to	   experimental	   groups.	   Contusion	   volume	  was	   calculated	  by	   multiplying	   contusion	   areas,	   A,	   by	   the	   distance	   between	   brain	   sections,	   d,	  (500µm),	  according	  to	  the	  following	  formula:	  	  
d/2	  *	  (A1	  +	  An)	  +	  d	  *	  (A2	  +	  A3	  +	  …	  +	  An-­‐1)	  	  Total	  injury	  contusion	  volume	  was	  determined	  by	  the	  above	  equation.	  Secondary	  injury	   was	   calculated	   by	   subtracting	   the	   primary	   contusion	   (measured	   15	  minutes	  after	  trauma)	  from	  the	  total	  injury	  at	  24	  hours.	  	  
2.3.6	  Statistical	  Analysis	  Significance	  was	  assessed	  using	  either	  a	  student’s	  t-­‐test	  or	  one-­‐way	  ANOVA,	  with	  Bonferroni’s	  post	  hoc	  test.	  For	  the	  5	  day	  survival	  experiments,	  a	  two-­‐way	  ANOVA	  with	  repeated	  measured	  with	  Bonferroni’s	  post	  hoc	  test	  was	  used.	  Factor	  1	  was	  treatment	   (xenon	   or	   control)	   and	   factor	   2	   was	   time	   post-­‐injury	   (e.g.	   1	   day,	   2	  days,	  3	  days,	  4	  days,	  or	  5	  days).	  Repeated	  measures	  ANOVA	  was	  thus	  used	  with	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factor	  1	  as	   the	   repeated	   factor.	  Two-­‐tailed	  hypothesis	   testing	  was	  used,	  with	  p	  values	  of	  less	  than	  0.05	  taken	  to	  indicate	  a	  significant	  difference	  between	  groups.	  Sample	  sizes,	  n,	  are	  indicated	  in	  figure	  legends.	  	  From	   pilot	   experiments,	   a	   sample	   size	   of	   10	   animals	   in	   each	   xenon	   treatment	  group	   was	   determined	   to	   provide	   statistical	   power.	   In	   certain	   of	   the	   xenon	  treatment	   groups,	   technical	   problems	  with	   the	   CCI	   surgery	   resulted	   in	   one	   or	  two	  animals	  being	  excluded.	  Separate	  control	  groups	  were	  pooled,	  resulting	  in	  a	  larger	   number	   of	   animals	   in	   this	   group.	   Error	   bars	   are	   standard	   error	   of	   the	  mean.	  Statistical	  tests	  were	  implemented	  using	  the	  SigmaPlot	  software	  package	  (Systat	  Inc.,	  Point	  Richmond,	  CA	  USA).	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   the	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  glycine	  site	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  Xenon	   has	   been	   shown	   to	   be	   neuroprotective	   against	   a	   variety	   of	   neuronal	  insults,	  in	  both	  in	  vitro	  and	  in	  vivo	  models	  [75,86,140].	  Most	  recently,	  it	  has	  been	  shown	   that	   xenon	   neuroprotection	   against	   hypoxic/ischemic	   injury	   and	  traumatic	  injury	  in	  vitro	  is	  mediated	  by	  xenon	  inhibition	  at	  the	  glycine	  site	  of	  the	  NMDA	   receptor	   [91].	   Inhibition	   of	   NMDA	   receptors	   at	   this	   site	   is	   a	   plausible	  mechanism	   for	   xenon	   neuroprotection	   in	   vivo	   –	   overactivation	   of	   the	   NMDA	  receptor	   is	  known	   to	  play	  a	   role	   in	  various	  pathological	   conditions,	   stroke	  and	  traumatic	   injury	   included	   -­‐	   however,	   a	   number	   of	   other	   receptor	   targets	   have	  emerged	   which	   might	   also	   play	   important	   roles	   in	   xenon’s	   neuroprotective	  properties.	  The	  two-­‐pore	  domain	  potassium	  channel	  TREK-­‐1	  and	  the	  adenosine	  triphosphate-­‐sensitive	  potassium	  channel	  are	  both	  activated	  by	  xenon.	  Further,	  the	   activation	   of	   both	   of	   these	   has	   been	   demonstrated	   to	   result	   in	  neuroprotection	  [63,141].	  	  With	  xenon	  now	  beginning	  clinical	  trials	  as	  a	  neuroprotectant,	  determination	  of	  the	   targets	   most	   important	   to	   xenon’s	   neuroprotective	   properties	   is	   timely.	  	  Advances	  in	  molecular	  genetics	  have	  allowed	  the	  generation	  of	  mouse	  lines	  used	  to	   determine	   the	   role	   of	   specific	   molecular	   targets	   in	   endpoints	   such	   as	  anaesthesia	   and	   neuroprotection,	   however	   due	   to	   the	   importance	   of	   NMDA	  receptors	   in	   normal	   physiological	   function,	   genetic	   knock-­‐out	   animals	   lacking	  NMDA	  receptors	  die	  soon	  after	  birth	  [142].	  An	  alternative	  strategy	  is	  a	  knock-­‐in	  mutation,	   in	  which	   the	   sensitivity	   to	   a	   drug	   is	   removed	  while	  normal	   receptor	  function	  is	  conserved.	  Such	  an	  approach	  has	  proven	  successful	  in	  understanding	  the	   pathways	   involved	   in	   propofol	   and	   etomidate	   anaesthesia,	   using	   knock-­‐in	  mice	  with	  a	  point	  mutation	  in	  the	  γ-­‐aminobutyric	  acid	  receptor	  type	  A	  (GABAA)	  β	  subunit	  [143-­‐146].	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Here	   I	   describe	   a	   series	   of	   experiments	   dissecting	   the	   molecular	   interactions	  xenon	   makes	   with	   the	   NMDA	   receptor,	   with	   the	   ultimate	   aim	   of	   identifying	  mutations	   in	   the	   NMDA	   receptor	   that	   will	   prevent	   xenon	   binding	   at	   the	   co-­‐agonist	   glycine	   site	   while	   leaving	   normal	   receptor	   function	   intact.	   The	  identification	  of	  such	  a	  mutation	  would	  open	  the	  possibility	  of	  generating	  genetic	  knock-­‐in	   animals	   of	   great	   use	   in	   dissecting	   out	   the	   role	   played	   by	   the	   NMDA	  receptor	  in	  the	  anaesthetic,	  analgesic,	  and	  neuroprotective	  properties	  of	  xenon.	  	  Previous	  molecular	  modelling	  simulations	  [48]	  have	  identified	  a	  small	  number	  of	  amino	   acids	   in	   close	   proximity	   to	   the	   binding	   site	   of	   xenon	  within	   the	   NMDA	  receptor	   crystal	   structure	   (Table	   3.1).	   These	   all	   lie	   within	   4	   angstroms	   of	   the	  xenon	  atoms,	  and	  are	  therefore	  most	  likely	  to	  interact	  with	  and	  contribute	  to	  the	  binding	  of	   xenon	   at	   the	   site	   (Figure	  3.1).	   Further,	   literature	   evidence	   indicates	  that	  one	  common	  feature	  of	  previously	   identified	  xenon	  binding	  sites	   is	   the	  co-­‐ordination	   of	   xenon	   atoms	   by	   aromatic	   amino	   acids	   [147,148].	   The	   mutation	  strategy	  employed	  was	   thus	   focussed	  on	   those	  aromatic	  amino	  acids	  closest	   to	  the	   xenon	   binding	   site,	   as	   identified	   by	   the	   previous	   modelling	   simulations	  (Figure	  3.2).	  	  	  	  
3.1	   Glycine	   affinity	   of	   wild-­‐type	   and	   mutant	   NMDA	  
receptors	  	  NMDA	   receptors	   consisting	   of	   GluN1/GluN2A	   subunits	   were	   used	   for	   all	  mutational	   and	   electrophysiological	   experiments,	   as	   this	   represents	   the	   most	  common	  subunit	  combination	  in	  the	  adult	  hippocampus	  and	  neocortex	  [36,149].	  As	  the	  aim	  of	  this	  study	  was	  to	  identify	  a	  receptor	  mutation	  that	  disrupts	  xenon	  binding	  while	  leaving	  normal	  receptor	  function	  intact,	  and	  because	  amino	  acids	  are	  necessarily	  being	  mutated	  within	  the	  co-­‐agonist	  glycine	  binding	  site,	   it	  was	  important	   to	   first	   characterise	   the	   glycine-­‐concentration	   response	   of	   each	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Table	   3.1:	   Amino	   acids	  within	   4	   angstroms	   of	   the	   predicted	   binding	   site	   for	   xenon,	   and	  
thus	  likely	  to	  interact	  with	  xenon	  atoms	  during	  binding.	  Interaction	  of	  these	  with	  glycine	  
is	  also	  indicated.	  Table	  re-­‐drawn	  from	  Dickinson	  et	  al,	  2007	  [48].	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Figure	   3.1:	  Modelling	   simulations	   predict	   that	   xenon	   atoms	   bind	   to	   the	   NMDA	   receptor	  
GluN1	   subunit	   co-­‐agonist	   glycine	   site.	   Xenon	   atoms	   are	   shown	   as	   red	   spheres.	   The	  
predicted	   xenon-­‐binding	   site	   is	   represented	   as	   a	   grey	   surface.	   Amino	   acids	   within	   4	  
angstroms	  of	   the	   xenon	   atoms	   -­‐	   and	   thus	   very	   likely	   to	   interact	  with	   xenon	   atoms	   -­‐	   are	  
shown	  as	  grey	  sticks.	  
	  
Figure	   3.2:	   The	   predicted	   xenon	   binding	   site	   on	   the	   NMDA	   receptor	   GluN1	   subunit	   has	  
xenon	  atoms	  coordinated	  by	  three	  aromatic	  residues;	  W731,	  F758,	  and	  F484.	  Interactions	  
with	  aromatic	  residues	  are	  important	  in	  the	  binding	  of	  both	  xenon	  and	  glycine	  at	  the	  site.	  
Xenon	  atoms	  are	  shown	  as	  red	  spheres.	  The	  aromatic	  amino	  acid	  residues	  co-­‐ordinating	  
the	  xenon	  binding	  site	  are	  shown	  as	  grey	  sticks.	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receptor.	  This	  is	  necessary	  in	  order	  to	  ensure	  that	  the	  glycine	  affinity	  of	  receptor	  mutants	  is	  not	  excessively	  altered,	  and	  to	  ensure	  that	  xenon	  inhibition	  of	  mutant	  and	  wild-­‐type	  receptors	  is	  compared	  at	  equivalent	  glycine	  concentrations.	  	  
3.1.1	  Glycine	  affinity	  of	  wild-­‐type	  GluN1/GluN2A	  receptors	  GluN1/GluN2A	   receptors	   were	   expressed	   transiently	   in	   HEK-­‐293	   cells	   and	  receptor	  currents	  measured	  in	  response	  to	  stimulation	  by	  100µM	  NMDA	  in	  the	  presence	  of	  eight	  concentrations	  of	  glycine	  ranging	  from	  0.3-­‐100µM.	  	  The	  glycine	  concentration-­‐response	  curve	  constructed	  from	  pooled	  data	  and	  fit	  by	   a	   Hill	   equation	   is	   shown	   in	   Figure	   3.3,	   while	   typical	   currents	   evoked	   are	  shown	  in	  Figure	  3.4.	  EC50,	  nH,	  and	  Imax	   for	  glycine	  were	  5.7±1.5µM,	  0.8±0.2,	  and	  1.05±0.11	  respectively.	  	  
3.1.2	  Glycine	  affinity	  of	  GluN1(W731)	  mutants	  Two	   mutants	   of	   the	   tryptophan	   731	   residue	   were	   produced;	  GluN1(W731A)/GluN2A,	  where	  the	  aromatic	  tryptophan	  was	  mutated	  to	  a	  non-­‐aromatic	   alanine;	   and	   GluN1(W731L),	   where	   the	   aromatic	   tryptophan	   was	  mutated	  to	  a	  non-­‐aromatic	  leucine.	  While	  both	  these	  mutants	  formed	  functional	  receptors,	  the	  apparent	  glycine	  affinity	  was	  reduced	  by	  some	  130-­‐fold.	  Receptor	  currents	   were	   measured	   in	   response	   to	   stimulation	   by	   100µM	   NMDA	   in	   the	  presence	  of	  eight	  concentrations	  of	  glycine	  ranging	  from	  10µM-­‐30mM.	  	  EC50,	  nH,	  and	  Imax	  for	  the	  W731A	  mutant	  were	  744±66µM,	  1.1±0.1,	  and	  1.01±0.02	  respectively	   (Figure	   3.5).	   For	   the	   W731L	   mutant,	   EC50,	   nH,	   and	   Imax	   were	  895±78µM,	  0.92±0.06,	  and	  1.06±0.02	  respectively	  (Figure	  3.7).	  In	  both	  mutants	  the	   maximum	   currents	   evoked	   (Figure	   3.6	   for	   W731A)	   were	   so	   greatly	  attenuated	   that	   it	   would	   not	   have	   been	   possible	   to	   accurately	   determine	   the	  degree	   of	   any	   inhibition	   by	   xenon.	   For	   this	   reason	   these	   mutants	   were	   not	  investigated	  further.	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Figure	   3.3:	   Glycine	   concentration-­‐response	   curve	   for	   wild-­‐type	   GluN1/GluN2A	   NMDA	  
receptors.	  NMDA	  receptor	  currents	  were	  measured	   in	  response	   to	  application	  of	  100µM	  
NMDA	  in	  the	  presence	  of	  eight	  concentrations	  of	  glycine.	  The	  curve	  shown	  is	  fit	  to	  the	  Hill	  
equation.	  EC50,	  nH,	  and	  Imax	  are	  5.7±1.5µM,	  0.8±0.2,	  and	  1.05±0.11	  respectively.	  Points	  are	  
mean	   values	   from	   an	   average	   of	   eight	   cells.	   Error	   bars	   are	   standard	   error	   of	   the	  mean.	  
Data	  are	  normalised	  to	  the	  maximal	  response	  by	  a	  saturating	  concentration	  of	  glycine.	  
	  
Figure	   3.4:	   Typical	   currents	   evoked	   from	   wild-­‐type	   GluN1/GluN2A	   NMDA	   receptors	   in	  
response	  to	  stimulation	  by	  100µM	  NMDA	  and	  varying	  concentrations	  of	  glycine.	  Receptors	  
were	   transiently	   expressed	   in	   HEK-­‐293	   cells,	   with	   cells	   voltage-­‐clamped	   at	   -­‐60mV.	   Ten	  
second	  applications	  of	  NMDA	  are	  shown	  as	  bars	  above	  responses.	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Figure	   3.5:	   Glycine	   concentration-­‐response	   curve	   for	   mutant	   GluN1(W731A)/GluN2A	  
NMDA	  receptors.	  Receptor	  currents	  were	  measured	  in	  response	  to	  application	  of	  100µM	  
NMDA	  in	  the	  presence	  of	  eight	  concentrations	  of	  glycine.	  The	  curve	  shown	  is	  fit	  to	  the	  Hill	  
equation.	  EC50,	  nH,	  and	  Imax	  are	  744±66µM,	  1.1±0.1,	  and	  1.01±0.02	  respectively.	  Points	  are	  
mean	   values	   from	   an	   average	   of	   eight	   cells.	   Error	   bars	   are	   standard	   error	   of	   the	  mean.	  
Data	   are	   normalised	   to	   the	  maximal	   response	   by	   a	   saturating	   concentration	   of	   glycine.	  
Grey	  line	  is	  the	  Hill	  curve	  fit	  for	  wild-­‐type	  GluN1/GluN2A	  receptors.	  
	  
Figure	  3.6:	  Typical	  currents	  evoked	  from	  mutant	  GluN1(W731A)/GluN2A	  NMDA	  receptors	  
in	   response	   to	   stimulation	   by	   100µM	   NMDA	   and	   varying	   concentrations	   of	   glycine.	  
Receptors	   were	   transiently	   expressed	   in	   HEK-­‐293	   cells,	   with	   cells	   voltage-­‐clamped	   at	   -­‐
60mV.	  Ten	  second	  applications	  of	  NMDA	  are	  shown	  as	  bars	  above	  responses.	  
	  
Figure	   3.7:	   Glycine	   concentration-­‐response	   curve	   for	   mutant	   GluN1(W731L)/GluN2A	  
NMDA	  receptors.	  Receptor	  currents	  were	  measured	  in	  response	  to	  application	  of	  100µM	  
NMDA	  in	  the	  presence	  of	  eight	  concentrations	  of	  glycine.	  The	  curve	  shown	  is	  fit	  to	  the	  Hill	  
equation.	  EC50,	  nH,	  and	   Imax	  are	  895±78µM,	  0.92±0.06,	  and	  1.06±0.02	  respectively.	  Points	  
are	  mean	  values	  from	  an	  average	  of	  five	  cells.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  
Data	   are	   normalised	   to	   the	  maximal	   response	   by	   a	   saturating	   concentration	   of	   glycine.	  
Grey	  line	  is	  the	  Hill	  curve	  fit	  for	  wild-­‐type	  GluN1/GluN2A	  receptors.	  	   	  
Data	  on	  this	  page	  courtesy	  of	  Paul	  Banks	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3.1.3	  Glycine	  affinity	  of	  GluN1(F758)	  mutants	  The	  aromatic	  phenylalanine	  758	  site	  was	  first	  mutated	  to	  a	  non-­‐aromatic	  alanine	  residue.	   The	   glycine	   concentration-­‐response	   for	   the	   GluN1(F758A)/GluN2A	  receptor	   was	   measured	   in	   response	   to	   stimulation	   by	   100µM	   NMDA	   in	   the	  presence	   of	   eight	   concentrations	   of	   glycine	   ranging	   from	   0.03µM-­‐1000µM	  (Figure	   3.8).	   The	   F758A	   mutation	   caused	   only	   a	   modest	   reduction	   in	   the	  apparent	   glycine	   affinity,	   with	   the	   EC50,	   nH,	   and	   Imax	   for	   this	   mutant	   receptor	  being	   30.0±2.5µM,	   1.2±0.1,	   and	   1.03±0.02	   respectively.	   Additionally,	   the	  maximum	   evoked	   currents	   for	   the	   F758A	   mutant	   compare	   well	   with	   those	  observed	  for	  the	  wild-­‐type	  receptor	  (Figure	  3.9).	  	  The	  phenylalanine	  758	  residue	  was	  next	  mutated	  to	  a	  leucine.	  The	  effects	  of	  the	  F758L	  mutation	  are	  similar	  to	  those	  observed	  for	  the	  F758A	  mutant;	  a	  modest,	  six-­‐fold	  reduction	   in	  glycine	  affinity	  compared	  with	   the	  wild-­‐type	  receptor.	  For	  the	  F758L	  mutant	  EC50,	   nH,	   and	   Imax	   for	   glycine	  were	  30.1±2.6µM,	  1.1±0.1,	   and	  1.04±0.03	   respectively	   (Figure	   3.10).	  Maximum	   evoked	   currents	   compare	  well	  with	  both	  the	  wild-­‐type	  and	  F758A	  mutant	  (Figure	  3.11).	  	  Mutation	   of	   the	   aromatic	   phenylalanine	   758	   residue	   to	   the	   non-­‐aromatic	  residues	   alanine	   or	   leucine	   produced	   functional	   receptors	   with	   only	   modest	  reductions	   in	   the	   apparent	   glycine	   affinity	   –	   indicating	   that	   aromaticity	   at	   this	  site	   is	   in	  some	  way	   important	   in	   the	  binding	  of	  glycine.	  The	  phenylalanine	  758	  site	   was	   thus	   next	   mutated	   to	   another,	   different	   aromatic	   residue;	   namely	  tryptophan.	   Receptor	   currents	   were	   measured	   in	   response	   to	   stimulation	   by	  100µM	  NMDA	   in	   the	   presence	   of	   eight	   concentrations	   of	   glycine	   ranging	   from	  0.3µM-­‐1000µM.	   The	   glycine	   concentration-­‐response	   curve	   for	   the	  GluN1(F758W)/GluN2A	  mutant	  is	  shown	  in	  Figure	  3.12,	  and	  typical	  currents	  in	  Figure	   3.13.	   For	   this	   mutant	   receptor,	   the	   EC50,	   nH,	   and	   Imax	   for	   glycine	   were	  5.2±0.2µM,	   1.1±0.1,	   and	   0.99±0.02	   respectively.	   Importantly,	   the	   apparent	  glycine	  affinity	  of	  the	  F758W	  mutant	  receptor	  does	  not	  differ	  significantly	  from	  that	   of	   the	   wild-­‐type	   (wild-­‐type	   EC50	   and	   nH	   for	   glycine	   being	   5.7±1.5µM	   and	  0.8±0.2	  respectively).	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Figure	   3.8:	   Glycine	   concentration-­‐response	   curve	   for	   mutant	   GluN1(F758A)/GluN2A	  
NMDA	  receptors.	  Receptor	  currents	  were	  measured	  in	  response	  to	  application	  of	  100µM	  
NMDA	  in	  the	  presence	  of	  seven	  concentrations	  of	  glycine.	  The	  curve	  shown	  is	  fit	  to	  the	  Hill	  
equation.	  EC50,	  nH,	  and	  Imax	  are	  30.0±2.5µM,	  1.2±0.1,	  and	  1.03±0.02	  respectively.	  Points	  are	  
mean	  values	   from	  an	  average	  of	   seven	   cells.	   Error	  bars	  are	   standard	  error	  of	   the	  mean.	  
Data	   are	   normalised	   to	   the	  maximal	   response	   by	   a	   saturating	   concentration	   of	   glycine.	  
Grey	  line	  is	  the	  Hill	  curve	  fit	  for	  wild-­‐type	  GluN1/GluN2A	  receptors.	  
	  
Figure	  3.9:	  Typical	  currents	  evoked	  from	  mutant	  GluN1(F758A)/GluN2A	  NMDA	  receptors	  
in	   response	   to	   stimulation	   by	   100µM	   NMDA	   and	   varying	   concentrations	   of	   glycine.	  
Receptors	   were	   transiently	   expressed	   in	   HEK-­‐293	   cells,	   with	   cells	   voltage-­‐clamped	   at	   -­‐
60mV.	  Ten	  second	  applications	  of	  NMDA	  are	  shown	  as	  bars	  above	  each	  response.	  	   	  
Data	  on	  this	  page	  courtesy	  of	  Paul	  Banks	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Figure	   3.10:	   Glycine	   concentration-­‐response	   curve	   for	   mutant	   GluN1(F758L)/GluN2A	  
NMDA	  receptors.	  Receptor	  currents	  were	  measured	  in	  response	  to	  application	  of	  100µM	  
NMDA	  in	  the	  presence	  of	  eight	  concentrations	  of	  glycine.	  The	  curve	  shown	  is	  fit	  to	  the	  Hill	  
equation.	  EC50,	  nH,	  and	  Imax	  are	  30.1±2.6µM,	  1.1±0.1,	  and	  1.04±0.03	  respectively.	  Points	  are	  
mean	  values	  from	  an	  average	  of	  nine	  cells.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  Data	  
are	  normalised	  to	  the	  maximal	  response	  by	  a	  saturating	  concentration	  of	  glycine.	  Grey	  line	  
is	  the	  Hill	  curve	  fit	  for	  wild-­‐type	  GluN1/GluN2A	  receptors.	  
	  
Figure	  3.11:	  Typical	  currents	  evoked	  from	  mutant	  GluN1(F758L)/GluN2A	  NMDA	  receptors	  
in	   response	   to	   stimulation	   by	   100µM	   NMDA	   and	   varying	   concentrations	   of	   glycine.	  
Receptors	   were	   transiently	   expressed	   in	   HEK-­‐293	   cells,	   with	   cells	   voltage-­‐clamped	   at	   -­‐
60mV.	  Ten	  second	  applications	  of	  NMDA	  are	  shown	  as	  bars	  above	  each	  response.	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Figure	   3.12:	   Glycine	   concentration-­‐response	   curve	   for	   mutant	   GluN1(F758W)/GluN2A	  
NMDA	  receptors.	  Receptor	  currents	  were	  measured	  in	  response	  to	  application	  of	  100µM	  
NMDA	  in	  the	  presence	  of	  seven	  concentrations	  of	  glycine.	  The	  curve	  shown	  is	  fit	  to	  the	  Hill	  
equation.	  EC50,	  nH,	  and	  Imax	  are	  5.2±0.2µM,	  1.1±0.1,	  and	  0.99±0.02	  respectively.	  Points	  are	  
mean	  values	  from	  an	  average	  of	  fourteen	  cells.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  
Data	   are	   normalised	   to	   the	  maximal	   response	   by	   a	   saturating	   concentration	   of	   glycine.	  
Grey	  line	  is	  the	  Hill	  curve	  fit	  for	  wild-­‐type	  GluN1/GluN2A	  receptors.	  
	  
Figure	   3.13:	   Typical	   currents	   evoked	   from	   mutant	   GluN1(F758W)/GluN2A	   NMDA	  
receptors	   in	   response	   to	   stimulation	   by	   100µM	   NMDA	   and	   varying	   concentrations	   of	  
glycine.	   Receptors	   were	   transiently	   expressed	   in	   HEK-­‐293	   cells,	   with	   cells	   voltage-­‐
clamped	   at	   -­‐60mV.	   Ten	   second	   applications	   of	   NMDA	   are	   shown	   as	   bars	   above	   each	  
response.	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Figure	   3.14:	   Glycine	   concentration-­‐response	   curve	   for	   mutant	   GluN1(F758Y)/GluN2A	  
NMDA	  receptors.	  Receptor	  currents	  were	  measured	  in	  response	  to	  application	  of	  100µM	  
NMDA	  in	   the	  presence	  of	  six	  concentrations	  of	  glycine.	  The	  curve	  shown	   is	   fit	   to	   the	  Hill	  
equation.	  EC50,	  nH,	  and	  Imax	  are	  4.8±0.5µM,	  1.4±0.2,	  and	  0.99±0.03	  respectively.	  Points	  are	  
mean	  values	  from	  an	  average	  of	  six	  cells.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  Data	  
are	  normalised	  to	  the	  maximal	  response	  by	  a	  saturating	  concentration	  of	  glycine.	  Grey	  line	  
is	  the	  Hill	  curve	  fit	  for	  wild-­‐type	  GluN1/GluN2A	  receptors.	  
	  
Figure	  3.15:	  Typical	  currents	  evoked	  from	  mutant	  GluN1(F758Y)/GluN2A	  NMDA	  receptors	  
in	   response	   to	   stimulation	   by	   100µM	   NMDA	   and	   varying	   concentrations	   of	   glycine.	  
Receptors	   were	   transiently	   expressed	   in	   HEK-­‐293	   cells,	   with	   cells	   voltage-­‐clamped	   at	   -­‐
60mV.	  Ten	  second	  applications	  of	  NMDA	  are	  shown	  as	  bars	  above	  each	  response.	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Finally,	   the	   phenylalanine	   758	   residue	   was	   mutated	   to	   an	   aromatic	   tyrosine	  residue.	  Again,	   receptor	  currents	  were	  measured	   in	  response	   to	  stimulation	  by	  100µM	  NMDA	   in	   the	   presence	   of	   eight	   concentrations	   of	   glycine	   ranging	   from	  0.3µM-­‐1000µM,	   with	   the	   glycine	   concentration-­‐response	   curve	   for	   the	  GluN1(F758Y)/GluN2A	   mutant	   shown	   in	   Figure	   3.14,	   and	   typical	   evoked	  currents	  in	  Figure	  3.15.	  As	  for	  the	  F758W	  mutant,	  the	  F758Y	  mutation	  does	  not	  have	  a	  significantly	  different	  apparent	  glycine	  affinity	  when	  compared	  with	  the	  wild-­‐type.	  For	  the	  F758Y	  mutant	  receptor,	  the	  EC50,	  nH,	  and	  Imax	  for	  glycine	  were	  found	  to	  be	  4.8±0.5µM,	  1.4±0.2,	  and	  0.99±0.03	  respectively.	  	  	  	  
3.2	  Inhibition	  of	  wild-­‐type	  and	  mutant	  NMDA	  receptors	  
by	  xenon	  	  In	   order	   to	   determine	   whether	   these	   GluN1(F758)	   receptor	   mutants	   have	  affected	  the	  binding	  of	  xenon	  at	  the	  glycine	  site,	  the	  degree	  of	  receptor	  inhibition	  by	   xenon	   was	   investigated	   at	   different	   concentrations	   of	   glycine.	   If	   xenon	  continues	   to	   bind	   at	   the	   glycine	   site	   (and	   thus	   compete	   with	   glycine	   for	  occupation	   of	   the	   site),	   then	   the	   degree	   of	   receptor	   inhibition	   by	   xenon	   will	  depend	  upon	  the	  concentration	  of	  glycine;	  xenon	  will	  inhibit	  the	  receptors	  more	  at	   low	   glycine	   concentrations,	   and	   less	   at	   high	   glycine	   concentrations.	   If	   the	  binding	  of	  xenon	  at	   the	  site	  has	  been	  disrupted	  by	   the	  site	  mutations,	   then	   the	  glycine	  dependence	  of	  the	  inhibition	  should	  be	  attenuated	  or	  abolished.	  	  The	  degree	  of	  receptor	  inhibition	  by	  xenon	  was	  measured	  for	  both	  the	  wild-­‐type	  and	  mutant	  NMDA	  receptors	  at	  a	   range	  of	  glycine	  concentrations	  spanning	   the	  glycine	  concentration-­‐response	  curve	  for	  each	  receptor,	  as	  determined	  in	  section	  3.1.	  Xenon	  was	  applied	  to	  receptors	  as	  a	  saturated	  solution	  of	  80%	  xenon/20%	  oxygen,	   prepared	   from	   gas-­‐saturated	   solutions	   described	   in	   Methods	   2.2.3.	  Control	  solutions	  were	  80%	  nitrogen/20%	  oxygen.	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3.2.1	  Xenon	  inhibition	  of	  wild-­‐type	  GluN1/GluN2A	  receptors	  Inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   receptors	   was	   found	   to	   be	   dependent	  upon	  glycine	  concentration,	   increasing	   from	  29±1%	  inhibition	  at	  high	  (100µM)	  glycine	   concentrations	   to	   59±5%	   inhibition	   at	   low	   (10µM)	   glycine	  concentrations	   (Figure	   3.16).	   This	   increase	   in	   inhibition	   at	   low	   glycine	  concentrations	  is	  significant	  (p<0.025),	  and	  is	  consistent	  with	  xenon	  competing	  with	  glycine	  for	  the	  same	  binding	  site.	  	  
3.2.2	  Xenon	  inhibition	  of	  GluN1(F758)	  receptor	  mutants	  Inhibition	  of	  the	  GluN1(F758A)	  mutant	  is	  shown	  in	  Figure	  3.17.	  In	  contrast	  to	  the	  wild-­‐type	   receptor,	   there	   is	   no	   glycine-­‐dependence	   to	   the	   inhibition	   of	   this	  mutant	  by	  xenon.	  Xenon	  inhibited	  F758A	  receptors	  by	  27±1%	  at	  high	  (1000µM)	  glycine	  concentrations,	  and	  by	  30±2%	  at	   low	  (2.5µM)	  glycine.	  Similarly,	   for	  the	  GluN1(F758L)	  mutant	  the	  glycine-­‐dependence	  of	  xenon	  inhibition	  was	  found	  to	  be	  absent,	  with	  80%	  xenon/20%	  oxygen	  inhibiting	  the	  F758L	  mutant	  by	  30±5%	  at	   high	   (1000µM)	   glycine,	   and	   by	   the	   same	   amount	   (30±3%)	   at	   low	   (5µM)	  glycine	  (Figure	  3.18).	  	  For	   the	   F758W	  mutant,	  which	   conserves	   glycine	   affinity	   at	  wild-­‐type	   levels,	   it	  was	  found	  that	  the	  glycine-­‐dependence	  of	  xenon	  inhibition	  had	  been	  abolished	  in	  a	   manner	   similar	   to	   the	   F758A	   and	   F758L	   mutants.	   80%	   xenon/20%	   oxygen	  inhibited	  the	  F758W	  mutant	  by	  27±3%	  at	  high	  (100µM)	  glycine,	  and	  by	  25±1%	  at	  low	  (1µM)	  glycine	  concentration	  (Figure	  3.19).	  	  Finally,	   in	  the	  F758Y	  mutant	  (which	  also	  conserves	  glycine	  affinity	  at	  wild-­‐type	  levels),	   the	  glycine-­‐dependence	  of	  xenon	  inhibition	  was	  also	  eliminated	  (Figure	  3.20).	   80%	   xenon/20%	  oxygen	   inhibited	   the	   F758Y	  mutant	   by	   31±2%	  at	   high	  (100µM)	  glycine,	   and	  by	  38±4%	  at	   low	   (1µM)	  glycine	   concentration.	   For	   all	   of	  these	   mutants	   of	   the	   phenylalanine	   758	   site,	   the	   abolishment	   of	   the	   glycine-­‐dependence	  of	  xenon	   inhibition	   is	  consistent	  with	  xenon	  and	  glycine	  no	   longer	  competing	  for	  the	  same	  receptor	  binding	  site.	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Figure	   3.16:	   The	   degree	   of	   inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   NMDA	   receptors	   by	  
xenon	  increases	  as	  glycine	  concentration	  is	  reduced.	  Reversal	  of	  inhibition	  by	  increasing	  
glycine	  is	  consistent	  with	  xenon	  and	  glycine	  competing	  for	  the	  same	  site.	  The	  %	  of	  control	  
represents	  the	  ratio	  of	  current	  in	  the	  presence	  of	  xenon	  to	  that	  in	  the	  absence	  of	  xenon	  at	  
each	  glycine	  concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  
are	   standard	   error	   of	   the	   mean.	   *p<0.025	   is	   significantly	   different	   from	   inhibition	   at	  
100µM	  glycine.	  
	  
Figure	  3.17:	  Inhibition	  of	  the	  mutant	  GluN1(F758A)/GluN2A	  receptor	  by	  xenon	  is	  glycine	  
independent.	   This	   lack	   of	   glycine	   dependence	   is	   consistent	   with	   the	   F758A	   mutation	  
abolishing	   xenon	  binding	  at	   the	   co-­‐agonist	   glycine	   site.	  The	  %	  of	   control	   represents	   the	  
ratio	  of	  current	   in	   the	  presence	  of	  xenon	  to	   that	   in	   the	  absence	  of	  xenon	  at	  each	  glycine	  
concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  are	  standard	  
error	  of	  the	  mean.	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Figure	  3.18:	  Inhibition	  of	  the	  mutant	  GluN1(F758L)/GluN2A	  receptor	  by	  xenon	  is	  glycine	  
independent.	   This	   lack	   of	   glycine	   dependence	   is	   consistent	   with	   the	   F758L	   mutation	  
abolishing	   xenon	  binding	  at	   the	   co-­‐agonist	   glycine	   site.	  The	  %	  of	   control	   represents	   the	  
ratio	  of	  current	   in	   the	  presence	  of	  xenon	  to	   that	   in	   the	  absence	  of	  xenon	  at	  each	  glycine	  
concentration.	   Bars	   are	  mean	   values	   from	   an	   average	   six	   cells.	   Error	   bars	   are	   standard	  
error	  of	  the	  mean.	  
	  
Figure	  3.19:	  Inhibition	  of	  the	  mutant	  GluN1(F758W)/GluN2A	  receptor	  by	  xenon	  is	  glycine	  
independent.	   This	   lack	   of	   glycine	   dependence	   is	   consistent	   with	   the	   F758W	   mutation	  
abolishing	   xenon	  binding	  at	   the	   co-­‐agonist	   glycine	   site.	  The	  %	  of	   control	   represents	   the	  
ratio	  of	  current	   in	   the	  presence	  of	  xenon	  to	   that	   in	   the	  absence	  of	  xenon	  at	  each	  glycine	  
concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  seven	  cells.	  Error	  bars	  are	  standard	  
error	  of	  the	  mean.	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Figure	  3.20:	  Inhibition	  of	  the	  mutant	  GluN1(F758Y)/GluN2A	  receptor	  by	  xenon	  is	  glycine	  
independent.	   This	   lack	   of	   glycine	   dependence	   is	   consistent	   with	   the	   F758Y	   mutation	  
abolishing	   xenon	  binding	  at	   the	   co-­‐agonist	   glycine	   site.	  The	  %	  of	   control	   represents	   the	  
ratio	  of	  current	   in	   the	  presence	  of	  xenon	  to	   that	   in	   the	  absence	  of	  xenon	  at	  each	  glycine	  
concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  are	  standard	  
error	  of	  the	  mean.	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3.3	  Inhibition	  of	  wild-­‐type	  and	  mutant	  NMDA	  receptors	  
by	   sevoflurane,	   isoflurane,	   nitrous	   oxide,	   and	  
cyclopropane	  	  It	   has	   previously	   been	   shown	   that	   the	   volatile	   anaesthetic	   isoflurane	   inhibits	  NMDA	   receptors	   via	   competitive	   inhibition	   of	   the	   co-­‐agonist	   glycine	   site	   [48],	  providing	  additional	  evidence	   for	  a	   role	  of	  NMDA	  receptor	  blockade	   in	  general	  anaesthesia.	   It	   is	   thus	   plausible	   that	   sevoflurane	   (a	   related	   halogenated	   ether	  also	   used	   in	   general	   anaesthesia)	   might	   also	   inhibit	   NMDA	   receptors	   at	   the	  glycine	   site.	   Here,	   sevoflurane	   and	   the	   gaseous	   anaesthetics	   nitrous	   oxide	   and	  cyclopropane	  are	  tested	  for	  their	  ability	  to	  inhibit	  NMDA	  receptors	  at	  the	  GluN1	  co-­‐agonist	  glycine	  site.	  	  
3.3.1	  Anaesthetic	  inhibition	  of	  wild-­‐type	  GluN1/GluN2A	  receptors	  Sevoflurane	   was	   applied	   to	   receptors	   as	   4	   and	   8%	   fractions	   of	   a	   saturated	  solution	  –	  equivalent	  to	  molar	  concentrations	  of	  0.47,	  and	  0.94mM	  respectively.	  	  At	   high	   (100µM)	   glycine	   concentrations,	   neither	   concentration	   of	   sevoflurane	  was	   found	   to	   inhibit	   NMDA	   receptor	   currents,	   however	   at	   low	   (1µM)	   glycine	  both	   0.47	   and	   0.94mM	   concentrations	   of	   sevoflurane	   resulted	   in	   a	   significant	  (p<0.025)	  inhibition	  of	  the	  receptor,	  by	  23±3%	  and	  28±3%	  respectively	  (Figure	  3.21).	   These	   data	   confirm	   the	   ability	   of	   sevoflurane	   to	   inhibit	   wild-­‐type	  GluN1/GluN2A	   receptors	   at	   the	   GluN1	   glycine	   site.	   This	   inhibition	   is	   glycine-­‐dependent	  and	  is	  abolished	  completely	  by	  raising	  the	  concentration	  of	  glycine	  –	  indicative	  of	  a	  purely	  competitive	  interaction	  between	  sevoflurane	  and	  glycine	  at	  the	  co-­‐agonist	  site.	  	  Similar	   is	   true	   of	   isoflurane	   inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   receptors;	  isoflurane	   (0.31mM	   and	   1.24mM)	   did	   not	   inhibit	   receptor	   currents	   at	   high	  (100µM)	  glycine	  concentrations,	  but	  inhibition	  increased	  significantly	  to	  38±2%	  and	  49±3%	  respectively	  at	  low	  (1µM)	  glycine	  (Figure	  3.22).	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Figure	   3.21:	   Inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   receptors	   by	   sevoflurane	   is	   glycine	  
dependent.	  Increasing	  the	  glycine	  concentration	  reduces	  the	  degree	  of	  receptor	  inhibition	  
by	  two	  concentrations	  of	  sevoflurane	  (blue	  bars	  0.47mM,	  black	  bars	  0.94mM),	  consistent	  
with	   glycine	   and	   sevoflurane	   competing	   for	   the	   same	   receptor	   binding	   site.	   The	   %	   of	  
control	  represents	  the	  ratio	  of	  current	  in	  the	  presence	  of	  anaesthetic	  to	  that	  in	  the	  absence	  
of	  anaesthetic	  at	  each	  glycine	  concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  nine	  
cells.	  Error	  bars	  are	  standard	  error	  of	   the	  mean.	  *p<0.025	   is	  significantly	  different	   from	  
inhibition	  at	  100µM	  glycine.	  
	  
Figure	   3.22:	   Inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   receptors	   by	   isoflurane	   is	   glycine	  
dependent.	  Increasing	  the	  glycine	  concentration	  reduces	  the	  degree	  of	  receptor	  inhibition	  
by	   isoflurane	   (black	   bars	   0.31mM,	   green	   bars	   1.24mM),	   consistent	   with	   glycine	   and	  
isoflurane	  competing	  for	  the	  same	  receptor	  binding	  site.	  The	  %	  of	  control	  represents	  the	  
ratio	  of	  current	  in	  the	  presence	  of	  anaesthetic	  to	  that	  in	  the	  absence	  of	  anaesthetic	  at	  each	  
glycine	  concentration.	  Bars	  are	  mean	  values	   from	  an	  average	  seven	  cells.	  Error	  bars	  are	  
standard	  error	  of	   the	  mean.	  *p<0.025	   is	  significantly	  different	   from	  inhibition	  at	  100µM	  
glycine.	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Figure	   3.23:	   Inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   receptors	   by	   80%	   nitrous	   oxide	   is	  
glycine	   dependent.	   Increasing	   the	   glycine	   concentration	   reduces	   the	   degree	   of	   receptor	  
inhibition	  by	  nitrous	  oxide,	   consistent	  with	   glycine	   and	  nitrous	  oxide	   competing	   for	   the	  
same	   receptor	   binding	   site.	   The	   %	   of	   control	   represents	   the	   ratio	   of	   current	   in	   the	  
presence	  of	  anaesthetic	  to	  that	  in	  the	  absence	  of	  anaesthetic	  at	  each	  glycine	  concentration.	  
Bars	  are	  mean	  values	  from	  an	  average	  six	  cells.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  
*p<0.025	  is	  significantly	  different	  from	  inhibition	  at	  100µM	  glycine.	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Nitrous	  oxide,	  applied	  to	  receptors	  as	  an	  80%	  saturated	  solution	  (80%	  N2O/20%	  oxygen),	   was	   found	   to	   inhibit	   wild-­‐type	   receptors	   to	   a	   lesser	   degree	   than	   the	  same	   concentration	   of	   xenon,	   but	   with	   glycine	   dependence	   of	   the	   inhibition	  intact	   (Figure	  3.23).	  Receptor	   inhibition	   increased	   significantly	   (p<0.025)	   from	  19.2±2.6%	   at	   high	   (100µM)	   glycine	   to	   29.8	   ±3.7%	   at	   low	   (1µM)	   glycine,	  consistent	  with	  nitrous	  oxide	  competing	  with	  glycine	  at	  the	  glycine	  binding	  site	  of	  the	  GluN1	  subunit,	  similar	  to	  xenon	  (and	  isoflurane	  and	  sevoflurane).	  	  	  Cyclopropane	  was	  found	  to	  inhibit	  wild-­‐type	  GluN1/GluN2A	  receptors	  in	  a	  dose-­‐dependent	  manner	  (Figure	  3.24).	   Inhibition	   increased	  from	  4±2%	  to	  61±4%	  as	  cyclopropane	   concentration	   was	   increased	   over	   the	   range	   of	   1%	   to	   80%	   of	   a	  saturated	   solution,	   with	   the	   EC50	   for	   cyclopropane	   inhibition	   determined	   as	  14±3%	  and	  the	  nH	  as	  1.1±0.1.	  However,	  contrary	  to	  the	  other	  anaesthetics	  tested,	  cyclopropane	   inhibition	   of	   NMDA	   receptors	   was	   found	   to	   be	   independent	   of	  glycine	   concentration	   (Figure	   3.25).	   10%	   cyclopropane	   inhibited	   wild-­‐type	  GluN1/GluN2A	   receptors	   by	  31±2%	  at	   high	   (100µM)	   glycine,	   and	  by	   the	   same	  amount	   (32	   ±2%)	   at	   low	   (1µM)	   glycine.	   This	   lack	   of	   glycine-­‐dependence	   for	  cyclopropane	   inhibition	   indicates	   that	   cyclopropane,	   unlike	   xenon,	   isoflurane,	  sevoflurane,	  and	  nitrous	  oxide,	  does	  not	  act	  via	  the	  glycine	  co-­‐agonist	  site	  of	  the	  NMDA	  receptor.	  	  
3.3.2	  Anaesthetic	  inhibition	  of	  GluN1(F758)	  receptor	  mutants	  Having	  identified	  two	  mutations	  (F758W	  and	  F758Y)	  of	  the	  GluN1	  subunit	  which	  eliminate	  xenon	  binding	  at	  the	  glycine	  site	  without	  altering	  the	  glycine	  affinity	  of	  GluN1/GluN2A	   receptors,	   it	   was	   next	   necessary	   to	   determine	   whether	   these	  mutations	  were	   specific	   to	   the	   binding	   of	   xenon,	   or	  whether	   they	   also	   disrupt	  binding	  of	  other	  anaesthetics	  at	  the	  site.	  	  For	  the	  F758W	  mutant,	  inhibition	  by	  both	  sevoflurane	  and	  isoflurane	  was	  found	  to	   remain	   glycine-­‐dependent.	   At	   high	   (100µM)	   glycine,	   receptors	   were	  insensitive	   to	   0.47mM	   sevoflurane,	   but	   inhibition	   increased	   significantly	  (p<0.001)	   to	   28.4±5.1%	   at	   low	   (1µM)	   glycine	   (Figure	   3.26).	   At	   high	   (100µM)	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Figure	   3.24:	   Inhibition	   of	   wild-­‐type	   GluN1/GluN2A	   NMDA	   receptors	   by	   cyclopropane	   is	  
concentration-­‐dependent.	   Inhibition	   of	   NMDA	   receptor	   currents	   was	   by	   cyclopropane	  
concentrations	  ranging	  from	  1%	  to	  80%.	  Receptor	  currents	  were	  measured	  in	  response	  to	  
the	   application	   of	   100µM	   NMDA	   and	   100µM	   glycine.	   The	   curve	   shown	   is	   fit	   to	   the	   Hill	  
equation.	  EC50	  and	  nH,	  are	  14±3%	  and	  1.1±0.1	  respectively.	  Points	  are	  mean	  values	  from	  
an	   average	   of	   six	   to	   fourteen	   cells	   at	   each	   cyclopropane	   concentration.	   Error	   bars	   are	  
standard	  error	  of	  the	  mean.	  
	  
Figure	  3.25:	  Inhibition	  of	  wild-­‐type	  GluN1/GluN2A	  NMDA	  receptors	  by	  10%	  cyclopropane	  
is	   glycine	   independent.	   Increasing	   glycine	   concentration	   has	   no	   effect	   on	   the	   degree	   of	  
receptor	   inhibition	   by	   cyclopropane,	   indicating	   that	   cyclopropane	   does	   not	   bind	   the	  
receptor	  at	  the	  co-­‐agonist	  glycine	  site.	  The	  %	  of	  control	  represents	  the	  ratio	  of	  current	  in	  
the	   presence	   of	   anaesthetic	   to	   that	   in	   the	   absence	   of	   anaesthetic	   at	   each	   glycine	  
concentration.	   Bars	   are	   mean	   values	   from	   an	   average	   thirteen	   cells.	   Error	   bars	   are	  
standard	  error	  of	  the	  mean.	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Figure	   3.26:	   Inhibition	   of	   the	   mutant	   GluN1(F758W)/GluN2A	   NMDA	   receptor	   by	  
sevoflurane	  (0.47mM)	  is	  glycine	  dependent.	  Increasing	  the	  glycine	  concentration	  reverses	  
the	  degree	  of	  receptor	  inhibition	  by	  sevoflurane,	  consistent	  with	  sevoflurane	  and	  glycine	  
still	  competing	  for	  the	  same	  binding	  site.	  The	  %	  of	  control	  represents	  the	  ratio	  of	  current	  
in	   the	   presence	   of	   sevoflurane	   to	   that	   in	   the	   absence	   of	   sevoflurane	   at	   each	   glycine	  
concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  are	  standard	  
error	  of	  the	  mean.	  *p<0.001	  is	  significantly	  different	  from	  inhibition	  at	  100µM	  glycine.	  
	  
Figure	  3.27:	  Inhibition	  of	  the	  mutant	  GluN1(F758W)/GluN2A	  NMDA	  receptor	  by	  isoflurane	  
(0.62mM)	  is	  glycine	  dependent.	  Increasing	  the	  glycine	  concentration	  reverses	  the	  degree	  
of	  receptor	  inhibition	  by	  isoflurane,	  consistent	  with	  isoflurane	  and	  glycine	  still	  competing	  
for	  the	  same	  binding	  site.	  The	  %	  of	  control	  represents	  the	  ratio	  of	  current	  in	  the	  presence	  
of	   isoflurane	   to	   that	   in	   the	  absence	  of	   isoflurane	  at	  each	  glycine	  concentration.	  Bars	  are	  
mean	   values	   from	   an	   average	   eight	   cells.	   Error	   bars	   are	   standard	   error	   of	   the	   mean.	  
*p<0.001	  is	  significantly	  different	  from	  inhibition	  at	  100µM	  glycine.	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Figure	   3.28:	   Inhibition	   of	   the	   mutant	   GluN1(F758Y)/GluN2A	   NMDA	   receptor	   by	  
sevoflurane	  (0.47mM)	  is	  glycine	  dependent.	  Increasing	  the	  glycine	  concentration	  reverses	  
the	  degree	  of	  receptor	  inhibition	  by	  sevoflurane,	  consistent	  with	  sevoflurane	  and	  glycine	  
still	  competing	  for	  the	  same	  binding	  site.	  The	  %	  of	  control	  represents	  the	  ratio	  of	  current	  
in	   the	   presence	   of	   sevoflurane	   to	   that	   in	   the	   absence	   of	   sevoflurane	   at	   each	   glycine	  
concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  are	  standard	  
error	  of	  the	  mean.	  *p<0.001	  is	  significantly	  different	  from	  inhibition	  at	  100µM	  glycine.	  
	  
Figure	  3.29:	  Inhibition	  of	  the	  mutant	  GluN1(F758Y)/GluN2A	  NMDA	  receptor	  by	  isoflurane	  
(0.62mM)	  is	  glycine	  dependent.	  Increasing	  the	  glycine	  concentration	  reverses	  the	  degree	  
of	  receptor	  inhibition	  by	  isoflurane,	  consistent	  with	  isoflurane	  and	  glycine	  still	  competing	  
for	  the	  same	  binding	  site.	  The	  %	  of	  control	  represents	  the	  ratio	  of	  current	  in	  the	  presence	  
of	   isoflurane	   to	   that	   in	   the	  absence	  of	   isoflurane	  at	  each	  glycine	  concentration.	  Bars	  are	  
mean	   values	   from	   an	   average	   eight	   cells.	   Error	   bars	   are	   standard	   error	   of	   the	   mean.	  
*p<0.001	  is	  significantly	  different	  from	  inhibition	  at	  100µM	  glycine.	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Figure	   3.30:	   Inhibition	   of	   the	   mutant	   GluN1(F758W)/GluN2A	   NMDA	   receptor	   by	   80%	  
nitrous	   oxide	   is	   glycine	   dependent.	   Increasing	   the	   glycine	   concentration	   reverses	   the	  
degree	  of	  receptor	   inhibition	  by	  nitrous	  oxide,	  consistent	  with	  nitrous	  oxide	  and	  glycine	  
still	  competing	  for	  the	  same	  binding	  site.	  The	  %	  of	  control	  represents	  the	  ratio	  of	  current	  
in	   the	   presence	   of	   nitrous	   oxide	   to	   that	   in	   the	   absence	   of	   nitrous	   oxide	   at	   each	   glycine	  
concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  are	  standard	  
error	  of	  the	  mean.	  *p<0.025	  is	  significantly	  different	  from	  inhibition	  at	  100µM	  glycine.	  
	  
Figure	   3.31:	   Inhibition	   of	   the	   mutant	   GluN1(F758Y)/GluN2A	   NMDA	   receptor	   by	   80%	  
nitrous	   oxide	   is	   glycine	   independent.	   Increasing	   the	   glycine	   concentration	   does	   not	  
reverse	  the	  degree	  of	  receptor	   inhibition	  by	  nitrous	  oxide,	  consistent	  with	  nitrous	  oxide	  
and	  glycine	  no	   longer	   competing	   for	   the	   same	  binding	   site.	  The	  %	  of	   control	   represents	  
the	  ratio	  of	  current	  in	  the	  presence	  of	  nitrous	  oxide	  to	  that	  in	  the	  absence	  of	  nitrous	  oxide	  
at	  each	  glycine	  concentration.	  Bars	  are	  mean	  values	  from	  an	  average	  eight	  cells.	  Error	  bars	  
are	  standard	  error	  of	  the	  mean.	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glycine,	   receptors	   were	   also	   insensitive	   to	   0.62mM	   isoflurane,	   with	   inhibition	  increasing	   significantly	   (p<0.001)	   to	   33.9±1.3%	   at	   low	   (1µM)	   glycine	   (Figure	  3.27),	  again	  in	  line	  with	  the	  wild-­‐type	  scenario.	  	  For	  the	  F758Y	  mutant,	  the	  same	  was	  found	  to	  be	  true;	  receptors	  were	  insensitive	  to	  both	  sevoflurane	  (0.47mM)	  and	  isoflurane	  (0.62mM)	  at	  high	  (100µM)	  glycine,	  with	  inhibition	  increasing	  significantly	  (p<0.001)	  to	  23.4±6.6%	  and	  39.0	  ±4.5%	  at	   low	  (1µM)	  glycine	   for	  sevoflurane	  (Figure	  3.28)	  and	   isoflurane	  (Figure	  3.29)	  respectively.	  	  Inhibition	  of	  the	  F758W	  mutant	  by	  80%	  nitrous	  oxide	  was	  found	  to	  conserve	  the	  glycine-­‐dependence	   of	   inhibition	   observed	   in	   the	   wild-­‐type	   receptor	   (Figure	  3.30).	   At	   high	   (100µM)	   glycine,	   inhibition	   by	   nitrous	   oxide	   was	   18.5±1.5%,	  increasing	  significantly	  (p<0.025)	  to	  29.8±3.9%	  at	  low	  (1µM)	  glycine.	  However,	  in	   the	   F758Y	   mutant,	   there	   was	   no	   significant	   difference	   in	   the	   degree	   of	  receptor	   inhibition	   by	   nitrous	   oxide	   at	   high	   (100µM)	   glycine	   and	   low	   (1µM)	  glycine	  (Figure	  3.31).	  	  These	   data	   indicate	   that	   the	   F758W	   mutation	   is	   able	   to	   selectively	   disrupt	  binding	   of	   xenon	   at	   the	   site,	   while	   leaving	   the	   binding	   of	   glycine,	   sevoflurane,	  isoflurane,	   and	   nitrous	   oxide	   intact.	   The	   F758Y	   behaves	   similarly,	   binding	  glycine,	  sevoflurane,	  and	  isoflurane	  in	  a	  manner	  similar	  to	  the	  wild-­‐type,	  but	  no	  longer	  binding	  either	  xenon	  or	  nitrous	  oxide	  at	  the	  site.	  	  	  	  
3.4	  Chapter	  Summary	  &	  Discussion	  
	  The	   anaesthetic	   gas	   xenon	   is	   an	   NMDA	   receptor	   antagonist	   [13].	   Inhibition	   of	  this	   receptor	  has	   recently	  been	   shown	   to	  mediate	   xenon	  neuroprotection	   in	   in	  
vitro	  models	  of	  hypoxic/ischemic	   injury	  [91].	   	  Described	  here	  are	  the	  efforts	  to	  produce	  an	  NMDA	  receptor	  GluN1	  subunit	  mutation	  that	  will	  selectively	  abolish	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the	   binding	   of	   xenon	   while	   leaving	   normal	   receptor	   function	   intact.	   Such	   a	  mutation	  would	  prove	   valuable	   in	   creating	   genetic	   knock-­‐in	   animals	   to	   dissect	  the	   role	   of	   the	   NMDA	   receptor	   in	   xenon	   neuroprotection,	   anaesthesia,	   and	  analgesia	  in	  vivo.	  	  Mutations	   of	   the	   aromatic	   W731	   site	   produced	   receptors	   with	   drastically	  reduced	   glycine	   affinity	   –	   indicating	   that	   an	   aromatic	   residue	   at	   this	   site	   is	  important	  in	  the	  binding	  of	  glycine.	  Mutation	  of	  the	  F758	  site	  to	  the	  non	  aromatic	  residues	  leucine	  (F758L)	  or	  alanine	  (F758A)	  produced	  functional	  receptors	  with	  modest	  (6-­‐fold)	  reductions	   in	  glycine	  binding	  affinity,	  but	  which	  also	  abolished	  xenon	  binding	  at	  the	  site.	  	  Mutation	   of	   the	   F758	   site	   to	   the	   aromatic	   residues	   tryptophan	   (F758W)	   or	  tyrosine	   (F758Y)	   produced	   receptors	   that	   bind	   glycine	   at	   wild-­‐type	   levels	   but	  which	  no	   longer	  bind	  xenon	  at	   the	   site.	   Further,	   both	  mutations	   are	  normal	   in	  respect	  to	  the	  binding	  of	  the	  volatile	  anaesthetics	  sevoflurane	  and	  isoflurane	  at	  the	  glycine-­‐binding	  site.	  	  Together	  these	  data	  indicate	  an	  important	  role	  for	  aromaticity	  at	  the	  F758	  site	  in	  the	  binding	  of	  xenon	  to	  the	  receptor.	  For	  the	  F758W	  and	  F758Y	  mutants,	  which	  retain	  aromaticity	  at	  the	  758	  site,	  it	  appears	  that	  glycine	  is	  able	  to	  interact	  with	  the	  aromatic	  ring	  of	  tryptophan	  and	  tyrosine	  just	  as	  well	  as	  the	  aromatic	  ring	  of	  phenylalanine,	   whereas	   xenon	   cannot.	   The	   reason	   for	   xenon’s	   particularly	  favourable	  interaction	  with	  phenylalanine	  at	  the	  758	  site	  is	  unclear,	  but	  may	  be	  attributed	   to	   either	   the	   particular	   stoichiometry	   of	   its	   aromatic	   ring	   and/or	  differences	   in	   molecular	   volume	   and	   polarity	   as	   compared	   with	   the	   larger	  tryptophan	  residue	  or	  the	  polar	  tyrosine	  residue.	  	  That	   the	   binding	   of	   both	   sevoflurane	   and	   isoflurane	   is	   conserved	   in	   these	   two	  F758	  mutants	   suggests	   that,	   like	   glycine,	   both	   are	   able	   to	   interact	   equally	  well	  with	   the	   wild-­‐type	   phenylalanine	   residue	   and	   the	   tryptophan	   and	   tyrosine	  residues	  in	  the	  mutant	  receptors.	  Together,	  this	  points	  towards	  an	  argument	  that	  anaesthetics	   and	   glycine	   bind	   distinct,	   but	   overlapping,	   sites	   on	   the	   GluN1	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subunit	  of	  the	  NMDA	  receptor,	  interacting	  differently	  with	  particular	  amino	  acid	  residues.	   In	   the	   case	   of	   xenon,	   phenylalanine	   at	   the	   758	   site	   appears	   to	   be	  particularly	  important	  for	  receptor	  binding.	  Conversely,	  the	  758	  site	  appears	  to	  be	   of	   lesser	   importance	   in	   the	   binding	   of	   sevoflurane	   and	   isoflurane,	   as	   both	  continue	   to	   bind	   and	   inhibit	   receptors	   regardless	   of	   the	   particular	   aromatic	  amino	  acid	  at	  this	  site.	  	  One	  main	  driver	   of	   the	   interest	   in	   the	  molecular	   interaction	  of	   xenon	  with	   the	  NMDA	  receptor	  glycine	  site	  has	  been	  the	  idea	  that	  it	  may	  be	  possible	  to	  identify	  a	  silent	  or	  near-­‐silent	  mutation	  eliminating	  xenon	  binding	  to	  the	  receptor	  without	  affecting	  the	  binding	  of	  glycine.	  Receptor	  mutants	  of	  this	  type	  would	  be	  of	  great	  value	  as	  molecular	   tools,	   useful	   in	  dissecting	   the	   role	  of	   the	  NMDA	  receptor	   in	  anaesthesia	  and	  neuroprotection	  in	  vivo	  once	  expressed	  in	  a	  transgenic	  animal.	  	  	  The	  F758W	  and	  F758Y	  mutants	  –	  silent	  in	  respect	  to	  the	  binding	  of	  glycine,	  but	  which	   no	   longer	   bind	   xenon	   –	   open	   the	   possibility	   of	   creating	   such	   genetic	  knock-­‐in	   animals,	   which	   in	   theory	   should	   behave	   normally	   at	   physiological	  glycine	  concentrations	  but	  have	  reduced	  sensitivity	  to	  the	  anaesthetic,	  analgesic,	  and	  neuroprotective	  properties	  of	  xenon,	  while	  still	  being	  normal	   in	   respect	   to	  the	  effects	  of	  other	  anaesthetic	  agents	  –	  e.g.	  isoflurane,	  sevoflurane	  -­‐	  acting	  at	  the	  GluN1	  site.	  	  	  These	  would	  be	  of	  great	  value	   in	  dissecting	  out	   the	  relative	  contribution	  of	   the	  NMDA	   receptor	   to	   xenon’s	   anaesthesia,	   analgesia,	   and	   neuroprotection,	   and	   in	  providing	   important	  validation	  of	   the	  NMDA	  receptor	  as	  a	  molecular	   target	   for	  anaesthesia	  and	  neuroprotection.	  Knock-­‐in	  animal	  lines	  with	  point	  mutations	  in	  the	   GluN1	   site	   have	   been	   generated	   previously	   [150].	   Similarly,	   knock-­‐in	  strategies	   have	   in	   the	   past	   been	   used	   successfully	   to	   dissect	   the	   molecular	  mechanisms	   involved	   in	   propofol	   and	   etomidate	   anaesthesia	   using	  mutants	   of	  the	  GABAA	  β	  subunit	  [143-­‐146].	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  That	   xenon	   is	   both	   anaesthetic	   and	   neuroprotective	   suggests	   that	   other	  members	  of	  the	  family	  of	  inert	  gases	  might	  also	  possess	  similar	  pharmacological	  activity,	   indeed	   following	   the	   discovery	   that	   xenon	   is	   neuroprotective	   against	  ischemic	   injury,	   many	   of	   the	   other	   gases	   have	   been	   tested	   for	   their	  neuroprotective	  potential.	  	  Neon	   and	   helium	   –	   the	   lightest	   of	   the	   group	   -­‐	   have	   been	   proven	   devoid	   of	  anaesthetic	   potency	   [93],	   and	   the	   sparse	   (and	   divisive)	   accounts	   of	   helium	  neuroprotection	   are	   believed	   to	   arise	   through	   a	   physical	   rather	   than	  pharmacological	  mechanism	   [133],	  whereby	  breathing	   helium	  at	   temperatures	  lower	  than	  37°C	  (body	  temperature)	  causes	  hypothermia	  [108].	  	  Heavier	   members	   of	   the	   group	   -­‐	   argon	   and	   krypton	   -­‐	   are	   both	   anaesthetic	   at	  elevated	   pressures:	   15atm	   and	   4.5atm	   respectively	   [93].	   Further,	   argon	   has	  displayed	  neuroprotective	  efficacy	  in	  both	  in	  vitro	  and	  in	  vivo	  models	  of	  ischemia	  [134-­‐137].	   However,	   one	   recent	   study	   has	   reported	   argon	   neuroprotection	   in	  
vitro	   but	   not	   in	   vivo.	   [134]	   The	   situation	   with	   krypton	   is	   even	   less	   clear;	   the	  single	   literature	   study	   investigating	   in	  vitro	   neuroprotection	  by	  krypton	   in	   fact	  reported	   a	   detrimental	   effect	   for	   krypton	   (as	   well	   as	   helium	   and	   neon)	   in	  ischemic	  injury	  [134].	  	  The	   only	   study	   to	   systematically	   assess	   the	   neuroprotective	   potential	   of	   the	  entire	   family	   of	   inert	   gases	   under	   identical	   conditions,	   in	   an	   in	   vitro	   model	   of	  traumatic	  brain	  injury,	  was	  recently	  performed	  by	  colleague	  Katie	  Harris.	  Under	  identical	   conditions,	   both	   xenon	   and	   argon	   were	   found	   to	   protect	   against	  traumatic	  brain	  injury	  in	  vitro.	  The	  other	  gases	  helium,	  neon,	  and	  krypton	  were	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Figure	  4.1:	  Neuroprotection	  by	  the	  noble	  gases	  helium,	  neon,	  argon,	  krypton,	  and	  xenon	  in	  
an	   in	   vitro	   hippocampal	   slice	   model	   of	   traumatic	   brain	   injury.	   The	   effects	   of	   50%	  
atmosphere	   of	   xenon	   (red	   bars),	   argon	   (blue	   bars),	   krypton	   (brown	   bars),	   and	   neon	  
(green	  bars)	  on	  control	  traumatic	  brain	  injury	  (grey	  bars,	  helium)	  at	  24,	  48,	  and	  72	  hours	  
after	   injury.	   Sham	   slices	   (white	   bars)	   were	   not	   subjected	   to	   trauma.	   Xenon	   and	   argon	  
provided	   significant	   neuroprotection	   at	   all	   time	   points.	   Xenon	   was	  more	   effective	   than	  
argon,	  with	  xenon-­‐treated	  slices	  being	  57±1%	  of	  control	  injury	  compared	  with	  70	  ±	  6%	  of	  
control	   injury	   for	   argon-­‐treated	   slices,	   72h	   after	   injury.	   None	   of	   the	   other	   inert	   gases	  
provided	  significant	  protection	  against	  injury	  at	  any	  of	  the	  time	  points.	  The	  error	  bars	  are	  
standard	  error	  of	  the	  mean.	  Data	  are	  normalised	  to	  the	  control	  injury	  at	  72	  h	  after	  injury.	  
*Indicates	  value	  significantly	  different	  (P	  <	  0.001)	  from	  control	  injury	  at	  each	  time	  point.	  
#Indicates	   value	   significantly	   different	   (P	   <	   0.01)	   from	   control	   injury	   (N	   =	   141	   control	  
traumatic	  injury;	  N	  =	  105	  sham;	  N	  =	  104	  xenon;	  N	  =	  44	  argon;	  N	  =	  45	  krypton;	  N	  =	  22	  neon).	  
An	   in	   vitro	   hippocampal	   slice	   model	   was	   used,	   with	   the	   membrane-­‐impermeable	   dye	  
Propidium	  Iodide	  used	  a	  marker	  of	  cell	  injury.	  	   	  
Data	  on	  this	  page	  courtesy	  of	  Katie	  Harris	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found	   to	   lack	   neuroprotective	   efficacy	   against	   traumatic	   injury	   in	   this	   model	  (Figure	  4.1).	  	  Regardless	  of	   the	  divisive	   literature	  evidence,	   that	  xenon	   is	  known	  to	  bind	  and	  inhibit	  NMDA	  receptors	  in	  a	  concentration-­‐dependent	  manner	  suggests	  that	  the	  other	   noble	   gases	   may	   exert	   a	   similar	   effect	   at	   the	   same	   receptor	   site.	   In	  particular,	  it	  is	  possible	  that	  argon’s	  neuroprotective	  effects	  may	  be	  mediated	  at	  the	  same	  site	  as	  xenon.	  It	  is	  possible	  that	  the	  other	  gases	  also	  influence	  the	  same	  receptor	   targets	   as	   xenon,	   but	   at	   levels	   too	   low	   to	   result	   in	   neuroprotective	  benefit.	   The	   true	   situation	   remains	   unclear,	   as	   to	   date	   there	   have	   been	   few	  studies	   investigating	   the	   effects	   of	   the	   inert	   gases	   –	   other	   than	   xenon	   –	   on	  molecular	  targets	  believed	  important	  in	  neuroprotection.	  	  Here	   I	   describe	   a	   series	   of	   experiments	   investigating	   the	   effects	   of	   the	   other	  noble	  gases	  on	  two	  known	  molecular	  targets	  of	  xenon	  –	  the	  NMDA	  receptor	  and	  the	  two-­‐pore	  domain	  potassium	  channel	  TREK-­‐1	  –	  in	  order	  to	  test	  the	  hypothesis	  that	   xenon	   and	   argon	   share	   a	   common	   mechanism	   for	   their	   neuroprotective	  effects.	   Inhibition	   of	   the	   NMDA	   receptor	   is	   known	   to	   underlie	   xenon	  neuroprotection	   against	   ischemic	   injury	   in	   vitro	   [91],	   while	   the	   activation	   of	  TREK-­‐1	   has	   been	   implicated	   in	   the	   neuroprotective	   actions	   of	   the	   fatty	   acid	  linolenate	  [63].	  	  	  	  
4.1	  Other	  noble	  gases	  at	  the	  NMDA	  receptor	  glycine	  site	  	  Xenon	  is	  a	  competitive	  inhibitor	  of	  the	  NMDA	  receptor	  glycine	  site,	  and	  thus	  the	  degree	  of	   receptor	   inhibition	  by	  xenon	   is	  higher	  at	   low	  glycine	   concentrations.	  NMDA	   receptors	   consisting	   of	   GluN1/GluN2A	   subunits	   –	   the	   most	   common	  subunit	   combination	   in	   adult	   hippocampus	   and	   neocortex	   [36,149]	   –	   were	  expressed	   transiently	   in	   HEK-­‐293	   cells,	   and	   the	   ability	   of	   the	   noble	   gases	   to	  inhibit	  these	  receptors	  measured	  at	  different	  glycine	  concentrations.	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4.1.1	  Helium	  80%	  Helium	  was	   applied	   to	   receptors	   as	   a	   saturated	   solution	   of	   80%	   helium/20%	  oxygen,	   prepared	   from	   gas-­‐saturated	   solutions	   as	   described	   in	   Methods	   2.2.3.	  Control	   solutions	  were	   80%	  nitrogen/20%	  oxygen.	   Helium	  was	   applied	   in	   the	  presence	   of	   both	   high	   and	   low	   concentrations	   of	   glycine	   (100	   and	   1µM	  respectively),	  and	  receptor	  currents	  activated	  by	  application	  of	  100µM	  NMDA.	  	  	  Figure	   4.2	   shows	   electrophysiological	   recordings	   from	   GluN1/GluN2A	   NMDA	  receptors	  in	  the	  presence	  and	  absence	  of	  80%	  helium/20%	  oxygen.	  	  	  
	  
Figure	  4.2:	  80%	  helium/20%	  oxygen	  has	  no	  effect	  on	  NMDA	  receptor-­‐mediated	  currents	  
at	   either	   high	   (100µM)	   or	   low	   (1µM)	   glycine.	   Traces	   show	   typical	   currents	   activated	   by	  
100µM	  NMDA	  and	  either	  1µM	  or	  100µM	  glycine,	   in	  HEK-­‐293	  cells	   transiently	  expressing	  
GluN1/GluN2A	  NMDA	  receptors.	  Cells	  were	  pre-­‐exposed	  to	  80%	  helium	  for	  90s	  before	  co-­‐
application	  of	  100µM	  NMDA.	  	  80%	  helium/20%	  oxygen	  had	  no	  effect	  on	  NMDA	  receptor-­‐mediated	  currents	  at	  either	   concentration	   of	   glycine.	   Recorded	   currents	   were	   100±0.4%	   (n=9)	   of	  control	  at	  high	  (100µM)	  glycine	  and	  99±1.0%	  (n=6)	  at	  low	  (1µM)	  glycine.(Figure	  4.4).	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4.1.2	  Neon	  80%	  Neon	  was	   applied	   to	   receptors	   as	   a	   gas-­‐saturated	   solution	   of	   80%	   neon/20%	  oxygen	  in	  the	  presence	  of	  both	  high	  and	  low	  concentrations	  of	  glycine	  (100	  and	  1µM	   respectively).	   NMDA	   receptor	   currents	   were	   activated	   by	   application	   of	  100µM	  NMDA.	  Recordings	  from	  GluN1/GluN2A	  NMDA	  receptors	  in	  the	  presence	  and	  absence	  of	  80%	  neon/20%	  oxygen	  are	  shown	  in	  Figure	  4.3.	  	  
	  
Figure	  4.3:	  80%	  neon/20%	  oxygen	  has	  no	  effect	  on	  NMDA	  receptor-­‐mediated	  currents	  at	  
either	   high	   (100µM)	   or	   low	   (1µM)	   glycine.	   Traces	   show	   typical	   currents	   activated	   by	  
100µM	  NMDA	  and	  either	  1µM	  or	  100µM	  glycine,	   in	  HEK-­‐293	  cells	   transiently	  expressing	  
GluN1/GluN2A	  NMDA	  receptors.	   Cells	  were	  pre-­‐exposed	   to	  80%	  neon	   for	  90s	  before	   co-­‐
application	  of	  100µM	  NMDA.	  	  As	  with	  helium,	  80%	  neon	  failed	  to	  inhibit	  NMDA	  receptor-­‐mediated	  currents	  at	  either	  concentration	  of	  glycine.	  The	  recorded	  currents	  were	  100±1.4%	  (n=5)	  of	  control	   at	   high	   (100µM)	   glycine	   and	   102±2.0%	   (n=6)	   at	   low	   (1µM)	   glycine	  (Figure	  4.5).	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Figure	   4.4:	   GluN1/GluN2A	  NMDA	   receptor	   currents	   are	   unaffected	   by	   80%	  helium/20%	  
oxygen	  at	  both	  high	  (100µM)	  and	  low	  (1µM)	  glycine.	  The	  %	  of	  control	  represents	  the	  ratio	  
of	   the	   current	   in	   the	   presence	   of	   80%	   helium	   to	   that	   in	   the	   absence	   of	   helium	   at	   each	  
glycine	  concentration.	  Bars	  are	  mean	  values	   from	  9	  cells	  at	  100µM	  glycine	  and	  6	  cells	  at	  
1µM	  glycine.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  
	  
Figure	   4.5:	   GluN1/GluN2A	   NMDA	   receptor	   currents	   are	   unaffected	   by	   80%	   neon/20%	  
oxygen	  at	  both	  high	  (100µM)	  and	  low	  (1µM)	  glycine.	  The	  %	  of	  control	  represents	  the	  ratio	  
of	  the	  current	  in	  the	  presence	  of	  80%	  neon	  to	  that	  in	  the	  absence	  of	  neon	  at	  each	  glycine	  
concentration.	   Bars	   are	  mean	   values	   from	   5	   cells	   at	   100µM	   glycine	   and	   6	   cells	   at	   1µM	  
glycine.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	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4.1.3	  Argon	  80%	  Argon	  was	  applied	   to	  receptors	  as	  a	  gas-­‐saturated	  solution	  of	  80%	  argon/20%	  oxygen,	   prepared	   from	   saturated	   solutions	   as	   described	   in	   Methods	   2.2.3.	  Control	   solutions	   substituted	   argon	   for	   nitrogen	   (i.e.	   80%	   nitrogen/20%.	  oxygen)	  Argon	  at	  this	  concentration	  is	  known	  to	  be	  neuroprotective	  in	  a	  number	  of	  both	  in	  vitro	  and	  in	  vivo	  studies.	  	  	  Electrophysiological	   recordings	   from	  GluN1/GluN2A	  NMDA	  receptors	  activated	  by	  100µM	  NMDA	  in	  the	  presence	  and	  absence	  of	  80%	  argon	  are	  shown	  in	  Figure	  4.6.	  80%	  argon/20%	  oxygen	  applied	   to	   receptors	   in	   the	  presence	  of	  both	  high	  and	  low	  glycine	  (100	  and	  1µM	  respectively)	  failed	  to	  inhibit	  receptor	  currents	  at	  either	  concentration.	  	  
	  
Figure	  4.6:	  80%	  argon/20%	  oxygen	  has	  no	  effect	  on	  NMDA	  receptor-­‐mediated	  currents	  at	  
either	   high	   (100µM)	   or	   low	   (1µM)	   glycine.	   Traces	   show	   typical	   currents	   activated	   by	  
100µM	  NMDA	  and	  either	  1µM	  or	  100µM	  glycine,	   in	  HEK-­‐293	  cells	   transiently	  expressing	  
GluN1/GluN2A	  NMDA	  receptors.	  Cells	  were	  pre-­‐exposed	  to	  80%	  argon	  for	  90s	  before	  co-­‐
application	  of	  100µM	  NMDA.	  	  Recorded	   currents	   were	   100±1.5%	   (n=10)	   of	   control	   at	   100µM	   glycine	   and	  100±1.0%	  (n=12)	  at	  1µM	  glycine	  (Figure	  4.8).	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4.1.4	  Krypton	  80%	  Krypton	   was	   applied	   to	   receptors	   as	   a	   gas-­‐saturated	   solution	   of	   80%	  krypton/20%	   oxygen,	   in	   the	   presence	   of	   both	   high	   (100µM)	   and	   low	   (1µM)	  concentrations	  of	  glycine,	  and	  with	  receptor	  currents	  activated	  by	  application	  of	  100µM	  NMDA.	  	  	  GluN1/GluN2A	   NMDA	   receptor	   currents	   in	   the	   presence	   and	   absence	   of	   80%	  krypton/20%	   oxygen	   are	   shown	   in	   Figure	   4.7.	   Krypton	   failed	   to	   inhibit	   the	  NMDA	  receptor	  currents	  at	  either	  concentration	  of	  glycine.	  	  	  
	  
Figure	  4.7:	  80%	  krypton/20%	  oxygen	  has	  no	  effect	  on	  NMDA	  receptor-­‐mediated	  currents	  
at	   either	   high	   (100µM)	   or	   low	   (1µM)	   glycine.	   Traces	   show	   typical	   currents	   activated	   by	  
100µM	  NMDA	  and	  either	  1µM	  or	  100µM	  glycine,	   in	  HEK-­‐293	  cells	   transiently	  expressing	  
GluN1/GluN2A	  NMDA	  receptors.	  Cells	  were	  pre-­‐exposed	  to	  80%	  krypton	  for	  90s	  before	  co-­‐
application	  of	  100µM	  NMDA.	  	  Currents	  were	  99±1.1%	  (n=9)	  of	  control	  at	  100µM	  glycine	  and	  101±1.6%	  (n=9)	  at	  1µM	  glycine	  (Figure	  4.9).	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Figure	   4.8:	   GluN1/GluN2A	   NMDA	   receptor	   currents	   are	   unaffected	   by	   80%	   argon/20%	  
oxygen	  at	  both	  high	  (100µM)	  and	  low	  (1µM)	  glycine.	  The	  %	  of	  control	  represents	  the	  ratio	  
of	  the	  current	  in	  the	  presence	  of	  80%	  argon	  to	  that	  in	  the	  absence	  of	  argon	  at	  each	  glycine	  
concentration.	  Bars	  are	  mean	  values	   from	  10	  cells	  at	  100µM	  glycine	  and	  12	  cells	  at	  1µM	  
glycine.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	  
	  
	  
Figure	  4.9:	  GluN1/GluN2A	  NMDA	  receptor	  currents	  are	  unaffected	  by	  80%	  krypton/20%	  
oxygen	  at	  both	  high	  (100µM)	  and	  low	  (1µM)	  glycine.	  The	  %	  of	  control	  represents	  the	  ratio	  
of	   the	  current	   in	   the	  presence	  of	  80%	  krypton	   to	   that	   in	   the	  absence	  of	  krypton	  at	  each	  
glycine	  concentration.	  Bars	  are	  mean	  values	  from	  9	  cells	  at	  both	  100µM	  glycine	  and	  1µM	  
glycine.	  Error	  bars	  are	  standard	  error	  of	  the	  mean.	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4.1.5	  Noble	  gases	  &	  NMDA	  receptor	  summary	  The	   noble	   gas	   xenon	   is	   an	   antagonist	   of	   the	   NMDA	   receptor,	   acting	   via	  competitive	  inhibition	  of	  the	  co-­‐agonist	  glycine	  site	  [48],	  as	  confirmed	  in	  Chapter	  3.	  Xenon	  will	  thus	  inhibit	  receptors	  more	  at	  low	  glycine	  concentrations,	  and	  less	  at	   high	   glycine	   concentrations.	   When	   applied	   as	   an	   80%	   saturated	   solution,	  xenon	   inhibits	   GluN1/GluN2A	   NMDA	   receptors	   by	   29±1%	   at	   high	   (100µM)	  glycine,	  increasing	  to	  59±5%	  at	  low	  (1µM)	  glycine	  (Figure	  4.10).	  	  	  This	  inhibition	  of	  the	  NMDA	  receptor	  glycine	  site	  has	  been	  confirmed	  to	  underlie	  xenon	   neuroprotection	   against	   traumatic	   brain	   injury	   in	   vitro	   (Figure	   4.11).	  Glycine	   reverses	   the	   neuroprotective	   effect	   of	   50%	   xenon,	   consistent	   with	  inhibition	  of	  the	  NMDA	  receptor	  glycine	  site	  underlying	  xenon	  neuroprotection.	  	  Argon,	   another	  known	  neuroprotectant,	  was	   found	   to	  have	  no	  effect	   on	  NMDA	  receptor	   currents	   at	   either	   high	   (100µM)	   or	   low	   (1µM)	   glycine	   (Figure	   4.10).	  This	  suggests	  that,	  unlike	  xenon,	  argon	  does	  not	  exert	  its	  neuroprotective	  effects	  via	  the	  NMDA	  receptor.	  	  	  This	   finding	  has	  been	   confirmed	   in	   an	   in	  vitro	  model	   of	   traumatic	   brain	   injury	  (Figure	   4.12).	   Glycine	   does	   not	   reverse	   the	   protective	   effects	   of	   argon	   in	   this	  model,	  indicating	  no	  role	  for	  competitive	  inhibition	  of	  the	  NMDA	  receptor	  glycine	  site	   in	   argon	   neuroprotection.	   This	   finding	   is	   consistent	   with	   the	   observation	  that	  argon	  does	  not	  inhibit	  NMDA	  receptor	  currents,	  with	  the	  molecular	  targets	  mediating	   argon	   neuroprotection	   thus	   still	   to	   be	   identified.	   The	   K2P	   channel	  TREK-­‐1	  is	  one	  plausible	  candidate.	  	  The	  other	  noble	  gases	  helium,	  neon,	  and	  krypton	  were	  found	  to	  have	  no	  effect	  at	  the	   NMDA	   receptor	   glycine	   site	   (Figure	   4.10).	   This	   lack	   of	   inhibition	   may	   be	  because	   elevated	   concentrations	   of	   these	   gases	   are	   required	   for	   any	   biological	  effect	  on	  NMDA	  receptors	   (both	  argon	  and	  krypton	  are	  anaesthetic	  at	  elevated	  pressures),	  or	  more	  simply	  may	  amount	  to	  no	  action	  for	  the	  noble	  gases	  –	  other	  than	  xenon	  -­‐	  at	  NMDA	  receptors.	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Figure	   4.10:	   The	   inert	   gases	   helium,	   neon,	   argon,	   and	   krypton	   have	   no	   effect	   on	   NMDA	  
receptors.	  NMDA	  receptor	  currents	  were	  unaffected	  by	  80%	  helium	  (grey	  bars),	  80%	  neon	  
(green	  bars),	  80%	  argon	  (blue	  bars),	  and	  80%	  krypton	  (brown	  bars).	  Converse	  to	  these,	  
NMDA	   receptor	   currents	   are	   inhibited	   by	   80%	   xenon	   (red	   bars);	   by	   29±1%	   at	   high	  
(100µM)	   glycine,	   and	   increasing	   to	   59±5%	   at	   low	   (1µM)	   glycine.	   Bars	   represent	   mean	  
values,	  error	  bars	  are	  standard	  error	  of	  the	  mean	  (100µM	  glycine:	  n=9,	  helium;	  n=5,	  neon;	  
n=10,	  argon;	  n=9,	  krypton;	  n=8,	  xenon.	  1µM	  glycine:	  n=6,	  helium;	  n=6,	  neon;	  n=12,	  argon;	  
n=9,	  krypton;	  n=8,	  xenon).	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Figure	   4.11:	   Xenon	   neuroprotection	   is	   reversed	   by	   glycine	   in	   an	   in	   vitro	   model	   of	  
traumatic	   brain	   injury.	   In	   an	   in	   vitro	  hippocampal	   slice	   model	   of	   TBI,	   50%	   xenon	   (red	  
bars)	  protects	  against	   traumatic	   injury	   (grey	  bars).	  Addition	  of	  100μM	  glycine	  abolishes	  
the	  protective	  effect	  of	  xenon.	  In	  the	  presence	  of	  glycine	  there	  was	  no	  difference	  between	  
injured	   slices	   in	   the	   presence	   (red	   crosshatched	   bars)	   and	   absence	   (grey	   crosshatched	  
bars)	  of	  50%	  xenon.	  This	   is	   consistent	  with	   xenon	  and	  glycine	  binding	  at	   the	   same	   site,	  
with	   the	   neuroprotective	   effects	   of	   xenon	  mediated	   by	   its	   action	   at	   this	   site.	   *Indicates	  
value	  significantly	  different	  (P<0.001)	  from	  the	  control	  injury	  at	  each	  time	  point.	  
	  
Figure	   4.12:	   Argon	   neuroprotection	   is	   not	   reversed	   by	   glycine	   in	   an	   in	   vitro	   model	   of	  
traumatic	  brain	   injury.	   In	  an	   in	  vitro	  hippocampal	   slice	  model	  of	   traumatic	  brain	   injury,	  
50%	  argon	   (blue	  bars)	   protects	   against	   traumatic	   injury	   (grey	  bars).	   In	   the	  presence	  of	  
100μM	  glycine,	  50%	  argon	  (blue	  crosshatched	  bars)	  retains	  a	  protective	  effect	  compared	  
with	  injured	  slices	  (crosshatched	  grey	  bars),	  consistent	  with	  glycine	  and	  argon	  binding	  at	  
different	   receptor	   sites.	   Error	   bars	   are	   standard	   error	   of	   the	   mean	   (n=141	   TBI;	   n=44	  
argon;	   n=37	   argon	   glycine;	   n=39	   glycine	   TBI).	   *Indicates	   value	   significantly	   different	  
(P<0.001)	   from	   the	   control	   injury	   at	   each	   time	   point.	   #Indicates	   value	   significantly	  





4.2	  Other	  noble	  gases	  and	  the	  TREK-­‐1	  channel	  	  The	   two-­‐pore	   domain	   potassium	   channel	   TREK-­‐1	   is	   known	   to	   be	   involved	   in	  both	   general	   anaesthesia	   and	   neuroprotection	   [151].	   Both	   these	   effects	   are	  pharmacological	   endpoints	   of	   xenon	   administration,	   and	   indeed	   xenon	   is	   an	  activator	  of	  the	  TREK-­‐1	  channel	  [19].	  The	  observation	  that	  argon	  does	  not	  inhibit	  NMDA	  receptors	   in	   the	  same	  manner	  as	  xenon	   leaves	  TREK-­‐1	  activation	  as	   the	  next	  obvious	  target	  for	  argon	  neuroprotection.	  	  TREK-­‐1	  channels	  were	  expressed	  transiently	  in	  HEK-­‐293	  cells,	  and	  the	  ability	  of	  the	  noble	  gases	  to	  activate	  these	  channels	  was	  measured.	  Cells	  expressing	  TREK-­‐1	   channels	   exhibited	   a	   characteristic	   large	   outward	   rectifying	   current	   that	  reversed	   at	   -­‐80mV,	   while	   untransfected	   cells	   passed	   only	   a	   few	   picoamperes	  when	   clamped	   at	   -­‐50mV.	   Volatile	   anaesthetics	   are	   known	   to	   activate	   TREK-­‐1,	  thus	   halothane	   (0.82mM)	   was	   used	   as	   a	   positive	   control	   (Figure	   4.13);	   this	  concentration	   of	   halothane	   potentiated	   TREK-­‐1	   currents	   by	   152±20%	  (mean±SEM,	   n=10,	   data	   not	   shown)	  measured	   at	   -­‐50mV.	   Xenon	  was	   found	   to	  markedly	  activate	  TREK-­‐1	  (Figure	  4.14),	  potentiating	  the	  current	  measured	  at	  -­‐50mV	  by	  39±5%	  (Figure	  4.19).	  	  
4.2.1	  Helium	  80%	  Figure	   4.15	   shows	   currents	   recorded	   from	   HEK-­‐293	   cells	   expressing	   TREK-­‐1	  channels	   in	   the	   presence	   and	   absence	   of	   helium.	   Helium,	   applied	   as	   a	   gas-­‐saturated	   solution	   of	   80%	   helium/20%	   oxygen,	   had	   no	   effect	   on	   TREK-­‐1	  currents,	   with	   no	   potentiation	   observed	   at	   -­‐50mV.	   Currents	   were	   1.0±1.5%	  (n=3)	  of	  control	  (Figure	  4.19).	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Figure	   4.13:	   Halothane	   (0.82mM)	   activates	   TREK-­‐1	   potassium	   channel	   currents.	   Traces	  
are	   recordings	   from	   voltage	   ramps	   (-­‐120	   to	   0mV	   in	   250ms)	   performed	   in	   the	   presence	  
(blue	   hatched	   line)	   and	   absence	   (solid	   line)	   of	   halothane.	   Activation	   by	   halothane	   was	  
used	   as	   a	   positive	   control	   for	   the	   noble	   gases.	   Data	   were	   sampled	   at	   20kHz,	   with	   each	  
trace	  containing	  3,000	  data	  points.	  Lines	  are	   through	   these	   individual	  points.	  Halothane	  
potentiates	  the	  current	  measured	  at	  -­‐50mV	  by	  152±20%	  (n=10).	  
	  
Figure	   4.14:	   80%	   xenon	   activates	   TREK-­‐1	   potassium	   channel	   currents.	   Traces	   are	  
recordings	   from	  voltage	  ramps	   (-­‐120	   to	  0mV	   in	  250ms)	  performed	   in	   the	  presence	   (red	  
hatched	   line)	  and	  absence	   (solid	   line)	  of	  xenon.	  Data	  were	  sampled	  at	  20kHz,	  with	  each	  
trace	  containing	  3,000	  data	  points.	  Lines	  are	  through	  these	  individual	  points.	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Figure	  4.15:	  80%	  helium	  has	  no	  effect	  on	  TREK-­‐1	  potassium	  channel	  currents.	  Traces	  are	  
recordings	  from	  voltage	  ramps	  (-­‐120	  to	  0mV	  in	  250ms)	  performed	  in	  the	  presence	  (grey	  
hatched	  line)	  and	  absence	  (solid	  line)	  of	  helium.	  Data	  were	  sampled	  at	  20kHz,	  with	  each	  
trace	  containing	  3,000	  data	  points.	  Lines	  are	  through	  these	  individual	  points.	  
	  
Figure	  4.16:	   80%	  neon	  has	  no	   effect	   on	  TREK-­‐1	  potassium	  channel	   currents.	  Traces	   are	  
recordings	  from	  voltage	  ramps	  (-­‐120	  to	  0mV	  in	  250ms)	  performed	  in	  the	  presence	  (green	  
hatched	   line)	   and	   absence	   (solid	   line)	   of	   neon.	   Data	  were	   sampled	   at	   20kHz,	  with	   each	  
trace	  containing	  3,000	  data	  points.	  Lines	  are	  through	  these	  individual	  points.	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4.2.2	  Neon	  80%	  As	   for	   helium,	   80%	   neon/20%	   oxygen	   failed	   to	   potentiate	   TREK-­‐1	   currents.	  Figure	   4.16	   shows	   currents	   recorded	   from	   HEK-­‐293	   cells	   expressing	   TREK-­‐1	  channels	  in	  the	  presence	  and	  absence	  of	  80%	  neon.	  Measured	  at	  -­‐50mV,	  currents	  were	  1.9±2.2%	  (n=4)	  of	  control	  (Figure	  4.19).	  	  
4.2.3	  Argon	  80%	  Figure	  4.17	  shows	  recordings	  from	  HEK-­‐293	  cells	  expressing	  TREK-­‐1	  channels	  in	  the	   presence	   and	   absence	   of	   argon.	   80%	   argon/20%	  oxygen	   did	   not	   have	   any	  effect	  on	  TREK-­‐1	  channels;	  no	  potentiation	  was	  observed,	  with	  TREK-­‐1	  currents	  measured	  at	  -­‐50mV	  being	  0.7±1.3%	  (n=3)	  of	  control	  (Figure	  4.19).	  	  
4.2.4	  Krypton	  80%	  Figure	   4.18	   shows	   currents	   recorded	   from	   HEK-­‐293	   cells	   expressing	   TREK-­‐1	  channels	  in	  the	  presence	  and	  absence	  of	  krypton.	  80%	  krypton/20%	  oxygen	  had	  no	  effect	  on	  TREK-­‐1	  currents,	  with	  no	  potentiation	  observed	  at	  -­‐50mV.	  Currents	  were	  1.9±1.9%	  (n=9)	  of	  control	  (Figure	  4.19)	  	  
4.2.5	  Noble	  gases	  &	  TREK-­‐1	  channel	  summary	  Xenon	   (80%)	   markedly	   activates	   TREK-­‐1	   channels	   (Figure	   4.14),	   potentiating	  the	   current	   measured	   at	   -­‐50mV	   by	   39±5%	   (Figure	   4.19).	   Conversely,	   argon	  (80%)	  has	  no	  effect	  on	  TREK-­‐1	  currents,	  suggesting	  no	  involvement	  for	  TREK-­‐1	  in	  the	  neuroprotective	  effects	  of	  argon.	  	  Similarly,	  the	  other	  noble	  gases	  helium,	  neon,	  and	  krypton	  are	  all	  without	  effect	  on	   TREK-­‐1.	   None	   of	   these	   potentiate	   the	   current	   measured	   at	   -­‐50mV	   (Figure	  4.19),	   with	   this	   lack	   of	   activation	   consistent	   with	   their	   apparent	   lack	   of	  neuroprotective	  efficacy.	  	  The	  lack	  of	  effect	  on	  both	  TREK-­‐1	  channels	  and	  NMDA	  receptors	   leaves	   the	   receptor	   and	   mechanism	   underlying	   neuroprotection	   by	  argon	  unknown.	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Figure	  4.17:	  80%	  argon	  has	  no	  effect	  on	  TREK-­‐1	  potassium	  channel	  currents.	  Traces	  are	  
recordings	  from	  voltage	  ramps	  (-­‐120	  to	  0mV	  in	  250ms)	  performed	  in	  the	  presence	  (blue	  
hatched	   line)	   and	  absence	   (solid	   line)	  of	   argon.	  Data	  were	   sampled	  at	  20kHz,	  with	  each	  
trace	  containing	  3,000	  data	  points.	  Lines	  are	  through	  these	  individual	  points.	  
	  
Figure	  4.18:	  80%	  krypton	  has	  no	  effect	  on	  TREK-­‐1	  potassium	  channel	  currents.	  Traces	  are	  
recordings	  from	  voltage	  ramps	  (-­‐120	  to	  0mV	  in	  250ms)	  performed	  in	  the	  presence	  (brown	  
hatched	  line)	  and	  absence	  (solid	  line)	  of	  krypton.	  Data	  were	  sampled	  at	  20kHz,	  with	  each	  
trace	  containing	  3,000	  data	  points.	  Lines	  are	  through	  these	  individual	  points.	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Figure	   4.19:	   80%	   xenon	   potentiates	   TREK-­‐1	   potassium	   channel	   currents,	   whereas	   80%	  
helium,	   neon,	   argon,	   and	   krypton	   do	   not.	   Currents	   were	   measured	   at	   -­‐50mV.	   Bars	   are	  
mean	   values,	   error	   bars	   are	   standard	   error	   of	   the	  mean	   (n=3,	   helium;	   n=4,	   neon;	   n=3,	  
argon;	  n=9,	  krypton;	  n=5,	  xenon).	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4.3	  Chapter	  Discussion	  	  The	  data	  presented	   in	   this	  chapter	  shows	   that	  neither	   the	  TREK-­‐1	  channel	  nor	  the	   NMDA	   receptor	  mediates	   neuroprotection	   by	   argon.	   One	   recent	   study	   has	  found	   that	   argon	   transiently	   increases	   levels	   of	   phosphorylated	   extracellular	  signalling	   kinase	   ½	   in	   vitro	   [152],	   but	   the	   involvement	   of	   this	   in	   argon	  neuroprotection	   remains	   to	   be	   determined.	   The	   molecular	   mechanism(s)	   by	  which	  argon	  produces	  its	  neuroprotective	  effects	  merits	  further	  investigation.	  	  The	   lack	   of	   involvement	   of	   the	   same	   molecular	   targets	   (NMDA	   receptor	   and	  TREK-­‐1	   channel)	   in	   neuroprotection	   by	   argon	   and	   xenon	   is	   particularly	  interesting	   as	   it	   makes	   a	   combination	   therapy	   of	   the	   two	   gases	   an	   enticing	  possibility.	   Xenon	   neuroprotection	   in	   vitro	   increases	   only	   modestly	   when	   the	  concentration	   is	   raised	   from	   30%	   to	   70%,	   while	   argon	   is	   protective	   at	  concentrations	  of	  50%	  and	  above	  (data	  from	  companion	  study	  by	  Harris	  et	  al).	  A	  balanced	  mixture	  of	  the	  two	  then,	  might	  provide	  a	  combined	  or	  even	  synergistic	  neuroprotection,	  greater	  than	  when	  the	  two	  are	  delivered	  separately.	  	  	  	  The	  use	  of	  combination	  therapies	  to	  achieve	  sustained	  neuroprotection	  where	  a	  single	  pharmacological	  intervention	  would	  otherwise	  fail	  to	  has	  been	  suggested	  for	  some	  time	  [153,154].	  It	   is,	  however,	  necessary	  to	  prove	  both	  gases	  safe	  and	  efficacious	  when	  applied	  separately	  before	  a	  combination	  therapy	  of	  the	  two	  can	  be	  considered.	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  5.0	  Xenon	  neuroprotection	   in	  an	   in	  vivo	  model	  of	  traumatic	  brain	  injury	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  Following	  the	  discovery	  that	  xenon	  is	  an	  antagonist	  of	  the	  NMDA	  receptor,	  xenon	  has	   been	   shown	   to	   be	   neuroprotective	   against	   ischemic	   injury	   in	   both	   in	  vitro	  and	   in	  vivo	  models	   [76,77,91].	   Indeed,	   xenon	   is	   currently	   in	   clinical	   trials	   as	   a	  treatment	   for	   ischemic	   injuries	   injuries	   such	   as	   neonatal	   asphyxia,	   cardio-­‐pulmonary	  bypass,	  and	  deficit	  following	  cardiac	  arrest	  [93].	  Xenon	  has	  also	  been	  proven	   neuroprotective	   in	   simple	   in	   vitro	   models	   of	   traumatic	   injury	   [75].	  However,	  it	  is	  currently	  unknown	  whether	  this	  neuroprotective	  effect	  for	  xenon	  is	  also	  present	  in	  more	  clinically	  relevant	  in	  vivo	  models	  of	  this	  type	  of	  injury.	  	  Here	  I	  describe	  a	  series	  of	  experiments	  assessing	  the	  neuroprotective	  efficacy	  of	  xenon	  against	  traumatic	  brain	  injury	  in	  vivo,	  using	  the	  rodent	  controlled	  cortical	  impact	   model.	   The	   aims	   of	   the	   study	   were	   to	   determine:	   whether	   xenon	   can	  protect	   against	   the	  development	  of	   secondary	   injury	   in	   traumatic	  brain	   injury;	  whether	   xenon	   can	   improve	   neurological	   outcome	   after	   traumatic	   injury;	   and	  whether	   xenon	   has	   a	   clinically	   relevant	   therapeutic	   time	   window	   in	   which	  treatment	   can	   be	   applied	   and	   still	   remain	   beneficial.	   Thanks	   are	   due	   to	   Anne	  Sebastiani,	   for	   performing	   the	   CCI	   surgeries,	   and	   to	   Rita	   Campos-­‐Pires	   for	   her	  contribution	  to	  brain	  slicing.	  	  	  	  	  
5.1	   Pre-­‐treatment	   and	   post-­‐treatment	   with	   xenon	  
protects	  against	  traumatic	  injury	  	  The	   effect	   of	   xenon	   treatment	   on	   neurological	   outcome	   and	   histological	  contusion	   volume	  was	   first	   investigated	  with	   xenon	   administered	   both	   before	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and	   after	   –	   but	   not	   during	   –	   experimental	   brain	   trauma.	   Treatment	   was	   75%	  xenon/25%	  oxygen,	  given	  2	  hours	  before	  and	  2	  hours	  after	  trauma.	  	  Animals	   treated	   with	   75%	   xenon	   both	   before	   and	   after	   trauma	   showed	  significant	   improvements	   (p<0.05)	   in	   functional	   outcome	   24	   hours	   after	  traumatic	   brain	   injury	   (Figure	   5.1),	   with	   the	   xenon	   treated	   cohort	   showing	   a	  40±11%	  improvement	  in	  neurological	  outcome	  score	  as	  compared	  with	  controls.	  Further,	  brain	  contusion	  volume	  was	  also	  reduced	  in	  xenon	  treated	  animals,	  by	  43±7%	   compared	   with	   controls	   (Figure	   5.2).	   This	   reduction	   was	   highly	  significant	  (p<0.01).	  	  	  	  
5.2	   Post-­‐treatment	   with	   xenon	   protects	   against	  
traumatic	  injury	  	  The	  neuroprotective	  efficacy	  of	  xenon	  was	  next	  investigated	  in	  a	  paradigm	  when	  xenon	  was	   administered	   only	   after	   the	   traumatic	   injury.	   Treatment	   with	   75%	  xenon/25%	   oxygen	   was	   found	   to	   markedly	   reduce	   the	   development	   of	  secondary	   injury	   following	   TBI	   (Figure	   5.3).	   Animals	   treated	   with	   75%	  xenon/25%	   oxygen	   for	   3	   hours	   -­‐	   with	   xenon	   administration	   beginning	   15	  minutes	  after	  CCI	  injury	  -­‐	  showed	  a	  36±6%	  (p<0.05)	  improvement	  in	  functional	  outcome	  at	  24	  hours	  after	  injury	  (Figure	  5.4).	  	  	  In	  order	  to	  determine	  how	  injury	  develops	  in	  the	  rodent	  CCI	  model,	  the	  primary	  injury	  contusion	  volume	  was	  measured	  15	  minutes	  after	  trauma,	  and	  compared	  with	   the	   secondary	   injury	   contusion	   volume	   measured	   24	   hours	   after	   injury	  (Figure	   5.5).	   Primary	   injury	   15	   minutes	   after	   trauma	   was	   found	   to	   be	  5.4±0.6mm3,	   with	   secondary	   injury	   increasing	   the	   contusion	   volume	   to	  37.5±1.4mm3	  after	  24	  hours.	  Xenon	  treatment	  for	  3	  hours,	  beginning	  15	  minutes	  after	  traumatic	  injury,	  reduced	  contusion	  volume	  by	  19±7%	  	  (p<0.05)	  compared	  with	  untreated	  controls	  (Figure	  5.5).	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Figure	   5.1:	   Xenon	   pre-­‐treatment	   and	   post-­‐treatment	   improves	   neurological	   outcome	  
following	  traumatic	  brain	  injury.	  Treatment	  with	  xenon	  before	  and	  after	  trauma	  results	  in	  
a	   40±11%	   improvement	   in	   neurological	   function	   compared	   with	   controls	   (*p<0.05).	  
Xenon	  treated	  animals	  (red	  bars)	  received	  75%	  xenon/25%	  xenon	  for	  2	  hours	  before	  and	  
2	   hours	   after	   injury.	   Control	   animals	   (blue	   bars)	   received	   75%	   nitrogen/25%	   oxygen.	  
Neurological	   outcome	  was	  measured	   24	   hours	   after	   trauma.	   Bars	   are	  mean	   values,	   and	  
error	  bars	  are	  standard	  error	  of	  the	  mean	  (n=6).	  	  
	  
Figure	  5.2:	  Xenon	  pre-­‐treatment	  and	  post-­‐treatment	  reduces	  contusion	  volume	  following	  
traumatic	  brain	  injury.	  Xenon	  treatment	  before	  and	  after	  injury	  reduces	  contusion	  volume	  
by	   43±7%,	   as	   compared	   with	   controls	   (#p<0.01).	   	   Xenon	   treated	   animals	   (red	   bars)	  
received	   75%	   xenon/25%	   oxygen	   for	   2	   hours	   before	   and	   2	   hours	   after	   injury.	   Control	  
animals	  (blue	  bars)	  received	  75%	  nitrogen/25%	  oxygen.	  Contusion	  volume	  was	  measured	  
24	   hours	   after	   experimental	   brain	   trauma.	   Bars	   are	   mean	   values	   and	   error	   bars	   are	  




Figure	   5.3:	   Xenon	   treatment	   reduces	   contusion	   volume	   24	   hours	   after	   traumatic	   brain	  
injury.	   Typical	   cresyl-­‐violet	   stained	   slices,	   2.2	   mm	   posterior	   to	   Bregma,	   show	   primary	  
injury	  15	  min	  after	   trauma	  (A),	   control	   injury	   (B),	  and	  xenon-­‐treated	   injury	  at	  24	  hours	  
after	   trauma	   (C).	   In	   the	  example	   shown	  xenon	   treatment	  was	  delayed	  until	  1	  hour	  after	  
trauma.	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Figure	   5.4:	   Xenon	   treatment	   after	   injury	   improves	   neurological	   outcome	   following	  
traumatic	   brain	   injury.	   Treatment	   with	   xenon	   15	   minutes	   after	   injury	   improves	  
neurological	   function	   by	   36±6%	   as	   compared	   with	   controls	   (*p<0.05).	   Xenon	   treated	  
animals	   (red	  bars)	   received	  75%	  xenon/25%	  oxygen	   for	  3	  hours,	  beginning	  15	  minutes	  
after	  experimental	  brain	  trauma.	  Control	  animals	  (blue	  bars)	  received	  75%	  nitrogen/25%	  
oxygen.	  Neurological	  outcome	  was	  measured	  24	  hours	  after	  trauma.	  Bars	  are	  mean	  values	  
and	  error	  bars	  are	  standard	  error	  of	  the	  mean	  (n=22,	  control;	  n=9,	  xenon).	  
	  
Figure	   5.5:	   Xenon	   treatment	   after	   injury	   reduces	   brain	   contusion	   volume	   following	  
traumatic	  injury.	  Treatment	  with	  xenon	  15	  minutes	  after	  injury	  reduces	  contusion	  volume	  
by	   19±7%	   as	   compared	   with	   controls	   (*p<0.05).	   Xenon	   treated	   animals	   (red	   bars)	  
received	  75%	  xenon/25%	  oxygen	   for	  3	  hours,	  beginning	  15	  minutes	  after	  experimental	  
brain	  trauma.	  Control	  animals	  (blue	  bars)	  received	  75%	  nitrogen/25%	  oxygen.	  Contusion	  
volume	  was	  measured	  24	  hours	  after	   trauma.	  Primary	   contusion	  volume	  was	  measured	  
15	  minutes	  after	  trauma.	  Bars	  are	  mean	  values	  and	  error	  bars	  are	  standard	  error	  of	   the	  
mean	  (n=4,	  primary;	  n=22,	  control;	  n=9,	  xenon).	  #p<0.01.	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5.3	  Delayed	  xenon	  treatment	  protects	  against	  traumatic	  
injury	  	  Having	  shown	  xenon	  to	  be	  neuroprotective	  when	  administered	  immediately	  (15	  minutes)	  after	   injury,	   it	  was	  next	  necessary	   to	   investigate	   the	   therapeutic	   time	  window	  during	  which	  xenon	  treatment	  will	  still	  remain	  effective.	  The	  effects	  of	  delaying	   treatment	   until	   1	   hour,	   3	   hours,	   and	   6	   hours	   after	   injury	   were	  investigated.	  	  At	   all	   time	   points	   tested,	   delayed	   xenon	   treatment	   improved	   the	   neurological	  outcome	  score	  at	  24	  hours	  after	  injury,	  by	  between	  27%	  and	  46%	  (Figure	  5.6).	  When	   xenon	   treatment	   was	   delayed	   by	   1	   hour,	   this	   reduction	   in	   neurological	  outcome	  score	  was	   significant	   (p<0.05),	  however	  when	   treatment	  was	  delayed	  by	  3	  hours	  and	  6	  hours	  the	  observed	  reductions	   in	  neurological	  outcome	  score	  were	  not	  significant.	  	  The	  effect	  of	  delayed	  xenon	  treatment	  on	  secondary	  contusion	  volume	  was	  next	  investigated.	   75%	   xenon	   significantly	   (p<0.05)	   reduced	   secondary	   contusion	  volume	  when	  treatment	  was	  administered	  15	  minutes,	  1	  hour,	  or	  3	  hours	  after	  trauma.	  Xenon	  treatment	  15	  minutes	  after	  trauma	  reduced	  secondary	  injury	  by	  22±8%,	   while	   treatment	   1	   hour	   and	   3	   hours	   after	   injury	   reduced	   secondary	  injury	  by	  22±6%,	  and	  28±5%	  respectively	  (Figure	  5.7).	  	  	  When	   treatment	   was	   delayed	   until	   6	   hours	   after	   injury,	   xenon	   did	   not	  significantly	   reduce	   the	   extent	   of	   secondary	   injury	   (5.8±3.0%	   reduction	  compared	  with	  controls;	  Figure	  5.7).	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Figure	  5.6:	  Delayed	  xenon	  treatment	  improves	  neurological	  outcome	  following	  traumatic	  
brain	   injury.	  Xenon-­‐treated	  animals	   (red	  bars)	   received	  75	  %	  xenon/25	  %	  oxygen	   for	  3	  
hours	  duration,	  beginning	  15	  minutes,	  1	  hour,	  3	  hours	  or	  6	  hours	  after	   trauma.	  Control	  
animals	   (blue	   bars)	   received	   75	   %	   nitrogen/25	   %	   oxygen.	   At	   all	   time	   points,	   delayed	  
xenon	   treatment	   improves	   the	   neurological	   outcome	   score.	   This	   improvement	   is	  
significant	  (*p<0.05)	  when	  treatment	  is	  delayed	  either	  15	  minutes	  or	  1	  hour.	  Neurological	  
outcome	  was	  measured	  24	  hours	  after	  trauma.	  Bars	  represent	  mean	  values	  and	  error	  bars	  
are	  standard	  error	  of	  the	  mean	  (N=34,	  control;	  N=21,	  xenon	  15	  min;	  N=8,	  xenon	  1	  hr;	  N=9,	  
xenon	  3hr;	  N=9,	  xenon	  6hr).	  
	  
Figure	  5.7:	  Delayed	  xenon	   treatment	   reduces	   secondary	   injury	  24	  hours	  after	   traumatic	  
brain	   injury.	  Xenon-­‐treated	  animals	   (red	  bars)	   received	  75	  %	  xenon/25	  %	  oxygen	   for	  3	  
hours	  duration,	  beginning	  15	  minutes,	  1	  hour,	  3	  hours	  or	  6	  hours	  after	   trauma.	  Control	  
animals	   (blue	   bars)	   received	   75	   %	   nitrogen/25	   %	   oxygen.	   Delayed	   xenon	   treatment	  
reduces	  secondary	  injury	  when	  treatment	  is	  administered	  15	  minutes,	  1	  hour,	  or	  3	  hours	  
after	   trauma	   (*p<0.05).	   Contusion	   volume	   was	   measured	   24	   hours	   after	   trauma.	   Bars	  
represent	  mean	  values	  and	  error	  bars	  are	  standard	  error	  of	  the	  mean	  (N=22,	  control;	  N=9,	  
xenon	  15	  min;	  N=8,	  xenon	  1	  hr;	  N=9,	  xenon	  3hr;	  N=9,	  xenon	  6hr).	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5.4	  Xenon	  and	  longer-­‐term	  outcome	  	  To	  determine	  whether	  xenon	  is	  neuroprotective	  in	  the	  longer-­‐term,	  neurological	  function	  was	  measured	  in	  groups	  of	  animals	  allowed	  to	  survive	  until	  5	  days	  after	  traumatic	   injury.	   Animals	   were	   treated	   with	   75%	   xenon/25%	   oxygen	   for	   3	  hours,	   with	   drug	   administration	   beginning	   15	   minutes	   after	   brain	   trauma.	  Neurological	   outcome	   was	   measured	   at	   24	   hour	   intervals	   up	   to	   day	   5	   after	  trauma.	  	  Animals	   treated	   with	   75%	   xenon/25%	   oxygen	   showed	   significant	   (p<0.05)	  improvements	   in	   neurological	   function	   compared	   with	   controls	   (75%	  nitrogen/25%	  oxygen),	  up	   to	  4	  days	  after	   injury	   (Figure	  5.8).	  The	  neurological	  outcome	  score	  was	  reduced	  by	  32±6%,	  28±15%,	  56±19%,	  and	  28±15%	  on	  day	  1,	   2,	   3,	   and	   4	   respectively.	   On	   day	   5,	   the	   neurological	   outcome	   score	   in	   xenon	  treated	  animals	  was	  better	  than	  for	  controls	  (a	  reduction	  of	  50±32%),	  however	  this	  difference	  was	  not	  significant	  (p=0.06).	  	  	  	  
5.5	  Chapter	  Summary	  &	  Discussion	  	  75%	   xenon/25%	   oxygen	   is	   neuroprotective	   against	   traumatic	   brain	   injury	   in	  
vivo.	   Neurological	   outcome	   scores	   were	   significantly	   better	   in	   xenon	   treated	  animals	  when	   functional	   outcome	  was	  measured	   in	   both	   early	   (24	   hours)	   and	  late	   (4	  days)	  phases	   after	   injury.	  This	   improvement	   in	   short-­‐term	  neurological	  outcome	  was	  significant	  when	  xenon	  treatment	  was	  given	  either	  15	  minutes	  or	  1	  hour	  after	  injury.	  	  75%	   xenon	   also	   reduced	   the	   degree	   of	   secondary	   injury,	   as	   measured	   by	  histological	  contusion	  volume.	  Secondary	  injury	  was	  reduced	  significantly	  when	  xenon	  treatment	  was	  given	  either	  15	  minutes,	  1	  hour,	  or	  3	  hours	  after	  injury.	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Figure	   5.8:	   Xenon	   treatment	   improves	   neurological	   outcome	   up	   to	   4	   days	   after	   trauma.	  
Xenon-­‐treated	  animals	  (red	  bars)	  received	  75	  %	  xenon/25	  %	  oxygen	  for	  3	  hours	  duration,	  
beginning	   15	   minutes	   after	   trauma.	   Control	   animals	   (blue	   bars)	   received	   75	   %	  
nitrogen/25	  %	  oxygen.	  Xenon	  treated	  animals	  show	  significant	   (*p<0.05)	   improvements	  
in	  neurological	  function	  up	  to	  4	  days	  after	  trauma.	  Neurological	  outcome	  was	  measured	  at	  
24	  hour	  intervals	  for	  5	  days	  after	  trauma.	  Bars	  represent	  mean	  values	  and	  error	  bars	  are	  
standard	   error	   of	   the	  mean	   (day	   1:	   N=22,	   control;	   N=21,	   xenon;	   	   day	   2-­‐3	   	   N=12,	   xenon;	  
N=12;	  day	  4-­‐5	  control	  N=11,	  xenon	  N=12).	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  These	   data	   provide	   the	   first	   evidence	   for	   xenon	   neuroprotection	   in	   an	   animal	  model	  of	  traumatic	  brain	  injury:	  75%	  xenon/25%	  oxygen	  improves	  neurological	  function	  following	  trauma,	  reduces	  the	  degree	  of	  secondary	  injury	  development,	  and	  remains	  efficacious	  even	  when	  treatment	  is	  delayed	  up	  to	  3	  hours	  after	  the	  onset	  of	  trauma.	  This	  is	  consistent	  with	  data	  from	  in	  vitro	  studies,	  in	  which	  xenon	  is	   able	   to	   protect	   against	   secondary	   injury	   development	   in	   a	   simple	   in	   vitro	  model	  of	  traumatic	  brain	  injury,	  even	  when	  xenon	  treatment	  is	  delayed	  [155].	  
	  The	   finding	   that	   xenon	   both	   improves	   functional	   outcome	   and	   reduces	  secondary	   injury	   suggests	   that	   xenon	   represents	   a	   realistic	   first-­‐line	   treatment	  for	  brain	  trauma	  patients.	  That	  xenon	  remains	  efficacious	  even	  when	  delivered	  up	  to	  3	  hours	  after	  is	  injury	  is	  also	  encouraging;	  medical	  personnel	  could	  feasibly	  begin	  delivery	  of	  xenon	  at	  the	  scene	  of	  the	  trauma	  and/or	  in	  the	  ambulance,	  but	  treatment	   should	   remain	   effective	   even	   when	   delivery	   is	   delayed	   until	   the	  patient	  arrives	  at	   the	   ITU.	  A	   recent	  clinical	   study	   in	  cardiac-­‐arrest	  patients	  has	  shown	  that	  xenon	  administration	  to	  ITU	  patients	  is	  practical	  for	  up	  to	  24	  hours	  [156].	  In	  clinical	  trials	  for	  xenon	  neuroprotection	  against	  neonatal	  asphyxia,	  a	  24	  hour	  duration	  for	  xenon	  treatment	  is	  also	  used.	  	  Given	  that	  there	  are	  currently	  no	  clinically	  available	  treatments	  that	  specifically	  target	   the	   reduction	   of	   secondary	   injury	   in	   brain	   trauma,	   further	   pre-­‐clinical	  studies	  to	  advance	  xenon	  towards	  clinical	  trials	  in	  TBI	  are	  justified.	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  The	   present	   study	   had	  multiple	   streams,	   linked	   together	   under	   the	   themes	   of	  molecular	   targets	   underlying	   neuroprotection	   and	   anaesthesia,	   and	   the	  neuroprotective	  potential	  of	  the	  entire	  series	  of	  inert	  gases.	  Interest	  in	  both	  has	  stemmed	   from	   the	   serendipitous	   discovery	   that	   xenon,	   an	   inert	   gas,	   has	  anaesthetic	  properties	  when	  inhaled	  [1].	  The	  identification	  of	  molecular	  targets	  for	  xenon	  –	  notably	  the	  NMDA	  receptor	  [13],	  but	  also	  the	  TREK-­‐1	  channel	  [19]	  –	  then	   prompted	   interest	   in	   xenon	   as	   a	   neuroprotective	   intervention,	   and	  eventually	  interest	  in	  the	  other	  noble	  gases	  in	  the	  same	  therapeutic	  capacity.	  	  	  The	  major	  portion	  of	   this	  study	  was	  spent	  dissecting	  the	   interaction	  between	  a	  number	  of	  anaesthetic	  agents	  and	  the	  GluN1	  site	  of	  the	  NMDA	  receptor,	  with	  the	  ultimate	  aim	  of	  identifying	  specific	  receptor	  mutations	  that	  would	  eliminate	  the	  binding	  of	   xenon	  at	   the	   site.	   	   The	   second	  portion	  of	   the	   study	   investigated	   the	  ability	   of	   the	   other	   inert	   gases	   to	   influence	   two	   known	   molecular	   targets	   of	  xenon,	  namely	  the	  NMDA	  receptor	  and	  the	  TREK-­‐1	  channel.	  These	  experiments	  formed	   one	   core	   part	   of	   a	   larger	   study	   investigating	   the	   mechanism	   of	  neuroprotection	  for	  the	  gases	  xenon	  and	  argon	  in	  an	  in	  vitro	  model	  of	  traumatic	  brain	  injury.	  	  The	   third	   and	   final	   portion	   of	   this	   study	   was	   an	   investigation	   of	   the	  neuroprotective	  efficacy	  of	  xenon	  against	  traumatic	  brain	  injury	  in	  vivo,	  using	  the	  rodent	   controlled	   cortical	   impact	   model	   of	   TBI.	   The	   entirety	   of	   the	   work	  undertaken	   in	   this	   study	   can	   thus	  be	   said	   to	   have	   a	   strong	   translational	   focus,	  beginning	   from	   basic	   molecular	   interactions	   between	  anaesthetic/neuroprotective	  agents	  and	   their	   receptor	   targets,	  moving	   through	  mechanistic	  studies	  in	  vitro,	  and	  ending	  with	  in	  vivo	  studies	  which	  form	  the	  first	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of	   the	   pre-­‐clinical	  work	   required	   to	  move	   xenon	   forward	   as	   a	   neuroprotective	  treatment	  in	  traumatic	  brain	  injury.	  	  TBI	   is	   the	   leading	   cause	  of	  death	  and	  disability	   in	  under	  45’s	   in	   the	  developed	  world	   [94],	   and	   yet	   there	   are	   currently	   no	   clinically	   available	   treatments	  designed	  to	  arrest	   the	   injury	  processes	  particular	   to	   this	   type	  of	  brain	  damage.	  Treatments	  for	  TBI	  are	  urgently	  required,	  with	  xenon	  showing	  early	  promise	  in	  this	  therapeutic	  capacity.	  	  	  	  
6.1	  Anaesthetics	   and	   the	  NMDA	  receptor	  GluN1	  glycine	  
site	  	  The	  NMDA	  receptor	  is	  one	  of	  three	  main	  receptor	  families	  upon	  which	  the	  search	  for	  general	  anaesthetic	  targets	  has	  focussed	  [5].	  NMDA	  receptors	  are	  expressed	  ubiquitously	  throughout	  the	  CNS	  and	  play	  an	  important	  role	  in	  normal	  excitatory	  transmission	   [35,36],	   thus	   they	   are	   plausible	   molecular	   targets	   for	   general	  anaesthetic	  agents.	  Inhibition	  of	  NMDA	  receptors	  has	  been	  demonstrated	  for	  the	  anaesthetic	  gases	  xenon	  and	  nitrous	  oxide	  [13,16,43],	  as	  well	  as	  for	  a	  number	  of	  other	  agents	  capable	  of	  producing	  general	  anaesthesia	  [44].	  	  Previous	  work	  in	  this	  lab	  has	  shown	  that	  both	  xenon	  and	  the	  volatile	  anaesthetic	  isoflurane	   inhibit	  NMDA	  receptors	  via	  a	  competitive	   interaction	  with	  glycine	  at	  the	  GluN1	  co-­‐agonist	  site	  [48].	  Other	  anaesthetic	  agents	  –	  e.g.	  cyclopropane	  [44]	  and	   nitrous	   oxide	   [16]	   –	   are	   also	   known	   to	   inhibit	   NMDA	   receptors,	   however	  whether	  this	  inhibition	  is	  also	  mediated	  at	  the	  GluN1	  glycine	  site	  was	  previously	  unknown.	  In	  the	  case	  of	  xenon	  inhibition	  of	  the	  NMDA	  receptor,	  there	  exists	  an	  additional	  inhibitory	  component	  that	  is	  mediated	  by	  a	  site	  other	  than	  the	  GLuN1	  glycine	  site	  [48].	  The	  site	  of	  this	  secondary	  inhibition	  is	  currently	  unknown,	  but	  is	  not	  the	  NMDA	  binding	  site	  on	  the	  GluN2	  subunit	  [13].	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In	   this	   study,	   the	   anaesthetic	   agents	   sevoflurane,	   isoflurane,	   nitrous	  oxide,	   and	  cyclopropane,	  were	  all	  shown	  to	  inhibit	  NMDA	  receptors.	  Receptor	  inhibition	  by	  both	   sevoflurane	   (Figure	   3.21)	   and	   isoflurane	   (Figure	   3.22)	   was	   reversed	   by	  increasing	   the	   glycine	   concentration,	   indicative	   of	   a	   common	   mechanism	   of	  action	  for	  the	  two:	  namely	  competitive	  inhibition	  of	  glycine	  binding	  at	  the	  GluN1	  site.	  Interestingly,	  for	  both	  these	  agents	  receptor	  inhibition	  could	  be	  completely	  reversed	  by	  increasing	  glycine,	  consistent	  with	  a	  purely	  competitive	  inhibition	  of	  the	  receptor	  at	  this	  site	  only.	  	  NMDA	  receptor	  inhibition	  by	  nitrous	  oxide	  was	  also	  reversed	  by	  increasing	  the	  glycine	   concentration	   (Figure	   3.23),	   however	   even	   at	   saturating	   glycine	  concentrations	   a	   residual	   amount	   of	   receptor	   inhibition	   remained.	   Thus,	  while	  nitrous	  oxide	  does	  inhibit	  NMDA	  receptors	  at	  the	  GluN1	  glycine	  site,	  it	  appears	  to	  have	  an	  additional	  inhibitory	  effect	  at	  a	  different	  allosteric	  site.	  This	  glycine	  non-­‐competitive	  inhibition	  may	  be	  at	  the	  same	  allosteric	  site	  via	  which	  xenon	  exerts	  its	   glycine	   non-­‐competitive	   inhibition	   of	   the	   same	   receptors,	   or	   may	   be	   at	  another	  site	  entirely.	  	  Finally,	   cyclopropane	   was	   shown	   to	   potently	   inhibit	   NMDA	   receptors	   in	   a	  concentration-­‐dependent	  manner	  (Figure	  3.24).	  This	  inhibition	  was	  not	  reversed	  by	   increasing	   glycine	   (Figure	   3.25),	   suggesting	   that	   cyclopropane	   –	   unlike	   the	  other	   agents	   tested	   –	   does	   not	   interact	  with	   the	   NMDA	   receptor	   at	   the	   GluN1	  glycine	  site.	  Two	  potential	  sites	  at	  which	  cyclopropane	  exerts	  its	  effects	  are	  the	  GluN2	  NMDA-­‐binding	  site	  and	  the	  allosteric	  site	  mediating	  xenon’s	  glycine	  non-­‐competitive	   inhibition,	   however	   the	   NMDA	   receptor	   is	   known	   to	   have	   a	   large	  number	  of	  allosteric	  binding	  sites	  for	  small	  molecule	  ligands	  [29],	  any	  of	  which	  could	  potentially	  represent	  the	  cyclopropane	  binding	  site.	  	  Together	   these	   data	   support	   a	   role	   for	   NMDA	   receptor	   inhibition	   in	   the	  mechanism	   of	   action	   of	   general	   anaesthetics.	   In	   the	   case	   of	   sevoflurane	   and	  isoflurane,	  actions	  at	  inhibitory	  GABAA	  receptors	  are	  likely	  to	  play	  an	  important	  –	   perhaps	   dominant	   –	   role	   in	   their	   anaesthetic	   activity,	   however	   it	   remains	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possible	  that	  the	  NMDA	  receptor	  is	  an	  important	  molecular	  target	  accounting	  for	  at	  least	  some	  portion	  of	  their	  anaesthetic	  and/or	  neuroprotective	  properties.	  	  	  Conversely,	   both	  nitrous	   oxide	   and	   cyclopropane	  have	  been	   shown	   to	   have	  no	  influence	  on	  GABAA	  receptors	  [16,43,44],	  and	  thus	  NMDA	  receptor	  inhibition	  is	  likely	   to	   form	   a	  more	  major	   -­‐	   although	   perhaps	   not	   exclusive	   -­‐	   component	   of	  their	   anaesthetic	  mechanism.	  Like	  xenon,	  both	  nitrous	  oxide	  and	   cyclopropane	  have	   been	   shown	   to	   activate	   the	   K2P	   TREK-­‐1	   channel	   [19],	   another	   known	  anaesthetic	  target.	  	  	  	  Nitrous	   oxide	   and	   xenon	   both	   have	   an	   additional	   inhibitory	   effect	   at	   a	   site	  distinct	   from	   the	   GluN1	   glycine	   site.	   Similarly,	   cyclopropane	   inhibition	   of	   the	  NMDA	  receptor	  is	  not	  at	  the	  GluN1	  site.	  It	  is	  possible	  that	  these	  three	  agents	  are	  all	   acting	   at	   the	   same	   site,	   however	   this	   is	   currently	   unknown.	   The	   NMDA	  receptor	  has	  a	  number	  of	  known	  allosteric	  modulatory	  sites,	  any	  of	  which	  might	  represent	  a	  molecular	  target	  for	  these	  anaesthetic	  agents.	  In	  the	  case	  of	  xenon	  at	  least,	  it	  is	  known	  that	  this	  second,	  non-­‐competitive,	  inhibition	  is	  not	  mediated	  at	  the	  GluN2	  NMDA	  binding	  site,	  nor	  by	  open	  channel	  blockade	  [14,157].	  	  These	   in	   vitro	   observations	   support	   a	   role	   for	   NMDA	   receptor	   inhibition	   in	  general	  anaesthetic	  mechanisms,	  however	  data	  from	   in	  vivo	  experiments	   is	  still	  required	  to	  prove	  this	  definitively.	  The	  case	  for	  NMDA	  receptor	  inhibition	  at	  the	  GluN1	  glycine	  site	  is	  further	  strengthened	  by	  the	  observation	  that	  this	  site	  is	  not	  believed	  to	  be	  saturated	  in	  vivo;	  microdialysis	  estimates	  place	  extracellular	  brain	  concentrations	   of	   glycine	   at	   approximately	   5µM	   [158-­‐160].	   This	   concentration	  would	   allow	   for	   competitive	   antagonism	   in	   vivo	   by	   all	   of	   those	   anaesthetics	  shown	  to	  act	  competitively	  at	  the	  GluN1	  glycine	  site	  in	  our	  in	  vitro	  experiments.	  	  	  Definitive	   data	   on	   the	   role	   of	   the	   NMDA	   receptor	   in	   general	   anaesthesia	   may	  come	  from	  in	  vivo	  experiments;	  advances	  in	  molecular	  genetics	  have	  allowed	  for	  the	  generation	  of	  mouse	   lines	  used	   to	  determine	   the	   role	  of	   specific	  molecular	  targets	   in	   pharmacological	   endpoints	   including	   general	   anaesthesia	   [63].	  Unfortunately,	  due	  to	  the	  importance	  of	  NMDA	  receptors	  in	  normal	  physiological	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function,	  genetic	  knock-­‐out	  animals	  lacking	  NMDA	  receptors	  die	  soon	  after	  birth	  [142].	  An	  alternative	  strategy	  making	  use	  of	  a	  genetic	  knock-­‐in	  animal	  to	  remove	  sensitivity	   to	   a	   drug	   while	   conserving	   normal	   receptor	   function	   remains	   one	  plausible	  possibility.	  	  	  	  
6.2	   Mutational	   studies	   at	   the	   NMDA	   receptor	   GluN1	  
glycine	  site	  	  The	   anaesthetic	   gas	   xenon	   has	   been	   shown	   to	   have	   neuroprotective	   effects	  against	  a	  number	  of	   injury	   types	   in	  both	   in	  vitro	   and	   in	  vivo	  models	   [75-­‐77,87-­‐90].	   Competitive	   inhibition	   at	   the	   NMDA	   receptor	   glycine	   site	   is	   a	   plausible	  mechanism	   for	  xenon	  neuroprotection;	   indeed	  xenon’s	  actions	  at	   this	  site	  have	  been	   shown	   to	   underlie	   its	   neuroprotective	   effect	   against	   hypoxic/ischemic	  brain	  injury	  in	  vitro	  [91].	  	  Described	   in	  Chapter	  3	   are	   a	   series	  of	   experiments	  designed	   to	   further	  dissect	  the	  molecular	   interaction	  between	  xenon	  and	   the	  NMDA	  receptor	  at	   the	  GluN1	  co-­‐agonist	   glycine	   site.	   The	   main	   aim	   of	   this	   chapter	   was	   to	   identify	   point	  mutations	   in	   the	  NMDA	   receptor	   that	   prevent	   xenon	   binding	   at	   the	   co-­‐agonist	  glycine	   site	   but	   which	   leave	   normal	   receptor	   function	   otherwise	   intact.	   Such	  mutations	  would	  prove	  useful	  in	  the	  generation	  of	  genetic	  knock-­‐in	  animals	  used	  to	   assess	   the	   relative	   contribution	   of	   the	   NMDA	   receptor	   in	   xenon	  neuroprotection	  and	  anaesthesia.	  	  Using	   site-­‐directed	  mutagenesis,	   two	  mutations	   of	   the	   rat	  NMDA	   receptor	   that	  eliminate	  xenon	  binding	  at	   the	  GluN1	  glycine	  site	  were	  created.	  The	  binding	  of	  glycine	   and	   the	   volatile	   anaesthetics	   sevoflurane	   and	   isoflurane	   to	   the	   same	  receptor	   site	   was	   retained	   in	   both	   mutations.	   These	   data	   confirm	   that	   xenon	  binds	   to	   the	   GluN1	   glycine	   site	   of	   the	   NMDA	   receptor	   [48],	   and	   highlight	   a	  particularly	   important	   interaction	   between	   xenon	   and	   the	   aromatic	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phenylalanine	  residue	  at	  the	  758	  site.	  Further,	  these	  data	  appear	  to	  confirm	  the	  hypothesis	   that	  xenon	  and	  glycine	  bind	   to	  distinct	  but	  overlapping	  sites	  on	   the	  GluN1	  subunit	  of	  the	  NMDA	  receptor.	  	  
6.2.1	  GluN1	  mutations	  and	  glycine	  binding	  The	   mutational	   strategy	   followed	   while	   attempting	   to	   dissect	   the	   molecular	  interactions	  of	  xenon	  with	  the	  GluN1	  glycine	  site	  focussed	  on	  those	  residues	  that	  interact	   with	   xenon	   but	   which	   are	   less	   likely	   to	   be	   critical	   for	   the	   binding	   of	  glycine.	  The	  binding	  of	  xenon	  to	  proteins	  has	  previously	  been	  characterised	  in	  a	  number	   of	   X-­‐ray	   crystallographic	   studies;	   these	   indicate	   that	   the	   presence	   of	  aromatic	  amino	  acid	  residues	  in	  close	  proximity	  to	  xenon	  atoms	  is	  an	  important	  factor	   in	   the	   ability	   of	   xenon	   to	   bind	   to	   a	   protein	   cavity.	   Aromaticity	   in	   close	  proximity	   to	   xenon	   atoms	   has	   been	   demonstrated	   for	   xenon	   binding	   sites	   on	  myoglobin,	  urate	  oxidase,	  β-­‐endotoxin	  CytB,	  and	  elastase	  [161-­‐163].	  	  Molecular	  modelling	  of	   the	   interaction	  between	  xenon	  and	   the	  NMDA	  receptor	  crystal	   structure	   predicted	   xenon	   atoms	   co-­‐ordinated	   by	   the	   three	   aromatic	  residues:	   phenylalanine	   at	   the	   484	   site,	   tryptophan	   at	   the	   731	   site,	   and	  phenylalanine	   at	   the	   758	   site	   [48].	   A	   similar	   co-­‐ordination	   of	   xenon	   atoms	   by	  three	  aromatic	  residues	  has	  been	  reported	  in	  both	  human	  serum	  albumin	  [147]	  and	   PsbO	   protein	   (a	   component	   of	   the	   Photosystem	   II	   complex)	   [148].	   The	  mutational	   strategy	   employed	  while	   attempting	   to	   eliminate	   xenon	   binding	   to	  the	  GluN1	  site	  was	  thus	  focussed	  upon	  these	  three	  aromatic	  amino	  acids.	  	  Mutation	   of	   the	   tryptophan	   731	   site	   to	   the	   non-­‐aromatic	   residues	   alanine	   and	  leucine	   resulted	   in	   large	   (over	  100-­‐fold)	   reductions	   in	   receptor	   glycine	   affinity	  (Figure	  3.5,	  Figure	  3.7),	  indicating	  an	  important	  influence	  for	  aromaticity	  at	  this	  site	   in	   the	  binding	  of	   glycine	   to	   the	   receptor.	   Interaction	  between	   the	  731	   site	  and	   glycine	   has	   been	   described	   previously	   [66],	   consistent	   with	   the	   observed	  effects	   of	   mutation	   on	   the	   apparent	   glycine	   affinity	   of	   the	   receptor.	   As	   the	  ultimate	  aim	  of	  the	  study	  was	  to	  produce	  functional	  receptor	  mutants,	  silent	   in	  regards	   to	   glycine	   affinity,	   mutants	   of	   the	   W731	   site	   were	   not	   investigated	  further.	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  Mutation	  of	  the	  phenylalanine	  758	  site	  to	  the	  non-­‐aromatic	  residues	  alanine	  and	  leucine	   also	   produced	   receptor	   mutants	   with	   reduced	   glycine	   affinity.	   These	  reductions	   were,	   however,	   more	   modest	   than	   for	   mutations	   of	   W731:	   an	  approximate	   6-­‐fold	   reduction	   when	   compared	   with	   the	   wild-­‐type	   (Figure	   3.8,	  Figure	   3.10).	   This	   relatively	  modest	   effect	   on	   glycine	   binding	   suggests	   a	  more	  limited	   involvement	   of	   aromaticity	   at	   the	   758	   site	   in	   the	   binding	   of	   glycine.	  Nevertheless,	  the	  observed	  reductions	  in	  apparent	  glycine	  affinity	  of	  the	  F758A	  and	   F758L	  mutants	   points	   towards	   at	   least	   some	   level	   of	   interaction	   between	  glycine	  and	  the	  aromatic	  ring	  of	  phenylalanine	  at	  this	  site.	  	  In	  order	  to	  test	  this	  prediction,	  the	  phenylalanine	  758	  site	  was	  next	  mutated	  to	  aromatic	  tryptophan	  (F758W)	  and	  tyrosine	  (F758Y)	  residues.	  In	  both	  cases,	  the	  apparent	  glycine	  affinity	  of	  these	  aromatic-­‐to-­‐aromatic	  mutants	  was	  unchanged	  from	  that	  of	  the	  wild-­‐type	  receptor;	  in	  terms	  of	  glycine	  binding,	  both	  the	  F758W	  and	   F758Y	  mutations	   are	   silent	   (Figure	   3.12,	   Figure	   3.14),	   consistent	  with	   the	  aromatic	   ring	   of	   tryptophan	   and	   tyrosine	   interacting	  with	   glycine	   in	   a	   similar	  manner	   to	   the	   wild-­‐type	   phenylalanine.	   An	   alternative	   interpretation	   of	   these	  data	   might	   be	   that	   the	   similar	   molecular	   volumes	   of	   the	   aromatic	   residues,	  compared	   with	   the	   smaller	   volume	   of	   leucine	   and	   alanine,	   accounts	   for	   the	  similar	  glycine	  affinity	  of	  F758W	  and	  F758Y	  receptor	  mutants.	  	  
6.2.2	  GluN1	  mutations	  and	  xenon	  binding	  The	   effect	   of	   GluN1	   glycine	   site	   mutations	   on	   the	   binding	   of	   xenon	   was	   next	  investigated,	  by	  measuring	  the	  degree	  of	  receptor	  inhibition	  by	  xenon	  at	  various	  concentrations	   of	   glycine.	   Xenon	   inhibits	   the	   wild-­‐type	   NMDA	   receptor	   via	  competitive	   interaction	  with	  glycine	  at	   the	  GluN1	  glycine-­‐binding	  site	  [48],	  and	  as	  such,	  xenon	  will	  inhibit	  receptors	  less	  at	  high	  glycine	  concentrations.	  It	  is	  thus	  important	   to	   test	   inhibition	   of	   receptor	  mutants	   over	   an	   appropriate	   range	   of	  glycine	  concentrations	  spanning	   the	  entire	  glycine	  dose-­‐response	  curve	   for	   the	  particular	  mutant.	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One	   previous	   study	   by	   Ogata	   et	   al	   [44]	   reported	   a	   GluN1	   subunit	   mutation	  (F639A)	  that	  appeared	  to	  reduce	  receptor	   inhibition	  by	  xenon,	  however	   in	   this	  case	  the	  authors	  failed	  to	  account	  for	  potential	  changes	  in	  glycine	  affinity	  in	  their	  mutant	  receptor.	  It	  was	  subsequently	  shown	  by	  Dickinson	  et	  al	  [48]	  that	  rather	  than	  reducing	  receptor	  inhibition	  by	  xenon,	  the	  F639A	  mutant	  in	  fact	   increases	  the	   receptor’s	   affinity	   for	   glycine.	   By	   assessing	   xenon	   inhibition	   at	   an	  inappropriate	  glycine	  concentration,	  an	  increase	  in	  receptor	  glycine	  affinity	  was	  misinterpreted	  as	  a	  reduction	  in	  xenon	  inhibition.	  	  Particular	   care	  was	   taken	   to	  assess	   the	   competitive	   interaction	  between	  xenon	  and	   glycine	   in	   our	   own	   receptor	   mutations	   at	   the	   most	   appropriate	   glycine	  concentration,	  so	  that	  any	  changes	  in	  glycine	  affinity	  were	  not	  misinterpreted	  as	  increases/reductions	  in	  receptor	  inhibition	  by	  xenon	  as	  was	  the	  case	  previously	  [44,48].	  Glycine	  concentration-­‐response	  curves	   for	   the	  F758	  site	  mutants	  were	  informative	   in	   this	   respect,	   ensuring	   that	   xenon	   inhibition	   was	   measured	   at	  glycine	  concentrations	  appropriate	  to	  the	  particular	  mutant	  receptor.	  	  	  Mutation	   of	   the	   F758	   site	   to	   the	   non-­‐aromatic	   residues	   alanine	   and	   leucine	  resulted	  in	  a	  modest	  6-­‐fold	  reduction	  in	  apparent	  glycine	  affinity,	  while	  mutation	  to	  the	  aromatic	  residues	  tryptophan	  and	  tyrosine	  had	  no	  effect	  on	  the	  apparent	  glycine	   affinity.	   Interestingly,	   for	   all	   four	   F758	  mutants,	   there	  was	   no	   glycine-­‐dependence	   to	   receptor	   inhibition	  by	  xenon	  –	   consistent	  with	  xenon	  no	   longer	  competing	  with	  glycine	  for	  occupation	  of	  the	  GluN1	  site	  (Figure	  3.17,	  Figure	  3.18,	  Figure	  3.19,	  and	  Figure	  3.20),	  i.e.	  xenon	  no	  longer	  binds	  the	  receptor	  at	  this	  site.	  	  	  That	  the	  F758A	  and	  F758L	  mutants	  eliminate	  xenon	  binding	  at	  the	  glycine	  site	  is	  also	   consistent	   with	   the	   hypothesis	   that	   interaction	   with	   aromatic	   residues	   is	  important	  in	  the	  binding	  of	  xenon	  to	  protein	  cavities	  [161-­‐163].	  For	  the	  F758W	  and	   F758Y	   mutants,	   which	   retain	   aromaticity	   at	   the	   758	   site,	   it	   appears	   that	  glycine	  is	  able	  to	  interact	  with	  the	  aromatic	  ring	  of	  tryptophan	  and	  tyrosine	  just	  as	  well	  as	  the	  aromatic	  ring	  of	  phenylalanine,	  whereas	  xenon	  cannot.	  	  
137	  
The	  reason	  for	  xenon’s	  particularly	  favourable	  interaction	  with	  phenylalanine	  at	  the	   758	   site	   is	   unclear,	   but	   may	   be	   attributed	   to	   either	   the	   particular	  stoichiometry	   of	   its	   aromatic	   ring	   and/or	  differences	   in	  molecular	   volume	  and	  polarity	   as	   compared	  with	   the	   larger	   tryptophan	   residue	   or	   the	   polar	   tyrosine	  residue.	  	  
6.2.3	  GluN1	  mutations	  and	  binding	  of	  sevoflurane,	   isoflurane,	  and	  nitrous	  
oxide	  Both	  sevoflurane	  and	  isoflurane	  were	  shown	  to	  inhibit	  wild-­‐type	  GluN1/GluN2A	  receptors,	  with	   this	   inhibition	   entirely	   competitive	  with	   the	   co-­‐agonist	   glycine.	  This	  is	  in	  contrast	  to	  xenon	  and	  nitrous	  oxide,	  which	  exhibit	  a	  mixed	  competitive	  and	  non-­‐competitive	  inhibition	  of	  NMDA	  receptors.	  For	  both,	  a	  residual	  degree	  of	  inhibition	   is	   observed	   at	   saturating	   glycine	   concentrations,	   likely	  mediated	   by	  their	   action	   at	   another	   non-­‐competitive	   site.	   	   The	   F758W	   and	   F758Y	   receptor	  mutants	  were	  found	  to	  eliminate	  the	  competitive	  component	  of	  xenon	  inhibition	  while	   retaining	   the	   binding	   of	   glycine	   at	   wild-­‐type	   levels.	   The	   ability	   of	   the	  anaesthetics	  sevoflurane,	   isoflurane,	  and	  nitrous	  oxide	   to	   inhibit	   these	  mutants	  at	  the	  GluN1	  site	  was	  thus	  investigated	  next.	  	  Surprisingly,	   inhibition	  of	  both	  F758W	  and	  F758Y	  mutants	  by	   sevoflurane	  and	  isolfurane	   remains	   glycine	   dependent	   (Figure	   3.26,	   Figure	   3.27,	   Figure	   3.28,	  Figure	   3.29);	   consistent	   with	   both	   of	   these	   anaesthetics	   still	   binding	   at	   the	  mutated	   receptor	   site.	   That	   the	   binding	   of	   neither	   anaesthetic	   is	   affected	   by	  mutation	  of	  the	  F758	  site	  suggests	  that,	  unlike	  xenon,	  sevoflurane	  and	  isoflurane	  are	   able	   to	   interact	   equally	  well	  with	   the	  wild-­‐type	   phenylalanine	   residue	   and	  the	  tryptophan	  and	  tyrosine	  residues	  in	  the	  mutant	  receptors.	  	  	  For	   nitrous	   oxide,	   binding	   to	   the	   GluN1	   site	   is	   retained	   in	   the	   F758W	  mutant,	  albeit	   rather	   more	   weakly	   than	   for	   the	   wild-­‐type	   (Figure	   3.30).	   In	   the	   F758Y	  mutant,	   the	   glycine-­‐dependence	   of	   receptor	   inhibition	   by	   nitrous	   oxide	   is	  abolished	  –	  indicating	  that	  nitrous	  oxide	  is	  no	  longer	  able	  to	  bind	  at	  the	  glycine	  site	  (Figure	  3.31).	  The	  reduction	  in	  the	  degree	  of	  inhibition	  in	  the	  F758W	  mutant	  suggests	   that	   nitrous	   oxide	   interacts	   more	   favourably	   with	   the	   wild-­‐type	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phenylalanine	  residue	  than	  the	  mutated	  tryptophan.	  The	  elimination	  of	  nitrous	  oxide	   binding	   by	   mutation	   to	   tyrosine	   further	   suggests	   that,	   like	   xenon,	  phenylalanine	   at	   this	   site	   is	   important	   for	   the	   binding	   of	   nitrous	   oxide.	   The	  reason	  for	  nitrous	  oxide’s	  particularly	  favourable	  interaction	  with	  phenylalanine	  (or	  alternatively,	  particularly	  unfavourable	  interaction	  with	  tyrosine	  as	  opposed	  to	  tryptophan)	  may	  be	  attributed	  to	  the	  particular	  stoichiometry	  of	  the	  aromatic	  rings	  and/or	  differences	  in	  molecular	  volume	  and	  polarity.	  	  Together	   these	   data	   point	   towards	   an	   argument	   that	   anaesthetics	   and	   glycine	  bind	  distinct,	  but	  overlapping,	  sites	  on	  the	  GluN1	  subunit	  of	  the	  NMDA	  receptor,	  interacting	  differently	  with	  particular	  amino	  acid	  residues.	  For	  both	  xenon	  and	  nitrous	  oxide,	  phenylalanine	  at	  the	  758	  site	  appears	  to	  be	  particularly	  important	  for	   binding	   of	   these	   agents.	   Conversely,	   the	   758	   site	   appears	   to	   be	   of	   lesser	  importance	  in	  the	  binding	  of	  sevoflurane	  and	  isoflurane,	  as	  both	  continue	  to	  bind	  and	  inhibit	  receptors	  regardless	  of	  the	  particular	  aromatic	  amino	  acid	  at	  this	  site.	  	  
6.2.4	  Xenon	   interaction	  with	   the	  glycine	  binding	  site	  and	   implications	   for	  
xenon	  anaesthesia	  and	  neuroprotection	  in	  vivo	  The	   potential	   for	   NMDA	   receptor	   antagonists	   (acting	   at	   the	   glycine	   site	   or	  otherwise)	   to	   act	   as	   neuroprotective	   treatments	   has	   been	   proposed	   for	   many	  years	  [84].	  Despite	  this,	  no	  treatments	  have	  yet	  made	  it	  to	  the	  clinic,	  hampered	  by	   either	   poor	   efficacy	   or	   undesirable	   side	   effects.	   The	   glycine-­‐site	   antagonist	  gavestinel,	  one	  high	  profile	  failure,	  showed	  early	  promise	  in	  pre-­‐clinical	  studies,	  but	  ultimately	   failed	  to	  produce	  significant	  neuroprotection	   in	  clinical	   trials	   for	  stroke	  [164,165].	  	  Xenon	  has	  shown	  promise	   in	  pre-­‐clinical	  studies,	  with	  xenon	  treatment	  proven	  neuroprotective	   against	   hypoxic/ischemic	   injury	   both	   in	   vitro	   and	   in	   vivo	  [86,88,89,91]	  and	  against	   traumatic	   injury	   in	  vitro	  [75].	  Xenon	  neuroprotection	  against	   hypoxic/ischemic	   injury	   in	   vitro	   has	   been	   shown	   to	   be	   mediated	   by	  competitive	  inhibition	  of	  the	  NMDA	  receptor	  GluN1	  glycine	  site	  [91].	  Similarly,	  a	  companion	  study	  by	  Harris	  et	  al	  has	  shown	  that	  xenon	  neuroprotection	  against	  traumatic	  injury	  in	  vitro	  is	  also	  mediated	  by	  glycine	  site	  inhibition.	  The	  molecular	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targets	  underlying	  xenon	  neuroprotection	   (and	  anaesthesia)	   in	  a	  whole	  animal	  system	  remain	  unknown,	  however	  NMDA	  receptor	  antagonism	  is	  one	  plausible	  mechanism.	  	  	  One	  main	  driver	   of	   the	   interest	   in	   the	  molecular	   interaction	  of	   xenon	  with	   the	  NMDA	  receptor	  glycine	  site	  has	  been	  the	  idea	  that	  it	  may	  be	  possible	  to	  identify	  a	  silent	  or	  near-­‐silent	  mutation	  eliminating	  xenon	  binding	  to	  the	  receptor	  without	  affecting	  the	  binding	  of	  glycine.	  Receptor	  mutants	  of	  this	  type	  would	  be	  of	  great	  value	  as	  molecular	   tools,	   useful	   in	  dissecting	   the	   role	  of	   the	  NMDA	  receptor	   in	  anaesthesia	  and	  neuroprotection	  in	  vivo	  once	  expressed	  in	  a	  transgenic	  animal.	  	  That	  xenon	  and	  glycine	  are	  structurally	  distinct	  suggests	  that	  they	  might	  interact	  with	  different	  amino	  acids	  at	  the	  site,	  indeed	  the	  data	  presented	  here	  appear	  to	  confirm	   this	   theory.	   The	   aromatic	   residues	   F758,	   F484,	   and	  W731	   co-­‐ordinate	  xenon	   atoms	   in	   the	   GluN1	   binding	   site,	   likely	   making	   London	   dispersion	   or	  induced-­‐dipole	   interactions	  with	   xenon.	   Data	   presented	   in	   Chapter	   3	   confirms	  the	   importance	   of	   aromatic	   residues	   in	   the	   binding	   of	   glycine	   at	   the	   site;	  mutation	  of	  the	  phenylalanine	  758	  site	  to	  non-­‐aromatic	  residues	  reduces	  glycine	  binding,	   while	   mutation	   to	   other	   aromatic	   residues	   leaves	   glycine	   affinity	  unchanged.	  Similarly,	  these	  data	  reconfirm	  the	  importance	  of	  aromatic	  residues	  in	   xenon	  binding	   to	  protein	   cavities.	  Mutation	  of	   the	  phenylalanine	  758	   site	   to	  non-­‐aromatic	   residues	   abolished	   xenon	   binding	   to	   the	   site.	   Interestingly,	  mutation	   of	   the	   758	   site	   to	   either	   tryptophan	   or	   tyrosine	   conserved	   glycine	  binding	  at	  wild-­‐type	  levels,	  but	  still	  abolished	  xenon	  binding	  at	  the	  site.	  	  The	   F758W	   and	   F758Y	   mutants	   –	   silent	   in	   respect	   to	   binding	   of	   glycine,	   but	  which	  no	   longer	  bind	  xenon	  –	  open	   the	  possibility	  of	   creating	  genetic	  knock-­‐in	  animals	  that	  should	  behave	  normally	  at	  physiological	  glycine	  concentrations	  but	  with	  which	  no	  longer	  bind	  xenon	  at	  the	  site.	  Knock-­‐in	  animals	  of	  this	  kind	  should	  be	   expected	   to	   have	   reduced	   sensitivity	   to	   the	   anaesthetic,	   analgesic,	   and	  neuroprotective	  properties	  of	   xenon,	  but	  be	  normal	   in	   respect	   to	   the	  effects	  of	  other	  anaesthetic	  agents	  –	  e.g.	  isoflurane,	  sevoflurane	  -­‐	  acting	  at	  the	  GluN1	  site.	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Two	   caveats	   exist;	   firstly,	   while	   both	   F758W	   and	   F758Y	  mutants	   are	   silent	   in	  respect	   to	   glycine	   affinity,	   both	   show	   small	   but	   significant	   (roughly	   2-­‐fold)	  reductions	  in	  NMDA	  affinity;	  and	  secondly,	  a	  small	  residual	   inhibition	  of	  NMDA	  receptors	  at	  a	  different,	  non-­‐competitive	  site	  remains	  for	  both	  xenon	  and	  nitrous	  oxide.	  	  Given	   that	   competitive	   inhibition	   of	   the	   NMDA	   receptor	   at	   the	   GluN1	   site	   has	  been	  shown	  to	  mediate	  xenon	  neuroprotection	  in	  vitro	  [91],	  it	  would	  be	  of	  great	  interest	   to	   test	   this	   same	   hypothesis	   in	   vivo.	   Xenon	   is	   known	   to	   affect	   only	   a	  limited	   number	   of	  molecular	   targets,	   notably	   NMDA	   receptors,	   2-­‐pore	   domain	  potassium	  channels,	  and	  the	  ATP-­‐sensitive	  potassium	  channel	  [13,14,17,19,166]	  –	  any	  and	  all	  of	  which	  may	  contribute	  to	  xenon’s	  favourable	  clinical	  properties.	  	  	  Inhibition	   of	   the	   NMDA	   receptor	   at	   the	   GluN1	   site	   remains	   a	   plausible	  mechanism	   for	   xenon	   neuroprotection	   (and	   anaesthesia)	   in	  vivo;	  microdialysis	  estimates	  of	  extracellular	  brain	  concentrations	  of	  glycine	  are	  approximately	  5µM	  [158,159],	   a	   concentration	   at	  which	   xenon	  will	   inhibit	   NMDA	   receptors	   at	   the	  glycine	  site.	  Knock-­‐in	  mice	  expressing	  NMDA	  receptors	  with	  either	  the	  F758W	  or	  F758Y	   mutation	   would	   thus	   be	   of	   great	   use	   in	   dissecting	   out	   the	   relative	  contribution	   of	   the	   NMDA	   receptor	   to	   xenon’s	   anaesthesia,	   analgesia,	   and	  neuroprotection	  and	  in	  providing	  important	  validation	  of	  the	  NMDA	  receptor	  as	  a	  molecular	  target	  for	  anaesthesia	  and	  neuroprotection.	  	  	  Global	   knockout	   of	   the	   NMDA	   receptor	   would	   in	   theory	   provide	   the	   same	  information,	   however	  NMDA	   receptor	   knockout	   animals	   die	   shortly	   after	   birth	  [142],	   likely	   due	   to	   the	   critical	   role	   these	   receptors	   play	   in	   development.	  Similarly,	  even	  in	  any	  case	  in	  which	  NMDA	  receptor	  knockout	  did	  not	  prove	  fatal,	  KO	  animals	  would	   likely	   exhibit	  multiple	   and	   severe	  deficits	  due	   to	   the	   crucial	  role	  of	  the	  NMDA	  receptor	  in	  learning	  and	  memory.	  	  	  An	   alternative	   knock-­‐in	   strategy	   using	   a	   receptor	   mutation	   in	   which	   the	  sensitivity	  to	  a	  drug	   is	  eliminated	  but	  the	  normal	   functioning	  of	   the	  receptor	   is	  preserved	   is	   thus	   both	   a	   more	   feasible	   and	   desirable	   option.	   Knock-­‐in	   animal	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lines	   with	   point	   mutations	   in	   the	   GluN1	   site	   have	   been	   generated	   previously	  [150].	   Similarly,	   knock-­‐in	   strategies	   have	   in	   the	  past	   been	  used	   successfully	   to	  dissect	   the	   molecular	   mechanisms	   involved	   in	   propofol	   and	   etomidate	  anaesthesia	  using	  mutants	  of	  the	  GABAA	  β	  subunit	  [143-­‐146].	  	  	  	  
6.3	  Noble	  gases	  and	  neuroprotective	  targets	  	  	  Following	  the	  discovery	  that	  xenon	  possesses	  neuroprotective	  properties,	  there	  has	   been	   an	   increase	   in	   interest	   in	   the	   other	   inert	   gases	   as	   potential	  neuroprotective	   treatments.	   Trudell	   et	   al	   [139]	   have	   suggested	   that	   all	   of	   the	  inert	  gases	  may	  interact	  with	  protein	  cavities	  in	  a	  similar	  manner,	  however	  there	  is	  currently	  no	  literature	  consensus	  regarding	  the	  neuroprotective	  efficacy	  of	  the	  other	  inert	  gases.	  	  	  Neon	  and	  helium	  –	  the	  lightest	  members	  of	  the	  group	  –	  have	  been	  proven	  devoid	  of	   anaesthetic	   potency	   [93],	   and	   the	   sparse	   (and	   divisive)	   accounts	   of	   helium	  neuroprotection	   are	   believed	   to	   arise	   through	   a	   physical	   rather	   than	  pharmacological	  mechanism	   [133],	  whereby	  breathing	   helium	  at	   temperatures	  lower	   than	   body	   temperature	   causes	   hypothermia.	   Hypothermia	   is	   known	   to	  result	  in	  neuroprotection,	  and	  is	  even	  used	  clinically	  for	  this	  purpose	  [108].	  	  	  Argon	   and	   krypton	   –	   closer	   in	   size	   and	  molecular	  weight	   to	   xenon	   –	   are	   both	  anaesthetic	  at	  elevated	  pressures:	  15atm	  and	  4.5atm	  respectively	  [93].	  However,	  krypton	  –	  xenon’s	  closest	  relative	  in	  the	  family	  of	  inert	  gases	  –	  has	  been	  found	  to	  have	  no	  neuroprotective	  effects	  against	  ischemic	  injury	  in	  vitro	  [134],	  nor	  against	  traumatic	   injury	   in	   vitro	   (Figure	   4.1).	   Conversely,	   argon	   has	   displayed	  neuroprotective	   efficacy	   in	   a	   number	   of	   in	   vitro	   studies	   against	   a	   variety	   of	  neuronal	  insults	  [134-­‐136],	  including	  traumatic	  injury	  (Figure	  4.1).	  	  	  Xenon	  is	  known	  to	  activate	  TREK-­‐1	  channels	  [19]	  and	  to	  inhibit	  NMDA	  receptors	  [13]	   in	   a	   concentration-­‐dependent	  manner.	   It	   is	   possible	   that	   the	   other	   noble	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gases	  may	   exert	   a	   similar	   effect	   at	   the	   same	   target	   sites,	   however	   prior	   to	   the	  present	   study	   the	   ability	   of	   the	   noble	   gases	   –	   other	   than	   xenon	   –	   to	   influence	  molecular	  targets	  important	  in	  anaesthesia	  and	  neuroprotection	  had	  never	  been	  investigated.	  	  The	  in	  vitro	  electrophysiological	  experiments	  described	  in	  Chapter	  4	  formed	  one	  part	   of	   a	   wider	   study	   investigating	   neuroprotection	   against	   TBI	   by	   the	   entire	  series	   of	   noble	   gases,	   performed	   in	   collaboration	  with	  Katie	  Harris.	   This	   study	  was	  the	  first	  to	  investigate	  the	  neuroprotective	  potential	  of	  the	  complete	  series	  of	  noble	  gases	  under	  identical	  conditions	  in	  an	  in	  vitro	  model	  of	  traumatic	  brain	  injury.	  Neuroprotective	  efficacy	  was	  reported	  for	  both	  xenon	  and	  argon,	  but	  not	  helium,	  neon,	   or	   krypton	   (Figure	  4.1).	  Described	   in	  Chapter	  4	   are	   experiments	  designed	   to	   investigate	   the	   effects	   of	   the	   noble	   gases	   on	   two	   putative	  neuroprotective	   targets	  –	   the	  NMDA	  receptor	  and	   the	  TREK-­‐1	  channel	  –	   in	   the	  first	   study	   to	   systematically	   explore	   the	   effects	   of	   these	   gases	   on	   molecular	  targets	  likely	  to	  be	  involved	  in	  neuroprotection	  and	  anaesthesia.	  	  Xenon	   is	   known	   to	   inhibit	   NMDA	   receptors	   and	   to	   activate	   TREK-­‐1	   channels	  [13,17,19],	  with	  competitive	  inhibition	  of	  the	  NMDA	  receptor	  previously	  shown	  to	   largely	   mediate	   xenon	   neuroprotection	   against	   hypoxic/ischemic	   injury	   in	  
vitro.	  [91]	  In	  the	  in	  vitro	  model	  of	  traumatic	  brain	  injury,	  xenon	  neuroprotection	  was	   reversed	   by	   adding	   saturating	   concentrations	   of	   glycine,	   consistent	   with	  xenon	   neuroprotection	   being	   mediated	   by	   NMDA	   receptor	   inhibition	   at	   the	  glycine	  site	  (Figure	  4.11).	  This	  finding	  clearly	  identifies	  the	  NMDA	  receptor	  as	  a	  molecular	  target	  for	  neuroprotection	  against	  traumatic	  injury.	  	  
6.3.1	  Helium,	  neon,	  argon,	  and	  krypton	  do	  not	  inhibit	  GluN1/GluN2A	  NMDA	  
receptors	  The	   well-­‐established	   inhibition	   of	   NMDA	   receptors	   by	   xenon	   and	   the	   role	   of	  same	  in	  xenon’s	  neuroprotective	  properties	  suggested	  that	  the	  other	  noble	  gases	  might	  also	  inhibit	  these	  receptors	  by	  the	  same	  mechanism.	  This	  hypothesis	  was	  particularly	   relevant	   for	   argon,	   which	   has	   previously	   been	   shown	  neuroprotective	  against	  hypoxic/ischemic	   injury	  both	   in	  vitro	   and	   in	  vivo	   [134-­‐
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137].	   Under	   identical	   conditions	   to	   xenon,	   argon	   was	   found	   to	   also	   be	  neuroprotective	  against	  traumatic	  brain	  injury	  in	  vitro	  (Figure	  4.1).	  	  	  Despite	  this,	  data	  presented	  in	  Chapter	  4	  show	  that	  argon	  has	  no	  effect	  on	  NMDA	  receptor	  mediated	  currents	  at	  either	  high	  or	  low	  glycine	  concentrations	  (Figure	  4.6,	  Figure	  4.8),	  consistent	  with	  no	  interaction	  between	  glycine	  and	  argon	  at	  the	  site.	   This	   finding	   is	   supported	   by	   the	   observation	   that	   argon	   neuroprotection	  against	  TBI	  in	  vitro	  is	  not	  reversed	  by	  saturating	  concentrations	  of	  glycine	  in	  the	  same	  way	  as	  xenon	  (Figure	  4.12).	  	  The	   other	   noble	   gases	   helium,	   neon,	   and	   krypton	  were	   also	   found	   to	   have	   no	  influence	   on	  NMDA	   receptor	   currents	   at	   high	   or	   low	   concentrations	   of	   glycine	  (Figure	  4.10).	  This	  lack	  of	  inhibition	  may	  be	  because	  elevated	  concentrations	  of	  these	  gases	  are	  required	  for	  any	  biological	  effect	  on	  NMDA	  receptors	  (both	  argon	  and	  krypton	  are	  anaesthetic	  at	  elevated	  pressures),	  or	  more	  simply	  may	  amount	  to	  no	  action	  for	  the	  noble	  gases	  –	  other	  than	  xenon	  -­‐	  at	  NMDA	  receptors.	  	  	  
6.3.2	  Helium,	  neon,	  argon,	  and	  krypton	  do	  not	  activate	  TREK-­‐1	  potassium	  
channels	  The	   TREK-­‐1	   potassium	   channel	   is	   involved	   in	   both	   general	   anaesthesia	   and	  neuroprotection	  [151].	  Xenon	  is	  an	  activator	  of	  the	  TREK-­‐1	  channel	  [19]	  (Figure	  4.14),	  and	  both	  anaesthesia	  and	  neuroprotection	  are	  recognised	  pharmacological	  endpoints	  of	  xenon	  administration.	  The	  contribution	  (if	  any)	  of	  TREK-­‐1	  channel	  activation	   to	   xenon’s	   neuroprotective	   properties	   remains	   to	   be	   determined,	  however	   in	   an	   in	   vitro	   model	   of	   traumatic	   injury,	   neuroprotection	   by	   xenon	  appears	  to	  be	  accounted	  for	   largely	  by	  inhibition	  of	  the	  NMDA	  receptor	  glycine	  site	   (Figure	   4.11).	   In	   the	   same	   in	   vitro	   trauma	   model	   and	   under	   identical	  conditions,	  the	  NMDA	  receptor	  was	  found	  to	  play	  no	  role	  in	  neuroprotection	  by	  argon	   (Figure	   4.12).	   The	   same	   conclusion	   was	   reached	   when	   observing	  inhibition	   of	   NMDA	   receptor	   mediated	   currents	   by	   argon	   using	  electrophysiology	   (Figure	   4.6),	   leaving	   TREK-­‐1	   activation	   as	   the	   next	   obvious	  candidate	  target	  mediating	  these	  effects.	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Data	   presented	   in	   Chapter	   4	   show	   that	   the	   noble	   gases	   helium,	   neon,	   and	  krypton	   have	   no	   effect	   on	   TREK-­‐1	   currents	   (Figure	   4.19).	   Together	   with	   an	  apparent	  lack	  of	  activity	  on	  NMDA	  receptor	  currents	  (Figure	  4.10),	  the	  evidence	  points	  increasingly	  towards	  a	  lack	  of	  pharmacological	  effect	  for	  both	  helium	  and	  neon,	   in	  agreement	  with	  other	   literature	  studies	  [133,134].	  The	   involvement	  of	  TREK-­‐1	   channel	   activation	   in	   anaesthesia	   produced	   by	   elevated	   pressures	   of	  krypton	  cannot,	  however,	  be	  ruled	  out.	  	  Argon	  was	  also	   found	  to	  have	  no	  effect	  on	  TREK-­‐1	  potassium	  channel	  currents	  (Figure	   4.17),	   indicating	   no	   involvement	   for	   the	   TREK-­‐1	   channel	   in	  neuroprotection	  by	  argon.	  The	  lack	  of	  effect	  on	  both	  TREK-­‐1	  channels	  and	  NMDA	  receptors	   leaves	   the	   receptor	   and	   mechanism	   underlying	   neuroprotection	   by	  argon	  unknown.	  	  	  
6.3.3	  Relevance	  to	  use	  of	  inert	  gases	  in	  neuroprotection	  Both	  xenon	  and	  argon	  were	  shown	  to	  be	  protective	  against	   traumatic	   injury	   in	  
vitro	  (Figure	  4.1).	  Neuroprotection	  by	  xenon	  was	  found	  to	  be	  mediated	  largely	  by	  inhibition	  of	   the	  NMDA	  receptor	  glycine	  site.	  The	  same	  was	  not	   true	   for	  argon,	  which	  has	  no	  effect	  on	  either	  NMDA	  receptors	  or	  TREK-­‐1	  channels	  (Figure	  4.10,	  Figure	  4.19).	  Both	  gases	  merit	  further	  investigation	  as	  putative	  neuroprotective	  therapeutics	  in	  pre-­‐clinical	  in	  vivo	  TBI	  studies.	  	  Like	  xenon,	  argon,	  has	  a	  favourable	  safety	  profile,	  with	  no	  adverse	  or	  toxic	  effects	  described	   for	   argon	   thus	   far	   [155].	   Argon	   is	   also	  much	  more	   abundant	   in	   the	  atmosphere	  than	  xenon,	  making	  it	  more	  cost-­‐effective	  than	  xenon	  –	  an	  important	  consideration	   in	   any	   medical	   therapy.	   Conversely,	   while	   xenon	   has	   relatively	  well	  characterised	  pharmacology,	  the	  molecular	  mechanism(s)	  underlying	  argon	  neuroprotection	   remain	   elusive.	   This	   is	   somewhat	   reflective	   of	   the	   relative	  infancy	   of	   clinical	   research	   in	   argon	   neuroprotection,	  while	   xenon	   has	   already	  advanced	   as	   far	   as	   clinical	   studies	   assessing	   neuroprotective	   efficacy	   against	  ischemic	   brain	   injuries	   like	   neonatal	   asphyxia,	   cardio-­‐pulmonary	   bypass,	   and	  deficit	  following	  cardiac	  arrest	  [93].	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The	  present	  study	  has,	  at	   least,	  shown	  that	  neither	  the	  TREK-­‐1	  channel	  nor	  the	  NMDA	  receptor	  mediates	  neuroprotection	  by	  argon.	  One	  recent	  study	  has	  found	  that	  argon	  transiently	  increases	  levels	  of	  phosphorylated	  extracellular	  signalling	  kinase	  ½	   in	   vitro	   [152],	   but	   the	   involvement	   of	   this	   in	   argon	   neuroprotection	  remains	   to	   be	   determined.	   The	   molecular	   mechanism(s)	   by	   which	   argon	  produces	  its	  neuroprotective	  effects	  merits	  further	  investigation.	  	  The	   lack	   of	   involvement	   of	   the	   same	   molecular	   targets	   (NMDA	   receptor	   and	  TREK-­‐1	   channel)	   in	   neuroprotection	   by	   argon	   and	   xenon	   is	   particularly	  interesting	   as	   it	   makes	   a	   combination	   therapy	   of	   the	   two	   gases	   an	   enticing	  possibility.	   Xenon	   neuroprotection	   in	   vitro	   increases	   only	   modestly	   when	   the	  concentration	   is	   raised	   from	   30%	   to	   70%,	   while	   argon	   is	   protective	   at	  concentrations	  of	  50%	  and	  above	  (data	  from	  companion	  study	  by	  Harris	  et	  al).	  A	  balanced	  mixture	  of	  the	  two	  then,	  might	  provide	  a	  combined	  or	  even	  synergistic	  neuroprotection,	  greater	  than	  when	  the	  two	  are	  delivered	  separately.	  	  	  	  The	  use	  of	  combination	  therapies	  to	  achieve	  sustained	  neuroprotection	  where	  a	  single	  pharmacological	  intervention	  would	  otherwise	  fail	  to	  has	  been	  suggested	  for	  some	  time	  [153,154].	  It	   is,	  however,	  necessary	  to	  prove	  both	  gases	  safe	  and	  efficacious	  when	  applied	  separately	  before	  a	  combination	  therapy	  of	  the	  two	  can	  be	  considered.	  	  Neuroprotection	  by	  xenon	   in	  vitro	  was	   found	   to	  be	  mediated	   largely	  by	  NMDA	  receptor	  inhibition	  (Figure	  4.11).	  It	  does,	  however,	  remain	  interesting	  that	  xenon	  is	   known	   to	   act	   at	   another	   molecular	   target	   likely	   to	   play	   a	   role	   in	  neuroprotection,	   namely	   the	   TREK-­‐1	   channel	   [19]	   (Figure	   4.19).	   Xenon’s	  particularly	  robust	  neuroprotection	  may	   in	   fact	  arise	  directly	   from	  its	  action	  at	  multiple	  targets,	  indeed	  it	  has	  been	  suggested	  previously	  that	  action	  at	  multiple	  targets	  might	  underlie	  neuroprotection	  by	  other	  anaesthetic	  agents	  [154,167].	  	  Xenon	  is	  particularly	  attractive	  as	  a	  neuroprotective	  therapy	  as	  it	  rapidly	  crosses	  the	  blood-­‐brain	  barrier,	  has	  good	  cardiovascular	  stability,	  and	  is	  not	  metabolised	  [93,113,114,120-­‐124].	   Further,	   drugs	   acting	   at	   the	  NMDA	   receptor	   glycine	   site	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6.4	   Xenon	   neuroprotection	   in	   an	   in	   vivo	   model	   of	  
traumatic	  brain	  injury	  	  Traumatic	   brain	   injury	   represents	   the	   leading	   cause	   of	   death	   and	   disability	   in	  under	  45’s	   in	   the	  developed	  world[94][94][94][94][94][94][94][94]responsible	  for	  close	  to	  a	  million	  visits	  to	  A&E	  in	  the	  UK	  each	  year	  [94]	  and	  with	  an	  estimated	  financial	   cost	   of	  €33	  billion	   annually	   in	  Europe	   alone	   [96].	   Blunt	   trauma	  TBI	   -­‐	  caused	   by	   an	   external	   trauma	   damaging	   the	   brain	   -­‐	   is	   one	   major	   form	   of	  traumatic	  injury,	  and	  is	  characterised	  by	  a	  “primary	  injury”	  -­‐	  the	  direct	  outcome	  of	   the	   traumatic	   insult	  –	   followed	  by	  a	   “secondary	   injury”	  beginning	  soon	  after	  the	  initial	  mechanical	  trauma	  and	  spreading	  into	  neighbouring	  brain	  tissue	  in	  the	  subsequent	  hours	  and	  days	  [95,97].	  	  	  Secondary	  injury	  is	  often	  the	  more	  damaging	  stage,	  responsible	  for	  the	  majority	  of	   short-­‐	   and	   long-­‐term	  neurological	   and	   cognitive	   impairments	   resulting	   from	  TBI.	   Disability	   and	   the	   resulting	   long-­‐term	   healthcare	   costs	   associated	   with	  survivors	  of	  brain	  trauma	  represent	  major	  financial	  and	  social	  burdens	  [95,96],	  and	   yet	   there	   are	   currently	  no	   clinically	   available	   treatments	   that	   are	   targeted	  specifically	   at	   limiting	   secondary	   injury.	   Treatments	   for	   traumatic	   brain	   injury	  are	  thus	  urgently	  required.	  	  The	   neuroprotective	   benefits	   of	   the	   noble	   gas	   xenon	   have	   been	   assessed	   in	   a	  number	   of	   in	   vitro	   and	   in	   vivo	   models	   of	   ischemic	   injury	   [76,77,87-­‐91],	   with	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xenon	   currently	   being	   evaluated	   in	   clinical	   trials	   for	   ischemic	   brain	   injuries	  including	   neonatal	   asphyxia,	   cardio-­‐pulmonary	   bypass,	   and	   deficit	   following	  cardiac	  arrest	  [93].	  Data	  regarding	  xenon’s	  neuroprotective	  efficacy	  in	  TBI	  is	  far	  scarcer,	   limited	   thus	   far	   to	   in	  vitro	  models	   [75]	   (Figure	  4.1,	   from	  a	   companion	  study	   by	   Katie	   Harris).	   Such	   in	   vitro	   models	   are	   useful	   in	   the	   screening	   of	  putative	   neuroprotectants	   and	   understanding	   their	   mechanism	   of	   action,	   but	  lack	   many	   important	   features	   found	   in	   vivo	   (functioning	   vasculature,	   oedema,	  blood	  brain	  barrier	  dysfunction,	  etc.)	  and	  cannot	  model	  behavioural	  neurological	  outcome	  –	  one	  of	  the	  most	  important	  end-­‐measures	  of	  efficacy	  for	  any	  potential	  neuroprotective	  drug.	  	  It	   is	   thus	   important	   to	   assess	   xenon	   neuroprotection	   in	   in	   vivo	   models	   of	   TBI	  which	  allow	  the	  assessment	  of	   improvements	  in	  neurological	   function	  and	  long	  term	   outcome	   following	   brain	   trauma.	   Chapter	   5	   was	   designed	   as	   the	   first	   of	  these	  pre-­‐clinical	   in	  vivo	  studies,	  which	  are	  required	  to	  advance	  xenon	  towards	  clinical	   trials	   for	   use	   in	   TBI.	   The	   effects	   of	   xenon	   treatment	   on	   both	   early	   (24	  hours)	   and	   late	   (2-­‐5	   days)	   phase	   outcome	   were	   investigated,	   with	   xenon	  administered	   15	   minutes,	   1	   hour,	   3	   hours,	   and	   6	   hours	   trauma	   in	   order	   to	  determine	  a	  therapeutic	  time	  window	  for	  xenon	  neuroprotection.	  	  
6.4.1	  Relevance	  of	  the	  controlled	  cortical	  impact	  model	  of	  traumatic	  brain	  
injury	  A	  number	  of	   in	  vivo	  models	  of	   traumatic	  brain	   injury	  have	  been	  developed,	   the	  most	  common	  of	  which	  are	  the	  controlled	  cortical	  impact	  (CCI),	  fluid	  percussion	  injury	  (FPI),	  and	  weight	  drop	  injury	  models	  [42].	  Weight	  drop	  injury	  uses	  a	  free	  falling	  weight	  to	  induce	  either	  focal	  [51,52]	  or	  diffuse	  [49,64]	  brain	  injury,	  while	  fluid	  percussion	  models	  injure	  the	  brain	  with	  a	  rapid	  fluid	  bolus	  delivered	  onto	  the	  intact	  dura,	  producing	  a	  largely	  diffuse	  injury	  [53].	  Controlled	  cortical	  impact	  uses	  a	  pneumatically	  driven	  impactor	  to	  induce	  focal	  injury	  [40,54].	  	  It	   is	  well	   recognised	   that	  no	   single	   animal	  model	  of	   traumatic	  brain	   injury	   can	  reproduce	  the	  entire	  spectrum	  of	  events	  that	  will	  occur	  with	  a	  human	  TBI.	  In	  the	  present	  study,	  xenon	  neuroprotection	  against	  traumatic	  brain	  injury	  in	  vivo	  was	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assessed	   using	   the	   rodent	   controlled	   cortical	   impact	   model.	   This	   model	   is	  recognised	   as	   an	   excellent,	   highly	   reproducible	   in	   vivo	   model	   of	   clinical	   TBI	  involving	   cortical	   compression,	   and	   reproduces	   many	   of	   the	   elements	  representative	   of	   a	   clinical	   TBI.	   These	   include	   oedema,	   elevated	   intra-­‐cerebral	  pressure,	   subdural	   haematoma,	   reduced	   cortical	   perfusion,	   blood-­‐brain	  barrier	  dysfunction,	  and	  axonal	  injury	  [169-­‐171].	  As	  the	  injury	  produced	  in	  this	  model	  is	  predominantly	   focal,	   the	   CCI	   model	   is	   arguably	   the	   most	   useful	   when	  investigating	  the	  pathophysiology	  of	  the	  secondary	  injury	  processes	  induced	  by	  blunt	  trauma	  TBI	  [42].	  	  The	  CCI	  model	  has	  been	  used	  widely	  in	  pre-­‐clinical	  TBI	  studies	  [172-­‐175];	  injury	  development	   in	   this	  model	   reflects	  many	  of	   the	   clinical	  outcomes	  of	  blunt	  TBI,	  including	   brain	   oedema,	   elevated	   intra-­‐cranial	   pressure	   and	   a	   spreading	   brain	  lesion	  which	  peaks	  at	  24	  hours	  post-­‐injury	  (in	  mice)	  [176].	  In	  the	  present	  study,	  a	  primary	  lesion	  of	  5.4±0.6mm3	  developing	  7-­‐fold	  to	  37.5±1.4mm3	  24	  hours	  after	  injury	  was	  observed	  (Figure	  5.5),	  consistent	  with	  a	  primary	  lesion	  triggering	  an	  expanding	   secondary	   lesion	   in	   neighbouring	   brain	   tissue,	   as	   per	   the	   clinical	  scenario	  [97,176].	  	  	  
6.4.2	  Xenon	  pre-­‐treatment	  and	  post-­‐treatment	  A	   protective	   effect	   for	   xenon	   delivered	   both	   before	   and	   after	   traumatic	   injury	  was	  predicted,	  based	  upon	  the	  observation	  that	  xenon	  treatment	  before	  ischemic	  injury	   is	   protective	   in	   neuronal	   and	   cardiac	   tissues,	   both	   in	   vitro	   and	   in	   vivo	  [92,122,166,177-­‐182].	  This	  study	  found	  that	  75%	  xenon/25%	  oxygen	  given	  for	  2	  hours	  before	  and	  2	  hours	  after	   traumatic	  brain	   injury	   improved	  outcome	  after	  24	  hours.	  	  Xenon	   treatment	   in	   this	   paradigm	   resulted	   in	   statistically	   significant	  improvements	  in	  both	  neurological	  outcome	  (Figure	  5.1)	  and	  contusion	  volume	  (Figure	   5.2).	   Xenon	   treated	   animals	   showed	   a	   40%	   improvement	   in	   the	  neurological	   severity	   score	   (p<0.05)	   and	   a	   43%	   reduction	   in	   brain	   contusion	  volume	  (p<0.01)	  measured	  24	  hours	  after	  traumatic	  injury.	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In	   reality,	   however,	   the	   clinical	   relevance	   of	   xenon	   neuroprotection	   in	   a	   pre-­‐treatment	   paradigm	   is	   limited	   to	   a	   small	   number	   of	   very	   specific	   scenarios.	  Xenon	   delivery	   before	   a	   traumatic	   injury	   would	   be	   possible,	   for	   example,	   in	  neurosurgical	   procedures	   with	   high	   risk	   of	   damage	   to	   neighbouring	   healthy	  tissue.	  The	  expense	  of	  xenon	   treatment	  and	   the	  practicalities	  of	  prediction	  and	  delivery	  do,	  however,	  mean	  that	  from	  a	  clinical	  perspective	  xenon	  pre-­‐treatment	  is	   much	   less	   practical	   than	   treatment	   with	   xenon	   only	   after	   injury,	   for	   the	  majority	  of	  scenarios	  presented	  in	  the	  clinic.	  	  
6.4.3	  Xenon	  post-­‐injury	  treatment	  The	  objective	  of	  the	  present	  study	  was	  to	  assess	  xenon	  neuroprotection	  against	  TBI	   under	   clinically	   relevant	   conditions.	   The	   ability	   of	   xenon	   to	   improve	  neurological	   function	   and	   reduce	   contusion	   volume	   was	   thus	   assessed	   in	   a	  paradigm	  in	  which	  xenon	  was	  administered	  only	  after	  brain	  trauma.	  	  	  Xenon	  administration	  beginning	  15	  minutes	  post	  injury	  was	  chosen	  based	  upon	  a	   clinically	   relevant	   scenario	   in	  which	  a	  patient	  might	   receive	   treatment	  at	   the	  scene	  of	  an	  injury	  within	  15-­‐20	  minutes.	  One	  reason	  why	  other	  neuroprotective	  treatments	  have	  shown	  efficacy	  in	   laboratory	  studies	  which	  ultimately	  failed	  to	  translate	  into	  real	  world	  efficacy	  in	  clinical	  trials	  may	  be	  that	  treatment	  is	  often	  given	   during	   or	   immediately	   after	   injury	   [110,183].	   This	   15	   minute	   delay	   in	  treatment	   is	   thus	   more	   representative	   of	   the	   clinical	   scenario,	   and	   should	  provide	   a	   more	   accurate	   representation	   of	   neuroprotection	   by	   xenon	   in	   any	  future	   clinical	   trials.	  A	  3	  hour	   treatment	  duration	   for	   xenon	  was	   chosen	  based	  upon	  previous	  studies	  in	  in	  vivo	  models	  of	  ischemic	  injury	  [77,184].	  	  75%	  xenon/25%	  oxygen	  administered	   for	  3	  hours,	  beginning	  15	  minutes	  after	  trauma,	   resulted	   in	   statistically	   significant	   improvements	   in	   early	   phase	  outcome.	   Giving	   75%	   xenon	   for	   3	   hours	   after	   trauma	   resulted	   in	   a	   significant	  (p<0.05),	   36%	   reduction	   in	   neurological	   severity	   score	   (Figure	   5.4),	   and	   a	  significant	  (p<0.05)	  19%	  reduction	  in	  contusion	  volume	  (Figure	  5.5).	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6.4.4	  Therapeutic	  time	  window	  for	  xenon	  treatment	  In	   any	   potential	   treatment	   for	   brain	   injury,	   the	   time-­‐window	   after	   injury	   in	  which	   treatment	   remains	   efficacious	   remains	   one	   of	   the	   most	   important	  considerations.	  In	  ischemic	  brain	  injury	  this	  has	  proven	  particularly	  problematic,	  for	   example	   in	   ischemic	   stroke	   it	   is	   often	  many	  hours	   after	   the	  onset	   of	   injury	  before	   patients	   present	   themselves	   for	   medical	   attention.	   In	   the	   case	   of	  traumatic	  brain	  injury,	  the	  need	  for	  medical	  intervention	  is	  much	  more	  apparent,	  indeed	   in	   cases	   in	   which	   a	   moderate	   to	   severe	   TBI	   will	   occur	   (motor	   vehicle	  crashes,	  etc.)	  medical	  attention	  will	  likely	  be	  sought	  reasonably	  quickly.	  	  	  It	   is	   conceivable	   that	   medical	   personnel	   could	   deliver	   a	   neuroprotective	  treatment	   at	   the	   scene	   of	   a	   trauma	   and/or	   in	   the	   ambulance;	   indeed	   one	  advantage	   of	   xenon	   gas	   is	   that	   it	   could	   be	   delivered	   relatively	   easily	   to	  spontaneously	   breathing	   patients.	   However,	   a	   more	   realistic	   scenario	   is	   that	  treatment	   is	   delayed	  until	   the	   patient	   arrives	   at	   the	   emergency	  department	   or	  ITU,	   thus	  there	  remains	  the	  need	  to	  determine	  the	  therapeutic	   time	  window	  in	  which	  xenon	  treatment	  remains	  neuroprotective	  following	  a	  traumatic	  injury.	  	  The	  therapeutic	  time	  window	  for	  xenon	  in	  the	  rodent	  CCI	  model	  was	  determined	  by	   delaying	   xenon	   treatment	   1	   hour,	   3	   hours,	   and	   6	   hours	   after	   inury.	   Xenon	  treated	  animals	  performed	  better	  in	  the	  neurological	  severity	  score	  in	  all	  groups,	  at	   24	   hours	   after	   injury.	   This	   difference	   was	   significant	   (p<0.05)	   when	   xenon	  was	  given	  up	  to	  1	  hour	   following	   injury,	  where	  a	  46%	  reduction	  was	  observed	  (Figure	  5.6).	  	  Secondary	  injury,	  as	  measured	  by	  contusion	  volume	  24	  hours	  after	  trauma,	  was	  reduced	   significantly	   (p<0.05)	   when	   xenon	   treatment	   was	   delayed	   by	   both	   1	  hour	  and	  3	  hours	  (Figure	  5.7).	  Delaying	  treatment	  until	  6	  hours	  after	  trauma	  did	  not	   result	   in	   a	   significant	   reduction	   in	   contusion	   volume	   as	   compared	   with	  controls.	  	  Together	  these	  data	  show	  that,	  in	  terms	  of	  secondary	  injury	  development,	  xenon	  provides	  significant	  neuroprotection	  when	  given	  up	  to	  3	  hours	  after	  injury,	  and	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produces	   significant	   improvements	   in	   neurological	   function	  when	   treatment	   is	  delayed	   up	   to	   1	   hour	   after	   injury.	   This	   is	   consistent	   with	   an	   in	   vitro	   study	   in	  which	  xenon	  treatment	  was	  neuroprotective	  up	  to	  3	  hours	  after	  trauma	  [75],	  and	  with	  a	  recent	   in	  vivo	   ischemic	  stroke	  model	   in	  which	  xenon	   improved	  outcome	  when	  treatment	  was	  delayed	  up	  to	  1.5	  hours	  after	  injury	  onset	  [185].	  	  
6.4.5	  Xenon	  treatment	  and	  late	  phase	  outcome	  One	  of	  the	  most	  important	  end-­‐measures	  of	  any	  neuroprotective	  treatment	  is	  the	  ability	  to	  provide	  improvements	  in	  neurological	  function	  in	  the	  long-­‐term.	  In	  this	  study,	   the	   effects	   of	   treatment	   with	   75%	   xenon/25%	   oxygen	   on	   longer-­‐term	  outcome	   was	   assessed	   using	   the	   neurological	   severity	   score,	   performed	   at	   24	  hour	  intervals	  up	  to	  5	  days	  after	  injury.	  The	  neurological	  severity	  score	  consists	  of	   tasks	   evaluating	   sensorimotor	   function,	   locomotor	   ability,	   balance,	   and	  general	   behaviour,	   and	   is	   useful	   in	   being	   relatively	  quick	   and	   easy	   to	  perform.	  Conversely,	   animals	   are	   known	   to	   show	   improvements	   in	   the	   neurological	  outcome	   score	   with	   time	   as	   part	   of	   their	   recovery	   following	   TBI,	   even	   in	   the	  absence	  of	  neuroprotective	  treatments	  [186].	  	  	  Nevertheless,	   the	   neurological	   severity	   score	   has	   been	   shown	   to	   be	   a	   good	  predictor	  of	  long-­‐term	  outcome,	  and	  to	  correlate	  with	  injury	  severity	  assessed	  by	  MRI	  at	  24	  hours	  [186].	  Sensorimotor	  function	  as	  measured	  by	  the	  neuroscore	  is	  mediated	  by	   complex	  neural	   networks	   linking	  multiple	  brain	  nuclei,	   the	   spinal	  chord,	   and	   neuromuscular	   signalling	   [55,187],	   while	   vestibulomotor	   tests	   like	  beam	  balance	   and	  beam	  walking	  measure	   fine	  motor	   co-­‐ordination	   and	  mimic	  the	  outcomes	  of	  TBI	  on	  patient	  balance,	  co-­‐ordination,	  and	  walking.	  	  	  Data	  presented	  in	  Chapter	  5	  show	  that	  control	  animals,	  which	  received	  only	  75%	  nitrogen/25%	   oxygen	   in	   place	   of	   75%	   xenon/25%	   oxygen,	   displayed	   an	  improvement	   in	   neurological	   outcome	   over	   the	   course	   of	   the	   5	   days	   following	  traumatic	  injury.	  In	  these	  control	  animals,	  the	  mean	  neurological	  outcome	  score	  reduced	  from	  6.3±0.6	  points	  24	  hours	  after	  injury,	  to	  1.4±0.4	  points	  5	  days	  after	  injury.	  This	   recovery	   in	  neurological	   function	  was	  expected,	   and	   is	   in-­‐line	  with	  previous	  studies	  using	  similar	  neurological	  outcome	  scores	  [186].	  Nevertheless,	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xenon	  treated	  animals	  still	  performed	  better	  in	  neurological	  scores	  on	  every	  day,	  performing	  on	  average	  42%	  better	  than	  un-­‐treated	  controls.	  This	  improvement	  was	  significant	  (p<0.05)	  up	  to	  day	  4	  after	  injury	  (Figure	  5.8).	  	  The	   observation	   that	   xenon	   significantly	   improves	   functional	   outcome	   in	   the	  neuroscore,	   even	   up	   to	   4	   days	   after	   trauma	   –	   where	   a	   normal	   reduction	   in	  functional	   deficits	  makes	   improvements	   progressively	   harder	   to	   tease	   out	   –	   is	  highly	   encouraging,	   and	   holds	   promise	   for	   xenon’s	   neuroprotective	   efficacy	   in	  the	  longer	  term.	  Even	  so,	  the	  neuroscore	  remains	  biased	  towards	  sensorimotor	  and	  vestibulomotor	  function	  and	  there	  remains	  a	  requirement	  for	  tests	  of	  (even)	  longer	  outcome,	  particularly	  on	  learning	  and	  memory	  which	  is	  not	  measured	  in	  the	  neuroscore’s	  battery	  of	  tests.	  	  
6.4.6	  Clinical	  relevance	  of	  these	  findings	  Interest	   in	   xenon	   as	   a	   neuroprotective	   treatment	   stems	   from	   the	   observation	  that	   xenon	   is	   an	   antagonist	   of	   the	   NMDA	   receptor	   [13],	   a	   relatively	   upstream	  target	   in	   the	   excitotoxic	   cascade	   implicated	   in	   many	   forms	   of	   brain	   injury.	  Xenon’s	   neuroprotective	   efficacy	   has	   been	   evaluated	   in	   various	   models	   of	  ischemic	   injury,	   both	   in	   vitro	   and	   in	   vivo	   [76,77,86,89-­‐91,140,185].	   Xenon	   is	  currently	   in	   clinical	   trials	   as	   a	   neuroprotective	   treatment	   in	   neonatal	   asphyxia	  and	  ischemic	  brain	  injury	  following	  cardiac	  arrest	  [156,188].	  	  	  The	   data	   presented	   in	   Chapter	   5	   provide	   the	   first	   evidence	   for	   xenon	  neuroprotection	  in	  an	  animal	  model	  of	  traumatic	  brain	  injury.	  75%	  xenon/25%	  oxygen	  improves	  neurological	   function	  following	  trauma,	  reduces	  the	  degree	  of	  secondary	  injury	  development,	  and	  remains	  efficacious	  even	  when	  treatment	  is	  delayed	  up	  to	  3	  hours	  after	  the	  onset	  of	  trauma.	  This	  is	  consistent	  with	  data	  from	  
in	   vitro	   studies,	   in	   which	   xenon	   is	   able	   to	   protect	   against	   secondary	   injury	  development	   in	   a	   simple	   in	   vitro	   model	   of	   traumatic	   brain	   injury,	   even	   when	  xenon	  treatment	  is	  delayed	  [75].	  
	  The	   finding	   that	   xenon	   both	   improves	   functional	   outcome	   and	   reduces	  secondary	   injury	   suggests	   that	   xenon	   represents	   a	   realistic	   first-­‐line	   treatment	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6.5	  Conclusion	  	  The	   present	   study	   had	  multiple	   streams,	   linked	   together	   under	   the	   themes	   of	  molecular	   targets	   underlying	   neuroprotection	   and	   anaesthesia,	   and	   the	  neuroprotective	  potential	  of	  the	  series	  of	  inert	  gases.	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The	  major	   portion	   of	   this	   study	  was	   spent	   dissecting	   the	   interaction	   between	  xenon	   and	   the	   GluN1	   site	   of	   the	   NMDA	   receptor.	   The	   importance	   of	   aromatic	  residues	   in	   the	  binding	  of	  both	  glycine	  and	  xenon	  at	   the	  site	  was	  highlighted	  –	  particularly	   in	   the	   case	   of	   phenylalanine	   at	   the	   758	   site,	  which	   is	   essential	   for	  xenon	   to	   bind	   to	   the	   receptor.	   Two	  mutations	   at	   this	   site	   (F758W	  and	  F758Y)	  were	   identified	  which	   leave	  normal	   receptor	   function	   largely	   intact,	   but	  which	  prevent	   xenon	   from	   binding	   to	   the	   GluN1	   site.	   These	  mutations	  may	   in	   future	  prove	  valuable	   in	  dissecting	   the	   relative	   contribution	  of	   the	  NMDA	  receptor	   to	  xenon’s	   clinical	   properties	   of	   anaesthesia,	   analgesia,	   and	   neuroprotection.	  Similarly,	  these	  mutations	  may	  prove	  valuable	  in	  validating	  the	  NMDA	  receptor	  as	  a	  molecular	  target	  for	  anaesthesia	  and	  neuroprotection	  in	  vivo.	  	  The	  second	  part	  of	   the	  study	   investigated	  the	  ability	  of	   the	  other	   inert	  gases	  to	  influence	  two	  known	  molecular	  targets	  of	  xenon,	  namely	  the	  NMDA	  receptor	  and	  the	  TREK-­‐1	  channel.	  There	  is	  literature	  evidence	  for	  pharmacological	  activity	  for	  certain	   of	   these	   gases,	   but	   few	   studies	   have	   ever	   examined	   directly	   their	  influence	   on	  protein	   targets.	   This	   portion	   of	   the	   study	  was	   intended	  mainly	   to	  test	  the	  hypothesis	  that	  xenon	  and	  argon	  share	  a	  common	  mechanism	  for	  their	  neuroprotection	   against	   traumatic	   brain	   injury	   in	   vitro,	   however	   argon	   was	  found	   to	   exert	   no	   influence	   over	   either	   the	   NMDA	   receptor	   or	   the	   TREK-­‐1	  channel.	   No	   involvement	   of	   NMDA	   receptors	   in	   argon	   neuroprotection	   was	  confirmed	   in	  an	   in	  vitro	  model	  of	  TBI,	   leaving	   the	  molecular	   targets	  underlying	  argon	   neuroprotection	   unknown.	   The	   other	   noble	   gases	   helium,	   neon,	   and	  krypton	  were	  also	  found	  to	  have	  no	  effect	  on	  either	  the	  NMDA	  receptor	  or	  TREK-­‐1	  channel.	  	  The	   third	   and	   final	   portion	   of	   the	   study	   was	   an	   investigation	   of	   the	  neuroprotective	   efficacy	   of	   xenon	   against	   traumatic	   brain	   injury	   in	   vivo.	   75%	  xenon/25%	  oxygen	  was	  found	  to	  provide	  a	  significant	  degree	  of	  neuroprotection	  in	   the	  mouse	   controlled	   cortical	   impact	  model,	   both	   reducing	   brain	   contusion	  volume	   and	   improving	   neurofunctional	   outcome,	   even	   when	   treatment	   was	  delayed	  by	  up	  to	  3	  hours.	  This	  represents	  the	  first	  evidence	  that	  xenon	  protects	  
155	  
against	  traumatic	  brain	  injury	  in	  vivo	  and	  suggests	  that	  xenon	  may	  be	  a	  realistic	  first-­‐line	  treatment	  for	  brain	  trauma.	  	  The	  work	  undertaken	   in	   this	   study	  had	   a	   strong	   translational	   focus,	   beginning	  from	   basic	   molecular	   interactions	   between	   xenon	   and	   the	   NMDA	   receptor	  glycine	   site,	   and	   ending	   with	   in	   vivo	   studies	   which	   form	   the	   first	   of	   the	   pre-­‐clinical	  work	  required	  to	  move	  xenon	  forward	  as	  a	  neuroprotective	  treatment	  in	  traumatic	  brain	  injury.	  Further	  work	  in	  this	  area	  is	  required,	  for	  example	  studies	  assessing	   xenon’s	   neuroprotective	   efficacy	   following	   CCI	   in	   the	   longer	   term,	  and/or	   assessing	   xenon’s	   impact	   upon	   learning	   and	   memory	   following	   brain	  trauma.	  	  	  The	  contributions	  of	  this	  study	  may	  be	  felt	  most	  significantly	  in	  the	  combination	  of	  the	  two	  streams	  of	  mutagenesis	  studies	  at	  the	  NMDA	  receptor	  GluN1	  site	  and	  
in	   vivo	   neuroprotection	   by	   xenon,	   which	   will	   provide	   important	   information	  regarding	  the	  molecular	  targets	  underlying	  neuroprotection.	  Similarly,	  knock-­‐in	  animals	   expressing	   either	   of	   the	   two	   mutant	   NMDA	   receptors	   may	   finally	  provide	   validation	   of	   the	   NMDA	   receptor	   as	   a	   molecular	   target	   for	   general	  anaesthesia.	  The	  final	  portion	  of	  this	  study	  is	  particularly	  significant	  in	  forming	  the	   first	   of	   the	   pre-­‐clinical	   studies	   required	   to	   move	   xenon	   forward	   as	   a	  treatment	   for	   traumatic	   brain	   injury	   –	   a	   clinical	   epidemic	   for	  which	   there	   are	  currently	  no	  treatments	  specifically	  targeting	  the	  reduction	  of	  secondary	  injury.	  	  
6.5.1	  Main	  findings	  	  1. Phenylalanine	   at	   the	   758	   site	   is	   essential	   for	   xenon	   binding	   to	   the	   NMDA	  receptor	  GluN1	  site.	  2. GluN1(F758W)	   and	   GluN(F758Y)	   receptor	   mutants	   abolish	   the	   binding	   of	  xenon	   at	   the	   GluN1	   site	   while	   leaving	   binding	   of	   glycine,	   sevoflurane,	   and	  isoflurane	  intact.	  	  3. Xenon	   inhibits	   NMDA	   receptors	   and	   potentiates	   TREK-­‐1	   channels,	   but	  helium,	  neon,	  argon,	  and	  krypton	  do	  not.	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4. Xenon	   is	   neuroprotective	   against	   traumatic	   brain	   injury	   in	   vivo,	   both	  reducing	  contusion	  volume	  and	  improving	  neurofunctional	  outcome.	  5. Xenon	  has	  a	  clinically	  relevant	  therapeutic	  time	  window	  of	  between	  1	  and	  3	  hours,	  during	  which	  delayed	  xenon	  treatment	  remains	  neuroprotective.	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